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The hepatitis C virus (HCV) is an enveloped +ssRNA virus, belonging to the 
family Flaviviridae. HCV is notable for displaying extraordinary genetic 
diversity and variability, having seven recognised genotypes and over sixty 
subtypes. HCV is responsible for the disease known as hepatitis C, which is 
associated with cirrhosis and hepatocellular carcinoma (HCC). The Global 
Hepatitis Report released by the World Health Organisation (WHO) in 2017 
estimated that viral hepatitis was responsible for 1,340,000 deaths in 2015. 
The report also estimated that 71,000,000 people have ongoing HCV 
infections. HCV is largely transmitted via exposure to infected blood, with 
intravenous drug use accounting for approximately 55% of cases. HCV 
infections can be categorised as acute or chronic. During chronic HCV 
infections, antibodies (Abs) are produced against HCV - however, the host 
Abs are unable to neutralise HCV and only accelerate the evolution of 
circulating HCV variants. HCV variants resistant to the current generation of 
host Abs become the dominant variant through selective pressure. The 
variants of HCV within a host are known as quasispecies. Although the host 
Ab response is not able to resolve the chronic HCV infection, some Abs can 
bind to particular HCV variants. These Abs form complexes with virus 
particles and are known as AAVs (antibody-associated virus). AAVs are 
detectable in the blood of patients with chronic HCV infections and 
examination of these AAVs could reveal conserved viral structures and 
vulnerable HCV epitopes.   
Twenty genotype 3a serum and plasma samples from patients with chronic 
HCV infections were obtained from the National Virus Registry Laboratory 
(NVRL) and from the Molecular Virology Research and Diagnostic 
Laboratory (MVDRL). HCV genotype 3a was chosen for this research project 
given its prevalence (estimated to account for 17.9% of chronic HCV 
infections), resistance to treatment, and increased risk of causing severe 
steatosis and HCC when compared to other genotypes. Building on previous 
research carried out by the MVDRL, the patient samples were screened for 




and used to generate HCV pseudoparticles (HCVpp). The HCVpp system is 
a model system that incorporates the E1E2 glycoprotein from HCV into a 
plasmid. The E1E2 glycoprotein is responsible for HCV entry and infection, 
meaning the HCVpp can be used to infectivity and Ab neutralisation assays. 
However, the E1E2 glycoproteins could not be extracted from the AAV+ 
patient samples. Instead, the IgG from the AAV+ samples was extracted and 
used for a series of neutralisation experiments on HCV pseudoparticles 
generated using the HCV H77 isolate. H77 (GenBank: AAB67037.1) is an 
infectious genotype 1a isolate that has undergone complete genome 
sequencing. The Abs that showed the greatest neutralisation potential 
against the H77 pseudoparticles were selected for epitope mapping. The 
epitope mapping procedure tested the selected Ab samples against a 
synthesised H77 E2 glycoprotein structure, and characterised the sites 
where the patient Abs bound to the synthesised E2. This revealed vulnerable 
epitopes on the HCV E2 glycoprotein. The epitope mapping also revealed a 
large number of glycosylation sites around the vulnerable epitopes – a 
phenomenon known as glycan shielding. Glycan shielding is used by a 
number of viruses (including HCV and HIV) to protect conserved and 
vulnerable epitopes from Abs. However, strategies are being developed to 
counter viral glycosylation, including modifications to glycosylation sites and 
the use of polysaccharides derived from non-mammalian sources as 
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The hepatitis C virus (HCV) is an enveloped +ssRNA (positive-sense (+) 
single-stranded (ss) ribonucleic acid (RNA)) virus, belonging to the family 
Flaviviridae. Flaviviridae is a family of +ssRNA viruses that includes the West 
Nile virus, Dengue virus, and Zika virus. The majority of Flaviviridae are 
spread through arthropod vectors. Viruses from the Flaviviridae family form 
40 – 60nm virions, and tend to have a single core protein (except for the 
Pegivirus genus), and 2 – 3 envelope glycoproteins. Genomes are between 
9 – 13kb. The Flaviviridae family contains four genera – Flavivirus, 
Pestivirus, Hepacivirus, and Pegivirus – and over sixty species of viruses. 
The Hepacivirus genus contains HCV, and a number of other hepaciviruses 
1.  
The whole HCV genome is 9,600 nucleotides, with a single opening reading 
frame (ORF) encompassing 9,000 nucleotides. The single ORF is 
surrounded by two untranslated regions (UTRs), termed the 5’-UTR and 3’-
UTR. The HCV RNA genome serves as translational template for the 
synthesis of viral proteins. The translation of the HCV genome produces both 
structural and non-structural (NS) proteins – the structural proteins include 
the core, and the E1 and E2 glycoproteins, and the NS proteins include p7, 
NS2, NS3, NS4A, NS4B, NS5A, and NS5B 2. The replication of HCV is 
consistent with the replication pathways of other +ssRNA viruses, with the 
process being cytoplasmic, and using membrane vesicles derived from the 
host endoplasmic reticulum (ER). The assembled HCV virions bud to the ER 
lumen, and are secreted through the vesicle transport pathway – see Figure 
1 for an overview of the HCV lifecycle, and see Section 1.3 for a detailed 
description of the process 1. HCV displays extraordinary genetic diversity, 
having seven recognised genotypes and >60 subtypes, with nucleotide 
sequences varying from 30% - 35% between genotypes, and ≤15% between 




– 2013 estimated that genotype 1 accounts for 46.2% of HCV infections, 
genotype 3 accounts for 30.1%, genotype 2, genotype 4, and genotype 6 
accounts for 22.8%, and genotype 5 accounts for the remaining <1% of HCV 
infections 4. Genotype 7 is an emerging genotype, originating from Central 




Figure 1 – A representation of the HCV lifecycle. HCV particles are bound through specific 
interactions with host surface receptors. Once the bound particles are internalised via 
endocytosis, the HCV particles undergo un-coating, and the genome is translated at the 
endoplasmic reticulum (ER). NS4B induces the formation of the membranous web (MW) – 
this acts as a framework for the virus replication complex. Once the genome has been 
translated and the appropriate HCV proteins expressed, progeny virions are assembled, and 
leave the host through the constitutive secretory pathway. “LD” indicates lipid droplets. 
Figure sourced from Alazard-Daly et al., 2019  3. 
HCV is transmitted via exposure to contaminated blood. Intravenous drug 
use and the transfusion of contaminated blood products and organs are two 
of the main transmission routes. Ireland began testing donated blood and 
organs for HCV around October 1991, and the Health Service Executive 
(HSE) recommends those that received donations before 1989 to undergo 
HCV testing 6. Other routes of transmission include sexual transmission, 




Centre for Disease Prevention and Control (ECDC)’s 2017 hepatitis C 
epidemiological report, 26% of cases reported had a known route of 
transmission. Intravenous drug use was the most common route of 
transmission, accounting for 40% of acute cases and 55% of chronic cases. 
Nosocomial transmission (17% of acute cases) and sexual transmission 
between men (15% of acute cases) were the second and third most common 
routes of transmission, respectively 7.  
HCV infections are largely categorised as acute or chronic infections. The 
2017 ECDC’s HCV report found that 3% of the cases reported were acute, 
22% were chronic, and 75% were “unknown” 7. The ECDC defines acute 
infections as the patient having a recent HCV seroconversion (with a 
negative test for HCV during the previous twelve months) or the presence of 
HCV nucleic acid or core antigen without the presence of HCV antibodies. 
Individuals with acute infections can be asymptomatic, but symptoms (fever, 
nausea, jaundice, and vomiting) can manifest among 20% - 30% of patients.  
The ECDC defines chronic HCV infections as the detection of HCV nucleic 
acid or core antigen for two samples at least twelve months apart. The 
potential complications arising from chronic HCV infections include hepatic 
fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Occult HCV infection 
(OCI) was first described by Castillo et al in January 2004, and is defined as 
the presence of HCV RNA in hepatocytes or peripheral blood mononuclear 
cells (PBMCs) without detectable serum HCV RNA 8 9.  
HCV underwent numerous names and characterisations before becoming 
known as the hepatitis C virus. Around the 1940s and 1950s, human viral 
hepatitis was thought to be caused by just two etiologic agents, a hypothesis 
formed from studies that examined the transmission and pathology of two 
infectious agents associated with hepatitis. The two variations of hepatitis 
were termed “infectious hepatitis” and “serum hepatitis” 10. Later, these would 
become known as hepatitis A (HAV) and hepatitis B (HBV). The inoculation 
of subjects with blood taken from suspected hepatitis patients would provide 
evidence that viral hepatitis was caused by transmissible agents, 11. 
However, these inoculation studies were unable to explain episodes of 




inconsistencies led to suggestions that there could be a third agent capable 
of causing hepatitis 12. 
Around the 1970s a number of serological tests were developed for the 
detection of HAV and HBV - namely a radioimmunoassay capable of 
detecting the hepatitis B surface antigen (HB-sAg). Testing donated blood 
products for HB-sAg reduced the number of cases of HBV infections, but 
studies found that 90% of transfusion hepatitis infectious were not related to 
HBV or HAV. This furthered suggestions that these cases of hepatitis were 
being caused by an infectious agent that had not been characterised 13 14. In 
1975, Alter et al. proposed the name “non-A, non-B” hepatitis for this 
mysterious infectious agent, observing that eight surgery patients had 
developed hepatitis from blood products that were negative for HB-sAg 15. A 
hypothesis emerged that there could be multiple agents capable of causing 
NANBH, and that these agents were related to HBV, but induced a separate 
immune response 16 17.  
In 1989 Choo et al. generated cDNA from the plasma of a patient diagnosed 
with NANBH, and isolated a clone generated from an RNA molecule present 
in NANBH infections. The clone consisted of about 10,000 nucleotides and 
was found to be positive stranded 18. The infectious agent was found to 
share features with Togaviridae and Flaviviridae – both members of Group IV 
of the Baltimore classification of viruses. The Baltimore classification 
categorises viruses into seven groups based on their genome and replication 
strategy, with Group IV comprising of +ssRNA viruses. Through a 
combination of genomic and taxonomic similarities, and the medical 
presentation of NANBH infection, NANBH became known as the hepatitis C 
virus. Figure 2 summarises the timeline of HCV, from the discovery of 
NANBH to the manufacturing and FDA ((United States) Food and Drug 
Administration) approval of modern therapeutics and treatments for chronic 














Hepatitis C – the disease caused by infection with HCV - remains a major 
disease burden, with previous reports from the World Health Organisation 
(WHO) estimating that there are 130 – 150m people with chronic HCV 
infections. The WHO had estimated that 700,000 deaths, per annum, could 
be contributed to complications from HCV infection, but the release of the 
Global Hepatitis Report 2017 has revised a number of these statistics 19. The 
Global Hepatitis Report 2017 found that viral hepatitis was responsible for 
1.34m deaths during 2015 - 720,000 deaths were from cirrhosis and related 
conditions, and 470,000 deaths were caused by HCC. Estimates of the 
current number of individuals with chronic HCV infections have been revised 
from 130 – 150m people to 71m 20. This decrease can be explained by 
changes to the methodologies used to evaluate the number of HCV cases. 
Previously, estimates focused on the presence of HCV antibodies as an 
indicator of HCV infection, but the mere presence of HCV antibodies is not 
enough to distinguish between previous and current infections. Instead, the 
presence of HCV RNA is used to determine the presence of a chronic HCV 
infection 21. As per Section 1, the ECDC stated that 31,273 cases of hepatitis 
C were reported in 29 EU/EEA Member States in 2017 7. 
HCV genotypes have distinct regional groupings - for example, a recent 
epidemiology study of HCV genotype distribution across Europe found that 
genotype 2 infections were more prevalent in Western Europe (8.9%), 
whereas genotype 4 was more prevalent for Central Europe (4.9% for 
genotype 4 versus 3.2% for genotype 2) 22. There are several population 
groups that are vulnerable to HCV infection. The CDC recommends that 
those born between 1945 – 1965, those who received blood transfusions 
and/or organ transplants before 1992, intravenous drug users (IDUs), HIV+ 
individuals, those who have had occupational HCV exposure, and children 
born to HCV+ mothers should be tested for HCV 23. Exposure to HCV 
through blood transfusions and organ transplantations was one of the major 




(from 1992 onwards in Ireland), has hugely decreased the number of cases – 
however, this problem does persist for developing countries 24.  
There have been several incidents involving the iatrogenic transmission of 
HCV. The improper sterilisation of equipment, combined with the lack of 
knowledge about HCV, caused the extensive transmission of HCV genotype 
4 during a vaccination campaign to combat schistosomiasis in Egypt during 
the 1950s – 1980s. A number of epidemiological studies have estimated that 
between 7.3% - 14.7% of the Egyptian population are HCV+, making Egypt 
the country with the highest prevalence of HCV 25. During February 1994, the 
Irish Health Boards (now the Health Service Executive (HSE)) discovered 
that anti-D immunoglobulin used from 1977 to 1978 had been contaminated 
with HCV from a single HCV+ donor. Anti-D immunoglobulin is administered 
to pregnant women to prevent Rh (Rhesus) isoimmunisation and is derived 
from human plasma. In Ireland, the routine screening of blood donors for 
HCV antibodies started in October 1991, with a regional study of donors from 
1991 to 1994 identifying 14 men and 15 women with HCV antibodies. The 
women did not match the typical donor demographic (older age and mostly 
Rh-negative) and it was found that 12 of these women had received anti-D 
immunoglobulin in 1997. Further investigations uncovered the HCV genotype 
1b contamination of anti-D immunoglobulin distributed in 1997 and 1998, 
which was confirmed through reverse transcription PCR (polymerase chain 
reaction) of stored samples from the suspected infected donor. A chronology 
of the infected donor and contaminated plasma was established – from 
October 1976 to January 1977, plasma from the donor was used to prepare 
five batches of anti-D immunoglobulin, but in November 1976 the donor had 
an adverse reaction to a transfusion, became jaundiced, and was diagnosed 
with a hepatitis C infection. Additional samples of plasma were obtained from 
the donor in January 1977 and used to prepare more batches of anti-D 
immunoglobulin. In total, 16 batches of anti-D immunoglobulin were prepared 
from the infected donor in 1977, with eight of those batches testing positive 
for HCV RNA 26. In March 1994 62,667 women who had received anti-D 
immunoglobulin between 1970 and 1994 were screened for HCV, and 704 




704 women were positive for serum HCV RNA and were referred for further 
assessment and treatment. 376 women accepted the treatment, and 
biopsies showed hepatic inflammation for 98%, with moderate hepatic 
inflammation for 52%. 51% showed evidence of fibrosis, and 2% had 
confirmed cases of cirrhosis. The Hepatitis C Compensation Tribunal paid 
€310 million to victims by 1998, with the 2018 cost of the incident estimated 
to be about €1.5 billion for the compensation and legal costs of >4,500 
claims 6 27 28.  
IDUs represent a major risk group for contracting and spreading HCV. A 
study surveying HCV prevalence among IDUs across Asia suggested that 
HCV prevalence rates range from 41% of IDUs in Taiwan, to 74% of IDUs in 
Vietnam 29. Also, because IDUs can become re-infected despite undergoing 
treatment and achieving a sustained virological response, several economic 
evaluations have been carried about the prioritisation of HCV treatment for 
IDUs. A study conducted by Martin et al. using a mathematical model 
concluded that treating infected IDUs with moderate and mild fibrosis was 
more economical than delaying treatment to the development of cirrhosis. 
The study estimated that treating a single infected IDU with DAAs (direct-
acting antiviral) could prevent two HCV infections, for scenarios where the 
prevalence of HCV is 20% among the IDU population. However, for 
scenarios with higher HCV prevalence among IDUs - 40% and 60% - the 
number of prevented infections dropped to 0.78 and 0.23, respectively, 
because of the increased rate of secondary HCV infections – these 






Figure 3 – A graph demonstrating the relationship between money spent on HCV treatment 
and the increase of QALYs per treatment. The most beneficial and economic treatment 
option is the treatment of IDUs with moderate disease amongst an IDU population with 20% 
HCV infection. Figure sourced from Martin et al., 2016 30. 
In 2008 the Scottish government launched its Hepatitis C Action Plan with 
the goal of improving access to screening and treatment services and to 
prevent further HCV transmission - particularly among PWID (people who 
inject drugs). In Scotland, 85% of those infected with HCV were infected from 
injecting drugs 31. The Action Plan was funded with £100m and utilised local 
and national monitoring services. It also used predictive models to estimate 
treatment outcomes and set government targets. The introduction of dried 
blood testing helped drive a 50% increase in the proportion of the infected 
population diagnosed (from 38% before 2008 to 55% in 2015), and a large 
increase in the numbers of people introduced to treatment for HCV (470 to 
1,050 in 2015). There was a particular increase of treatment uptake among 
PWID, from 300 before the start of the Action Plan, to 840 as of 2015 32. A 
further study has been planned for 2019 onwards to evaluate the impact of 
DAA treatment for PWID involving an intervention site in Tayside, Scotland. 
In the Tayside site, HCV treatments have been expanded to include 
specialist treatment centres and needle and syringe exchange programmes 
(NSPs). From 2017 - 2018, 500 PWID were treated at the Tayside centre, 




Tayside area should be reduced from 26% to 10%. Treatment responses 
and re-infection rates are going to be monitored and compared to control 
sites in Scotland and England to evaluate the success of the programme 33. 
The worldwide prevalence of HCV infection among children is estimated to 
be 0.05% - 0.4% for developed countries, and 2% - 5% for developing 
countries, with vertical transmission and iatrogenic infection being the 
primary causes of paediatric HCV infections – however, intravenous drug 
use is a noted transmission route for adolescents in developed countries 34. 
Vertical transmission refers to the passage of pathogens or infectious agents 
through the placenta, through direct contact during the birthing process, or 
through breastfeeding. The United States has an estimated 23,000 – 46,000 
paediatric cases of HCV, with 34 iatrogenic HCV cases between January 
2008 and April 2013 35. The vertical transmission rate is estimated to be 2% - 
8%, with the risk factors being increased maternal viral load, intrapartum 
invasive procedures (foetal scalp blood sampling, etc.) and episiotomy 
procedures. Vertical transmission rates are increased for mothers with 
HIV/HCV co-infections, with the transmission rates estimated to be 15% - 
20% 36 37.  
The prevalence of HCV is higher amongst the prison population than the 
general population. In a 2018 study four prisoner groups (n = 46) from two 
prisons in Dublin were interviewed and asked about their knowledge of 
hepatitis C and barriers they had experienced with accessing HCV screening 
and treatment 38. IDUs are over-represented in the prison population 
compared to the wider community, with 26% of prisoners reporting having 
used intravenous drugs. A 2014 study of Irish prisoners found that HCV 
prevalence in Irish prisons was estimated to be 13% 39. A major barrier was 
lack of knowledge - it was found that the participants were aware of HCV, but 
were also aware of their ignorance about the modes of HCV transmission 
and the differences between HBV and HCV. Other barriers included the fear 
of invasive treatments and biopsies, and the delayed and bureaucratic 
process of screening and treatment - even when the participants were 
enthusiastic about engaging with the services. The participants also 




stigmatisation by other prisoners and the wider community when going to 
out-patient hospital appointments. The participants suggested an “opt-out” 
screening upon arrival as one method of improving access. The participants 
praised the fibroscanning (measurement of fibrosis and steatosis using 
ultrasound technology) procedure, stating that it was non-invasive and easy 
to access. Another major facilitator to HCV screening and treatment, was the 
removal of external stressors (eg. lack of accommodation and money) when 
incarcerated - once these needs were met by the prison service, participants 
were able to focus on treatment. DAA treatment has been found to be cost 
effective when used in the prison system and the prison system represents a 
valuable chance to treat and educate a large population of people with HCV 
40. 
1.1.2 Diagnosis 
The diagnosis of HCV infections is done through the detection of HCV 
antibodies and HCV RNA. If HCV antibodies are detected during initial 
examinations, HCV infection can be confirmed using a nucleic acid test 
(NAT) to detect the HCV RNA from the provided serum or plasma sample. A 
NAT is necessary because the presence of HCV antibodies could indicate an 
ongoing or a resolved infection, whereas the presence of HCV RNA is 
associated with a current infection. HCV antibodies are detectable 4 - 10 
weeks post-exposure, and HCV RNA becomes detectable at 2 - 3 weeks 
post-exposure 41. A surrogate marker known as a sustained virologic 
response (SVR) is used to evaluate the effectiveness of treatments, and 
refers to having no detectable HCV RNA 12 or 24 weeks (SVR12 or SVR24) 
post-treatment completion 42. However, many modern DAA treatment 
regimens can produce a SVR before 12 weeks – for example, Ohya et al. 
saw a SVR achieved in three paediatric patients at just four weeks of DAA 
treatment 43. The HSE website for the National Hepatitis C Treatment 
Programme states that most treatment regimens take between 8 – 12 weeks, 
with only a minority needing 24 weeks of treatment 44. HCV diagnosis is 
largely carried out by the detection of HCV RNA from serum or plasma 
samples, but recent advancements have seen the development of screening 




to perform than a traditional serum/plasma sample, and are convenient for 
locations with lower resources and/or high numbers of potential HCV patients 
45. Additionally, a number of quick and automated serological assays have 
been developed for the detection of hepatitis C core antigen (HCVAg) 
instead of the detection of HCV RNA. HCV RNA and HCVAg become 
detectable at the same stage of HCV infection, and both the WHO and EASL 
(European Association for the Study of the Liver) has declared HCV RNA 
and HCVAg assays as comparable for the diagnosis of HCV infection. 
Instead of screening for anti-HCV antibodies and then screening for HCV 
RNA, Galli et al. proposes that solely screening for HCVAg could be used to 
diagnose HCV infection. Galli notes that for chronic untreated HCV 
infections, HCV RNA has been observed to be detectable when <0.5% - 7% 
of HCVAg tests have shown target-not-detected (TND) depending on the 
method used – but this limitation could be balanced by the greater stability of 
HCVAg in biological samples, making it a convenient strategy for locations 
where samples are taken at point-of-care (POC) and sent to a central 
laboratory for processing 46.  
1.1.3 Treatment 
Historically, HCV infection was treated with a combination of ribavirin (RBV) 
and pegylated interferon-α (PEG-IFNα), over 24 or 48 weeks. Ribavirin is 
ribonucleic analogue and nucleoside inhibitor used to inhibit vRNA synthesis 
and mRNA capping. It can mimic guanosine or adenosine, causing mutations 
upon vRNA incorporation and incapacitating the virus. RBV has also been 
found to promote p53 activity through the ERK1/2 pathway 47. α-interferon, 
given as subcutaneous injections, was one of the first immunomodulatory 
agents used to treat HCV infection, and was approved as a treatment for 
NANBH in 1986 48 49. Interferons (IFNs) belong to the cytokine group of 
proteins and are produced as a response to the presence of pathogens, 
upregulating and activating numerous immunological pathways to combat 
infection. IFN-α is largely produced by plasmacytoid dendritic cells (pDCs). 
Interferon Alfa is the International Non-Proprietary Name for the 
pharmaceutical drug composed of natural IFN-α produced from human 




(PEG-IFN) refers to polyethylene glycol polymer chains that are added to the 
interferon molecule to improve various pharmacological properties, such as 
reducing the immunogenicity of IFN and improving circulatory time 50.   
However, there were several problems associated with PEG-IFN/RBV 
combination therapy. SVR rates remained suboptimal at 54-56%, and 
numerous contraindications to RBV prevented a significant percentage of 
patients from receiving the combination therapy. These contraindications 
included pregnancy, asthma, diabetes, thyroid disease, pulmonary diseases, 
and various autoimmune disorders. > 50% of those with HCV genotype 1 
infections had positive treatment outcomes after a course of the combination 
therapy. PEG-IFN became notorious for adverse events, with fever, 
headache, nausea, insomnia, alopecia, and musculoskeletal pain being 
common. There was also a risk of patients developing depression and 
psychosis, hepatic complications, and thrombi. It became apparent that 
numerous patients are unable to receive, tolerate, or complete PEG-
IFN/RBV combination therapy, and that treatment regimens that did not 
require interferon-α needed to be developed 51.   
Direct-acting antivirals (DAAs) represented a significant treatment 
advancement for those with chronic HCV infections. Once in vitro models for 
studying HCV were developed and the HCV genome could be characterised, 
a number of HCV non-structural proteins were identified as potential 
therapeutic targets. There are four categories of DAAs based on their 
mechanism of action and therapeutic targets – NS3/4A protease inhibitors 
(PIs), NS5B nucleoside polymerase inhibitors (NPIs), NS5B non-NPIs, and 
NS5A inhibitors 52. 
2002 saw the development of the first NS3 PI (BILN 2061, CILUPREVIR®), 
which showed promise at the start of the testing period. However, a number 
of adverse outcomes prevented further development 53. 2011 saw the 
approval of two oral DAA treatments – boceprevir and telaprevir. These 
protease inhibitor DAAs were combined with peg-IFN-α and RBV to form a 
“triple therapy” for patients with genotype 1 infections, with SVR rates 




combination treatment 54. However, there were several problems associated 
with this “triple therapy”. The treatment was expensive, demanded strict 
dietary requirements, and patients needed to take 9 – 18 tablets per day 55. 
In 2013, simeprevir (SMV) and sofosbuvir (SOF) were introduced to the 
market, becoming the first DAA treatments that only required a single tablet 
per day. Simeprevir and sofosbuvir were tolerable and produced SVR rates 
of >90% when combined, or with simeprevir/sofosbuvir and PEG-IFN/RBV. 
Simeprevir is a NS3/4A PI that was commonly used for genotype 1 and 
genotype 4 infections but demonstrated some effectiveness against 
genotype 2 and genotype 6. Sofosbuvir is a nucleotide analogue that targets 
the NS5B polymerase and was approved by the FDA for the treatment of 
genotype 1, 2, 3, and 4 infections when combined with RBV – PEG-IFN was 
optional depending on the genotype and patient. The release of simeprevir 
and sofosbuvir marked the advancement towards treatment regimens that no 
longer need PEG-IFN 56.  
At present, many therapeutic regimens are based on the combination of two 
or more DAAs, depending on the genotype and subtype of the HCV infection 
and the patient’s hepatic condition. For example, in 2019 the American 
Association for the Study of Liver Diseases (AASLD) has issued a simple 
algorithm for treating treatment-naïve patients that do not have cirrhosis 
which recommends glecaprevir (300mg)/pibrentasvir (120mg) taken for eight 
weeks in conjunction with sofosbuvir (400mg)/velpatasvir (100mg) taken for 
twelve weeks 57. RBV is not commonly used in treatment regimens, but there 
are circumstances where RBV may be added to a course of DAA treatments 
– for example, the 2018 EASL HCV treatment recommendations states that 
patients with decompensated cirrhosis without HCC and who are awaiting 
liver transplantation be given RBV based on their body weight for 12 weeks. 
Modern HCV treatment regimens are estimated to achieve >95% SVR, and 
represent a huge improvement when compared to the RBV and PEG-IFN-α 
combination treatment 55.   
Despite the vast improvements DAAs have made to HCV treatment, there 
are several outstanding problems. A notable criticism of DAAs has been the 




development of generic DAAs has improved access to DAA treatments, but 
the WHO emphasises that access must improve further to have a meaningful 
impact on the global burden of HCV 21. According to the Comptroller and 
Auditor General 2017 report, the cost of hepatitis C treatment in Ireland 
ranges from €23,000 - €92,000 – however the HSE’s National Hepatitis C 
Treatment Programme provides DAA treatment for free for patients 28 44.  
The considerable cost of DAA treatments has necessitated the prioritisation 
of particular patients. As described during Section 1.1.1, the treatment of 
chronic HCV among individual IDUs can reduce the incidence of HCV among 
the broader IDU population – but this is balanced by the risk that the treated 
individuals could relapse and become re-infected with HCV without proper 
support and treatment for drug dependencies. The 2016 European 
Association for the Study of the Liver (EASL) recommendations state that 
treatment should immediately be considered for patients with significant 
fibrosis (measured using the METAVIR system for assessing inflammation 
and fibrosis, with fibrosis being defined as a METAVIR score >F2) or 
cirrhosis (METAVIR score >F4), patients with significant extra-hepatic 
complications, patients with HCV reoccurrence post-transplantation, and 
patients that risk transmitting HCV to other individuals (IDUs, MSM (men-
who-have-sex-with-men), incarcerated individuals, and women who wish to 
become pregnant). IDUs and MSM should be encouraged to use 
preventative measures alongside DAA treatment. The recommendations also 
state that treatment is not advised for patients “with limited life expectancy 
due to non-liver-related co-morbidities) 58.  
The EASL recommendations also compare and contrast drug combinations 
for various HCV genotypes. For example, for genotype 3 infections, 
sofosbuvir + ribavirin is considered sub-optimal, and instead sofosbuvir + 
velpatasvir or sofosbuvir + daclatasvir is recommended. Ribavirin can be 
added to the above combinations, and the combination of peg-IFN/RBV + 
sofosbuvir remains acceptable when latest-generation DAAs are not 




Another consideration for DAAs is that several resistance-associated 
variants (RAVs) have been observed in vitro and during treatment. A 2016 
study examined GenBank HCV sequences and found that 58.7% of 
sequences examined had one dominant RAV. The highest RAV frequency 
was observed for genotype 6 sequences, (99%) with 50% of genotype 3 
sequences displaying a known RAV. 40% of the sequences examined had 
RAVs associated with NS5A inhibitors, and 29.6% had RAVs associated with 
NS3 protease inhibitors. That said, RAVs associated with NS5B inhibitors 
and nucleotide inhibitors (NI) were only detected among <4% of the 
sequences, supporting the suggestion that regimens using combinations of 
NI-based DAAs had the lowest prevalence of RAVs 59. The 2019 AASLD 
recommends NS5A RAV screening for genotype 3a patients before 
treatment commences, and states that those without the Y93H RAV can be 
treated with 12 weeks of sofosbuvir/velpatasvir, but patients with the Y93H 
RAV should be treated with glecaprevir/pibrentasvir or an alternative regimen 
57. 
Genotype 3 infections show greater resistance to DAA treatments when 
compared to non-genotype 3 infections. During the period of the PEG-IFN-
α/RBV combination treatment, genotype 3 was considered a treatable 
genotype, and ~70% of genotype 3a patients achieved SVR. However, 
genotype 3 has proven to be resistant to PIs and SOF. This poses a 
significant problem, as SOF forms the foundation of many treatment 
strategies, and was considered a pan-genotypic drug. SOF was thought to 
have a “genetic barrier” to drug resistance, but Ramirez et al. proved that 
substantial SOF resistance could be induced using a JFH1-based genotype 
3a model system. The RAVs demonstrated increased HCV persistence, and 
increased DAA resistance, including resistance to nucleoside analogues and 
non-nucleoside analogues. 60. A study conducted by Lawitz et al. 
demonstrated that genotype 3 infections treated with a SOF-RBV 
combination had a lower response rate compared to genotype 2 infections – 
56% versus 97% 61. Genotype 3a is associated with frequent and severe 
steatosis, increased fibrosis progression rates, and elevated incidences of 




estimated to account for 10% – 15% of chronic HCV infections, and is 
prevalent across European and IDU populations – therefore, the 
development of effective treatment strategies for genotype 3 infections is 
crucial.  
One potential strategy for the effective prevention and eradication of HCV is 
the development of a HCV vaccine – this is discussed in further detail in 
Section 1.5. 
1.2 HCV GENOME AND PROTEINS 
 
The HCV genome consists of approximately 9,600 nucleotides and encodes 
a polyprotein that is cleaved by virus and host proteases to produce three 
structural proteins (the core protein and the envelope glycoproteins E1 and 
E2) and seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, 
and NS5B). The 5’-UTR and 3’-UTR are located at the N-terminal and C-
terminal of the genome – a genomic conformation common among members 
of the Flaviviridae family.  
 
Figure 4 – The organisation of the HCV genome, demonstrating the position of the structural 
and non-structural proteins. The scale at the top of the figure indicates the number of 
nucleotides 63. 
1.2.1 Untranslated Regions 
The 5’-UTR and 3’-UTR are regions of vRNA that do not code for proteins 
but do have structural elements and sequences important for HCV 
translation and replication. The 5’-UTR is located at the N-terminal of the 
genome, and the 3’-UTR is located at the C-terminal.   
The 5’-UTR consists of 341 nucleotides located upstream of the translation 
initiation site of the ORF. The 5’-UTR is one of the most conserved regions of 
the HCV genome, showing ~90% nucleotide sequence identity among 




member of the Flaviviridae family and was previously known as the hepatitis 
G virus (HGV) 63 64. The 5’-UTR has four structural domains – Domain I, II, 
III, and IV. These domains have a number of conserved structural features, 
such as pseudoknots and stem-loops. The initial 40 nucleotides constitute 
Domain I and are needed for RNA replication. The remaining 5’-UTR 
domains and the start of the core protein constitute an internal ribosome 
entry site (IRES), which directs the cap-independent translation of HCV RNA 
65. Cap-independent translation refers to the fact that eukaryotic mRNAs 
have a 5’ cap structure to bind translation initiation factors, whereas virus 
mRNAs tend not to have a 5’ cap. Instead, these viruses using cap-
independent translation elements to initiate translation, and recruit translation 
initiation factors and ribosomal subunits to vRNA.  
Domain II and III contain multiple stem-loop structures, which are conserved 
across HCV genotypes and subtypes. The base of Domain III forms a 
structural pseudoknot – this pseudoknot is important for IRES activity, and 
forms part of the binding site for the 40S ribosome subunit. Domain IV has a 
stem-loop structure that houses a translation initiation codon, but this stem-
loop structure is not needed for the internal entry of ribosomes. In fact, one 
paper found that the stability of this structure was negatively correlated with 
the translation of HCV RNA, and proposed that the Domain IV stem-loop 
structure could instead regulate translation through a feedback mechanism 
66. The HCV IRES forms a stable pre-initiation complex through binding the 
40S ribosomal subunit without the need for typical translation initiation 
factors – this event probably constitutes the first stage of HCV polyprotein 
translation 63. 
The 3’-UTR contains 200 – 235 nucleotides and contains three distinct 
regions – a non-conserved variable region of 30 – 40 nucleotides, a 
polyuridine (polyU/UC) tract of 20 – 200 nucleotides, and a conserved region 
that forms three stem-loop structures and contains 98 nucleotides (known as 
the “X” region) 65 67. The variable region is located next to the termination 
codon of the HCV polyprotein. The variable region sequence composition 
varies between genotypes but is conserved among HCV isolates of the same 




eukaryotic mRNA needed for production of mature mRNA) but uses the 
poly(U/C) tract. The 3’-UTR is thought to be important for the in vivo 
infectivity of HCV. A “knockout” study of the 3’-UTR using infectious cDNA 
clones, deletion mutants, and the chimpanzee model found that HCV 
mutants lacking the poly(U/C) region and the “X” region were unable to infect 
the chimpanzee, implying that these two regions are critical for infection 68.  
1.2.2 Core Protein 
The mature form of the core protein is a 21-kDa protein that forms the HCV 
capsid. The capsid protects the genomic RNA as the virus moves throughout 
the host and can modulate several host pathways. The core protein has a α-
helical conformation for roughly 50% of the protein and can have two 
conformations based on the presence or absence of detergents – with 
detergents the protein assembles as dimers, and lacking detergents the core 
protein forms soluble aggregates. The core protein has two domains – D1 
and D2 – which are separated by their amino acid compositions and 
hydrophobicity. The D1 domain is located at the N-terminal and is 
hydrophilic, whereas the D2 domain encompasses the C-terminal and has 
hydrophobic properties.  D1 can be further divided into BD1, BD2, and BD3, 
(BD = basic domain), and D1 is thought to be involved with the 
oligomerisation needed for particle formation and RNA binding. The D2 
domain contains two α-helices, and is responsible for the core’s association 
with the endoplasmic reticulum (ER) and lipid droplet (LD) membranes 69 70. 
The synthesis of the core protein involves a number of stages. First, the core 
protein is cleaved at position 191 by host signal peptidase (SP) to separate 
the protein from the precursor polyprotein. The immature form of the core 
protein is cleaved by host SP peptidase (SPP) at the C-terminal 
transmembrane region – this generates the mature form of the core protein. 
The cleavage of the HCV core protein by host signal peptidases is essential 
for proper HCV assembly 71. The HCV core protein has a major impact on 
HCV pathogenesis, and has been shown to impact transcription regulation 




1.2.3 E1 and E2 Glycoproteins 
The HCV genome encodes two envelope glycoproteins – E1 and E2. These 
HCV glycoproteins contain N-terminal ectodomains and C-terminal 
hydrophobic transmembrane regions. E1 and E2 are Type I transmembrane 
proteins. Once cleaved by host signal peptidases from the precursor 
polyprotein, the ectodomains are targeted to the ER lumen, and the 
transmembrane domains are inserted into the ER membrane. The C-terminal 
of the immature core protein contains a signal sequence that assists the 
translocation of the E1 ectodomain to the ER lumen. Once the HCV 
glycoproteins have been synthesised and translocated, the glycoprotein 
transmembrane domains form a non-covalent heterodimer – E1E2. E1E2 is 
present on the surface of the HCV particle, and can be considered as the 
functional subunit of the HCV envelope, facilitating HCV entry and infectivity 
through interaction with surface molecules and receptors 73.  
The ectodomains of the glycoproteins are glycosylated - a property that 
impacts the folding and entry functions of E1 and E2, and can modulate host 
responses. E1 and E2 demonstrate N-linked glycosylation, which occurs 
when oligosaccharides are transferred from lipid intermediates to Asn 
residues within Asn-X-Thr/Ser sequences, where the X can be any amino 
acid except proline. E1 has six glycosylation sites, and E2 has eleven. A 
number of these N-glycosylation sites are conserved across HCV genotypes 
74 75. The physical and chemical structure of the glycoproteins has been hard 
to characterise. Separating E2 from the E1E2 heterodimer causes E1 to form 
misfolding aggregates, complicating structural analysis. Incomplete crystal 
structures of the E1 and E2 ectodomains have been proposed, and a 
number of research groups have used computational models to explore the 
unresolved sections. A number of disulphide bridges across the E1 and E2 
glycoproteins have been discovered, and a “heterohexamer/trimer” model 
was proposed by Falson et al. that supported by other groups and 
immunological and computational data 76 77.  
The sequence variation among the E1 and E2 glycoproteins can exceed 
37% between isolates. Because the glycoproteins are used for HCV entry 




development of preventative treatments. The extreme sequence variation 
can be attributed to the presence of three hypervariable regions (HVRs) on 
the E2 glycoprotein. HVR1 displays the greatest sequence diversity across 
the entire genome and consists of a 26 – 27 aa region at the N-terminus of 
E2. HVR2 and the inter-genotypic variable region (IgVR) are located 
proximal to the CD81-binging region and the transmembrane domain of E2 
respectively 78.  
1.2.4 Glycosylation of E1 and E2 
The ectodomains of E1 and E2 are highly glycosylated, with E1 having five 
conserved glycosylation sites and E2 having eleven glycosylation sites 
conserved across genotypes. Glycans account for a third of the molecular 
mass of the E1E2 heterodimer. Despite the large genetic diversity between 
genotypes and subtypes, the N-glycosylation sites tend to be conserved 
across genotypes and have been shown to modulate several functions of the 
envelope glycoproteins. N-linked glycosylation is the attachment of an 
oligosaccharide (a carbohydrate consisting of a number of sugar molecules 
and known as a glycan) to a nitrogen atom.  HCV particles are assembled in 
the ER, meaning that they must cross the secretory pathway before being 
released. As the HCV particle crosses the secretory pathway, the HCV 
glycoproteins are modified by glycosyl transferases and glycosidases. The 
first evidence of glycan modifications being related to the secretion of HCV 
particles came from the HCV pseudoparticle (HCVpp) and HCV cell culture 
(HCVcc) systems, with HCVpp E1E2 glycoproteins displaying complex 
glycans and HCVcc E1E2 glycoproteins displaying high mannose and 
complex glycans. The presence of complex glycans is associated with the 
movement of protein through the Golgi apparatus. HCVcc particles display 
immature glycans (implying that some glycans are not accessible to Golgi 
enzymes) and HCVpp particles display mature glycans. This corresponds to 
the fact that HCVcc articles assemble near the ER, whereas HCVpp particles 
assemble post-Golgi apparatus. 79 80  
Glycosylation is crucial for the proper assembly and release of HCV. For 
example, site-directed mutagenesis (SDM) was performed by Helle et al. to 




information. It was found that E2N8 was important for E1E2 folding and 
heterodimerisation, with E2N8 knockouts have poor infectivity. E2N6 
knockouts had the same infectivity and core release as the wildtype HCV, 
but were more sensitive to antibody neutralisation – see Table 1 for the 
breakdown of how glycan knockouts impacted HCVcc/HCVpp infectivity, 







Core Release Sensitivity to 
Neutralisation 
Wild Type +++ +++ ++ + 
E2N6 +++ ++ ++ ++ 
E2N7 +/- +++(+) + ND 
E2N8 - - +/- ND 
 
Table 1 – Findings by Helle et al. regarding the importance of E2 glycans using SDM 
techniques. Percentage of infectivity: +++ = >90%, ++ = 30% - 90%, + = 10% - 30%, +/- = 
2% - 10%. Percentage of core release: ++ = >75%, + = 30% - 75%, +/- = 12% - 30%. 
Sensitivity to antibody neutralisation: + = similar to wild type, ++ = >5x more sensitivity to 
antibodies tested. ND = not determined.81  
 
Besides serving a number of functions for the assembly of the virus, 
glycosylation of the HCV envelope glycoproteins protects epitopes from 
neutralising antibodies (nAbs). Known as “glycan shielding”, this strategy is 
used by several viruses to prevent nAbs from accessing sensitive epitopes. 
For HCV, the virus uses the host to synthesise the glycoproteins, meaning 
that the viral glycoproteins are recognised as “self” structures by the immune 
system. The physical and biochemical structure of the glycans also “block” 
access to the vulnerable antigens, providing a two-pronged defence.  
1.2.5 p7 
The HCV p7 protein is 63aa residue located between the E2 glycoprotein 
and the NS2 protein. p7 is Class IIA viroporin, meaning that p7 has two 
transmembrane regions that are separated by a cytoplasmic loop, and has 
both its N-terminal and C-terminal orientated towards the ER lumen. The 
transmembrane α-helices are known as TM1 and TM2. Because p7 displays 
high hydrophobicity and forms oligomers, it has been proposed that p7 could 
act as a pH-activated ion channel for HCV-infected hepatocytes. The 




alkalinisation of those organelles, protecting the HCV glycoproteins from mis-
folding and inactivation, and enabling the final stages of HCV assembly and 
escape 82 83. Experiments using mutational analysis have shown that p7 is 
needed for host infection 84. p7 is also involved with the process of capsid 
assembly and envelopment 85. 
1.2.6 NS2 and NS3 
The HCV NS2/3 protein is a hydrophobic protease responsible for the 
cleavage of the HCV polypeptide between NS2 and NS3. Extending from 
positions 810 – 1206, the NS2/3 protease is the first protease needed for 
HCV polyprotein processing, and the first NS protein that undergoes 
translation. The N-terminal of NS2 is cleaved from p7 using host signal 
peptidases, and the serine protease located at the C-terminus of NS3 is 
responsible for cleavage at the NS3/4A junction 86. HCV mutants without 
NS2/3 proteases were unable to cause persistent infections on the 
chimpanzee model, indicating that the NS2/3 protease is needed for HCV 
replication and persistence 87. Once cleavage at the NS2 and NS3 junction 
has occurred, the cleaved NS2 protein is moved to the ER membrane. From 
there, NS2 has been proposed to modulate gene expression and apoptosis, 
and contribute to the phosphorylation of HCV NS5A 88.  
NS3 protease activity depends on the presence of zinc ions – the ions are 
needed for hydrolytic activity and contribute to the structural integrity of the 
NS3 protein. Additionally, NS3 cooperates with NS4A to induce 
conformational changes that enhance hydrolytic activity 89. These hydrolytic 
and enzymatic changes enable NS3 to mediate the proteolytic release of 
mature NS4A, NS4B, NS5A, and NS5B proteins 90. A number of PIs 
targeting the NS3 and NS4A region have been developed, but amino acid 
substitutions (polymorphisms) across the NS3 domain can counteract these 
PIs 91.  
1.2.7 NS4A and NS4B 
NS3 and NS4A combine to create the NS3-4A complex, with NS3 providing 
the enzymatic activity and NS4A functioning as the co-factor. The NS3-4A 
complex cleaves host proteins – such as TC-PTP (T cell protein tyrosine 




transduction, which is needed for HCV replication. The NS3-4A complex can 
block innate immune responses by cleaving CARDIF (CARD adaptor 
inducing IFN-β) and TRIF (Toll-interleukin-1 receptor domain-containing 
adaptor inducing IFN), which are important for RIG-I (retinoic acid inducible 
gene I) and TLR (Toll-like receptor) cascades. The RIG-I and TLR pathways 
are crucial for the production of IFNs, and disruption of these pathways 
hampers the innate immune response 92.  
NS4B is a membrane protein possessing four transmembrane domains, and 
is cleaved from the HCV precursor polyprotein by NS3-4A serine protease 
activity. NS4B induces the membrane changes needed to form the 
membranous web. Once the changes are complete, the HCV replication 
complex associates and assembles using the membranous web. NS4B can 
also interact with other NS proteins, and displays NTPase activities 93.   
1.2.8 NS5A and NS5B 
NS5A consists of approximately 447 amino acids, and contains an N-
terminal amphipathic alpha helix and three structural domains – Domain I, II, 
and III. Two low-complexity sequences are found between the structural 
domains, and are known as LCS1 and LCS2. NS5A is a phosphoprotein, 
with hyperphosphorylation thought to act as the “switch” that regulates its 
functions (replication and formation of the HCV particle). Domain I contains 
Zn2+-binding and RNA-binding regions that are important for replication. 
Domain II has been associated with HCV replication. Domain III interacts 
with the core protein and is necessary for HCV assembly. Domains II and III 
appear to be unfolded domains, and can interact with several virus and host 
proteins 94 95. 
 
NS5B is a membrane-associated phosphoprotein and an RNA-dependent 
RNA polymerase (RdRp) 96. Because the HCV genome does not enter the 
host nucleus, an RNA polymerase must be encoded by the HCV genome to 
permit RNA synthesis. NS5B controls the synthesis of negative strand RNA 
from a positive strand template, and the negative strand becomes the 
template for RNA synthesis. The RNA templates can be stored for future 




important target for drug development. The catalytic site of NS5B does not 
tolerate many amino acid substitutions, being conserved throughout 
genotypes and subtypes. That said, a HCV isolate resistant to SOF (which 
targets NS5B) has already been described in vitro 97. 
1.3 HCV LIFECYCLE 
 
The entry and infection of HCV is thought to be mediated by interactions with 
host surface molecules, including CD-81, SR-B1, and LDLR, and other host 
receptors and proteins. CD-81 (cluster of differentiation – 81) is a member of 
the tetraspanin family of membrane proteins, and contains four hydrophobic 
transmembrane domains. The LEL (large extracellular loop) of CD-81 has 
been found to bind the E2 glycoprotein, and can mediate E2 binding to 
hepatocytes. The four cysteine residues present on the LEL create two 
disulphide bridges with the E2 glycoprotein, stabilising the interaction. A 
2000 study found that only 30% of the experimental CD81-HCV complexes 
were internalised – a low uptake suggesting that CD-81 was not the only 
host receptor responsible for HCV entry 98. SR-B1 (scavenger receptor class 
B – member 1), is a 509-aa integral membrane protein that enables the 
uptake of cholesteryl esters from HDLs (high-density lipoproteins). Because 
HDL originates from the liver, SR-B1 is found on hepatocytes – the primary 
target of HCV. HDLs and cholesterol are manipulated by a range of viruses 
to facilitate pathogenesis, including Dengue virus, another member of the 
Flaviviridae family. HCV E2 binds to hepatocytes via SR-B1, through the 
interaction of the SR-B1 LEL and the HVR1. SR-B1 and CD-81 have been 
found to cooperate to mediate HCV entry 99. CD81 and SR-B1 can be 
considered as the primary host receptors for HCV, but several other host 
receptors are thought to participate, including LDL-R, glycosaminoglycans, 
DC-SIGN and L-SIGN, and asialoglycoprotein receptors 63. 
The next stage covers involves HCV entry and fusion. The nucleocapsid of 
enveloped viruses is released into the cytoplasm through a fusion process 
that combines the virus envelope and endosome membrane. First, HCV 




These vesicles have clathirn and actin components. The actin components 
form the framework of the vesicle and clathirn components produce the 
coating. The endocytic vesicles mature and become endosomes, and the 
endosomes undergo the acidification process – this acidification process is 
what categorises HCV fusion as being pH-dependent. The acidic 
environment is thought to induce structural changes to the E1 and E2 
glycoproteins, exposing regions to host fusion peptides. The fusion of the 
virus membrane and endosome membrane causes the decapsidation of the 
HCV particle, and enables the HCV +ssRNA to enter the host cytoplasm 100. 
The HCV +ssRNA serves as mRNA for the synthesis of the HCV polyprotein. 
The IRES and a number of host proteins regulate the synthesis. Once the 
genome has been translated and the precursor polyprotein produced, the 
precursor polyprotein is targeted to the ER. There, the core protein and the 
E1 glycoprotein translocate the polyprotein to the ER lumen, where the 
polyprotein undergoes further processing by host signal peptidases. The 
signal peptidases cleave various segments of the polyprotein, causing the 
maturation and development of functional HCV proteins. This leads to the 
formation of the HCV replication complex. NS4B recruits the proteins needed 
to produce the membranous web, and NS5B RdRp initiates the replication 
process. The +ssRNA serves as a template for the negative strand 
intermediate. The intermediate becomes the template for positive strands, 
and the positive strands are used for polyprotein translation or packaged to 
form virus particles 101 63.   
The mechanism of HCV assembly and release has not been completely 
characterised, but the assembly and release process does appear to involve 
lipoproteins. LDs are storage organelles used for metabolic functions and 
membrane synthesis, and been shown to associate with the HCV core 
protein. Experiments that removed LDs from the model system found that 
virus production was hampered, and another experiment proposed that the 
core protein captured new RNA from surface of LDs, using the RNA from the 




1.4 HCV INFECTION AND THE IMMUNE RESPONSE 
 
HCV targets hepatocytes. Hepatocytes can be categorised as parenchymal 
hepatocytes and non-parenchymal cells (NPCs). NPCs include LSEC 
(sinusoidal endothelial cells), KCs (Kupffer cells), HSCs (hepatic stellate 
cells), and the population of immune cells that circulate throughout the 
hepatic system – such as DCs (dendritic cells), NKs (natural killer cells), 
lymphocytes, neutrophils, and monocytes. LSECs, HSCs, and KCs can 
express pathogen recognition receptors (PRRs) and respond to HCV 
infection 104 105. 
1.4.1 The Innate Immune Response to HCV Infection  
The initial detection of HCV infection is carried out by the innate immune 
system, which is composed of various receptors capable of recognising 
structures present on pathogens. These structures are known as PAMPs 
(pathogen-associated molecular patterns) and are recognised by various 
host receptors, such as TLRs (Toll-like receptors), RLRs (RIG-I-like 
receptors), and NLRs (NOD-like receptors). Once the specific PAMP has 
been recognised, these PRRs trigger the expression of genes for the 
inflammatory and immunological response. RIG-I or MDA5 (melanoma 
differentiation antigen 5) can recognise cytoplasmic ssRNA produced by 
HCV, and the HCV 5’-UTR and the polyU/UC region of the 3’-UTR are also 
considered to be HCV PAMPs.  
Once the PRRs have recognised the HCV PAMPs, the innate response is 
triggered. PAMP recognition by PRRs induces the activation of downstream 
pathways, which activate the production of cytokines, chemokines, IFN-I, and 
IFN-λ. IFN molecules are drawn to surface receptors and start a signal 
cascade that activates the JAK-STAT (Janus kinase – signal transducer and 
activator of transcription) pathway. The JAK-STAT pathway triggers the 
transcription and expression of genes that regulate apoptosis, oncogenesis, 
and immunological functions. The JAK-STAT pathway involves interactions 
between three components - a surface receptor, the JAK proteins, and the 
STAT proteins. The JAK proteins phosphorylate IFN receptors, and the 




STAT proteins act as transcriptional activators for ISGs (IFN-stimulated 
genes). The major advantage of using IFN molecules to activate responses 
is that the molecular components needed for the process are present from 
the start, reducing the delay between pathogen recognition the host 
response 106. ISGs have range of functions, from enhancing the detection 
and recognition of PAMPs by PRRs, to triggering an “antiviral state” that 
targets the ssRNA produced by HCV.  
Several virus species have evolved to target the JAK-STAT response and 
interrupt ISG activation, but activation of STING (stimulator of interferon 
genes) and/or MAVS (mitochondrial antiviral-signalling protein) can be used 
as another means of ISG production via the NF-κβ pathway. Once NF-κβ 
has been translocated to the nucleus, NF-κβ binds to specific sites on the 
IFN-β promoter and to promotors of ISGs.  
1.4.2 HCV Innate Immune Response Evasion 
HCV implements several strategies to modulate the host immunological 
response. MAVS is found throughout the membranes of mitochondria near 
the ER and forms an aggregate that recruits TRAFs (TNF receptor 
associated factors) to activate the downstream IRF (interferon regulatory 
factor) and NF-κβ processed required for IFN production. HCV NS3-4A 
protease can cleave MAVS near the transmembrane domain, preventing 
MAVS from starting IFN production 107.  
IFN receptors interact with JAK-STAT to transmit signals to the nucleus. 
Type I and Type III IFNs induce the transcription factors STAT1, STAT2 and 
IRF9. HCV can block the JAK-STAT pathway by having various regions (see 
Table 2) of the HCV genome bind STAT1, preventing STAT1 from activating 
the relevant ISGs 108. Table 2 summarises the proposed mechanisms 
employed HCV to evade the innate immune response, and further shows 
that the majority of the HCV genome has methods of inhibiting and 
suppressing the host response to infection.   
Viral Elements Possible Mechanisms 
Unknown Impair JAK/STAT signalling by inducing miR-373 to 




Core Impair JAK/STAT signalling by binding STAT-1 to block 
its phosphorylation and dimerization with STAT-2. 
Impair JAK/STAT signalling by inducing SOCS3. 
Suppress IRF1 transcription. 
E2 Inhibit PKR-dependent phosphorylation of eIF2a. 
NS2 Inhibit IRF3 phosphorylation by interacting with IKKε and 
TBK1 
NS3 Inhibit IRF3 activation by interacting with TBK1. 
Inhibit TNF-α induced NF-κβ activation via binding to 
LUBAC. 
NS3/4A Impair RLR signalling by cleaving MAVS. 
Impair TLR3 signalling by cleaving TRIF. 
NS4B Impair RLR signalling by disrupting interactions of STING 
and MAVS. 
Impair RLR signalling by disrupting interactions of STING 
and TBK1. 
Inhibit RLR signalling by suppressing STING 
accumulation. 
NS5A Inhibit IRF-7 activation via interacting with IRF-7.  
Impair JAK/STAT signalling by binding STAT-1 to block 
its function. 
Impair TLR-MyD88 signalling via binding to MyD88. 
Inhibit PKR activity via interacting with PKR. 
Interact with 2′–5′ OAS/RNase L to block its function. 
Table 2 – HCV strategies to avoid and modulate the innate immune response 109.  
 
1.4.3 The Adaptive Immune System 
Adaptive immunity can be considered the second stage of the immunological 
response and provides defence against specific antigens and pathogens. 
Adaptive immunity creates an immunological memory, which protects against 
subsequent infections from the specific pathogen. Adaptive immunity has two 
components – humoral immunity and cellular immunity. Humoral immunity 
refers to the aspects of the immune response that are mediated by 




immunity refers to the responses generated by phagocytes, cytotoxic T 
lymphocytes (CTLs), and cytokines.    
The adaptive immune response to HCV infection can take weeks to develop. 
HCV RNA can be detected around 1 – 3 weeks post-exposure, but HCV-
specific antibodies and CTLs can only be observed at around 1 – 2 months 
post-exposure.  
1.4.4 The Cellular Immune Response to HCV Infection 
CD4+ T helper cells and CTLs are both produced as a response to HCV. 
Macrophages, B lymphocytes, TNF-α, and DCs produce various types of 
interleukin (IL-12, IL-18, IL-6, etc.) which promote the growth and 
development of CD4+ T helper 2 (Th2) cells. Th2 mediates B lymphocyte 
activation, antibody production, and the regulation of Th1 responses.  
CTLs are generated from CTL precursors (naïve TC (cytotoxic T cells)) using 
three sequential signals. The majority of CTLs are CD8+ and target MHC 
Class I molecules. CTLs have two methods of triggering apoptosis. The first 
method is the cytotoxic protein pathway and uses granzymes and perforins 
to trigger endogenous apoptosis. The second method is the Fas ligand 
pathway and uses Caspase 1 to trigger DNA fragmentation. Cytokines are a 
group of soluble proteins that include chemokines, interferons, TNFs, and 
interleukins. Cytokines act as receptors that help coordinate the innate and 
adaptive responses to infection and are important for the clearance of HCV 
and removing damaged tissue.   
Depicted in Figure 5, a study of patients who resolved acute HCV infections 
found that a large amount of IFN-γ was detectable at the early disease stage. 
IFN-γ is a cytokine needed for the activation of macrophages and the 
induction of the Class II major histocompatibility complex (MHC), and is 
produced by NKs, NKTs (natural killer T cells), CD4+ Th1 and CTLs. The 
study observed that IFN-γ produced by CD4+ Th1 peaked at the very start of 
the disease state and continued once HCV had been cleared, becoming a 
persistent defence against infection 110. Those who resolved acute HCV 
infections or became “target not detected” showed broader CTL responses 





Figure 5 – A figure demonstrating HCV viral load versus ALT levels, presence of specific 
CTLs, and the presence of detectable IFN-γ over the course of an acute HCV infection. IFN-
γ production persists even after HCV decreases 112. 
1.4.5 HCV Cellular Immune Response Evasion 
One of the main reasons for chronic HCV persistence is thought to be the 
rapid development of HCV escape mutations, but there are several other 
factors that contribute to HCV persistence – namely CD8+ exhaustion and 
the HCV-mediated secretion and induction of regulatory cytokines and 
modulatory Tregs (regulatory T cells) 111.  
HCV-specific CD8+ responses are thought to be necessary for the control of 
HCV infection, as evidenced by in vivo CD8+ studies using chimpanzee 
models and functional analysis of the CD8+ responses of patients 
undergoing acute HCV infections 113. During a chronic HCV infection, the 
continuous exposure to HCV antigens is thought to contribute to the 
exhaustion of CD8+ functions. The study examining CD8+ responses during 
chronic HCV infections found that the expression of granzyme A (a serine 
protease released by NK and CTL cytoplasmic granules to trigger apoptosis) 
was decreased, TNF-α production was decreased, and CTLs were unable to 
properly degranulate when stimulated by peptides. The CTL effector 




impairments are not direct reason for the persistence of HCV, but contribute 
to the weakened immunological state that enables persistence 114.  
HCV interferes with the cytokine network by inducing Th2/Tc2 cytokine 
responses, causing inflammatory molecules to migrate to damaged tissue. 
Promoted by the presence of IFN-γ, hepatocytes infected with HCV secrete 
chemokines (such as the CXC chemokine ligands CXCL9, CXCL10, and 
CXCL11) that trigger the migration of non-specific mononuclear cells. CXC 
chemokines are a type of chemokine where the two N-terminal cysteines are 
separated by a single amino acid, represented by the “X”. The presence of 
these causes chronic inflammation and activates hepatic myofibroblasts and 
fibroblasts, leading to the development of fibrosis and cirrhosis. A number of 
extrahepatic diseases associated with HCV infection – such as thyroid 
disorders, type 2 diabetes, and mixed cryoglobulinemia – have been found to 
be connected to the dysregulation of the cytokine network and the induction 
of inflammatory chemokines 115.  
1.4.6 The Humoral Immune Response to HCV Infection 
As previously stated, humoral immunity refers to the aspects of the immune 
response that are mediated by antibodies (also known as immunoglobulins 
(Ig)), complement proteins, and antimicrobial peptides. Antibodies are Y-
shaped glycoproteins produced as a response to specific antigens being 
presented to plasma cells (also known as plasma B cells). An antibody 
consists of two Ig heavy chains and two Ig light chains bound together by 
disulphide bonds. Both heavy and light chains feature constant and variable 
domains. Two fragment antigen-binding (Fab) variable regions form the arms 
of the Y-shaped structure and – as the name suggests – are used to bind 
antigens. The end of the Fab arms contain the antigen-binding site (also 
known as a paratope) and are considered to be hypervariable regions due to 
the vast range of antibody paratopes that can be produced. The process that 
drives paratope diversity is known as V(D)J or VJ recombination. Three 
genes (variable (V), joining (J), and diversity (D)) are responsible for the 
antibody paratope, and these genes randomly recombine to produce a wide 
array of paratopes. The fragment crystallisable region (Fc) forms the stem of 




system through a conserved glycosylation site. The heavy Ig chain 
(encompassing the Fc region and the lower segment of the Fab regions) 
determine the isotype of the antibody - the isotype determines the broad 
function and location of the antibody. In humans, there are five major 
isotypes: IgA, IgD, IgG, IgE, and IgM.   
IgM is the first antibody produced as a response to antigen exposure and 
activates the classical complement pathway. The HCV capsid antigen is the 
first target of IgM 116. IgM can re-emerge during chronic HCV infections, as 
the body responds to what it interprets as a new HCV infection – instead, this 
re-emergence of IgM is evidence of the continual evolution of HCV antigenic 
epitopes 117. IgG first targets the HCV core protein, emerging almost at the 
same time as IgM. IgG accounts for about 75% of human serum antibodies, 
and is required for complement pathway activation, agglutination, toxin 
neutralisation, and several other immunological functions.    
During the HCV disease state, both neutralising antibodies (nAbs) and non-
nAbs are produced, targeting structural and NS HCV proteins. nAbs bind to 
surface structures of virus and other infectious agents to prevent the 
interaction with host surface receptors. nAbs “prevent” infection from viruses, 
and immunity from nAbs is also known as sterilising immunity. Non-nAbs do 
not neutralise infectious agents, but can contribute to the humoral immune 
response by flagging the infectious agent for downstream neutralisation by 
other components of the immune system. For example, a 2017 study 
performed by Long et al. found that non-nAbs induced a strong HCV-specific 
antibody-dependent CD56+ NK response in chronic HCV patients. NK 
antibody-dependent cellular cytotoxicity (NK-ADCC) is caused by the 
activation of the CD16 region on NKs by the Fc region of IgG bound to 
infectious agent. NKs bind the infectious agent and degranulate, releasing 
granzymes and perforin to lyse the target. Long et al. examined the NK-
ADCC responses of 31 chronic and untreated HCV patients and found that 
their NK-ADCC responses were significantly impaired compared to healthy 
controls – however Long et al. acknowledged that there was ongoing 
controversy about whether or not NK-ADCC responses and NK natural 




demonstrating unchanged or increased responses 118.  17 linear epitopes 
across the E1E2 glycoprotein for HCV genotypes 1b and 2a were generated 
for the study, with fiver epitopes shown to reduce a robust NK-ADCC 
response. Four of these epitopes did not overlap with known any putative 
neutralising epitopes, suggesting that non-nAbs form a part of the humoral 
response to HCV infection 119.  
The antibodies produced during acute HCV infections tend to target epitopes 
on the structural and NS HCV proteins, but during chronic HCV infections 
nAbs tend to only target epitopes on the HCV envelope glycoproteins and 
the E1E2 heterodimer. The ectodomain of E2 contains three regions that are 
targeted by nAbs; HVR1, HVR2, and the IgVR. HVR1 contains the dominant 
nAb epitopes, and the strongest E2 nAbs target the C-terminus of E2, where 
the E2 glycoprotein interacts with host SR-BI. Regions of the E2 glycoprotein 
that interact with entry factors (CD81 and SR-BI, etc.) are prime targets for 
nAbs. A percentage of nAbs that recognise conformational epitopes on the 
E1E2 heterodimer recognise epitopes for a range of HCV genotypes – these 
are known as broadly-neutralising antibodies (bnAbs). Because the HVR1 
mutates and produces numerous variants, nAbs that target the HVR1 tend to 
be target a single genotype. 120. The role of nAbs during acute and chronic 
HCV infections has not been completely characterised, but there are 
suggestions that nAbs can prevent subsequent infections. Chronic HCV 
patients have been found to show delayed nAb development, but the target 
range of nAbs does increase as time passes. Individuals that have 
detectable bnAbs at the acute stages of HCV infection have a greater 
chance of spontaneous clearance, and those who have experienced 
spontaneous clearance of one HCV infection have a greater chance of 
clearing subsequent infections 121 122.  
1.4.7 HCV Humoral Immune Response Evasion 
HCV evades the humoral immune response through genetic variation, the 
protection of vulnerable epitopes using glycosylation, the production of LVPs, 
and stimulating the production of competing antibodies. It has been proposed 




and non-nAbs, creating a form of competitive inhibition which prevents nAbs 
from accessing vulnerable epitopes. 
The extraordinary replication rate of HCV – estimated to be around 1012 
particles/day for chronic HCV infections – enables the virus to produce a 
huge range of variants resistant to nAbs. It has been shown that the 
evolution of the E1 and E2 glycoproteins (and HVR1) is strongly shaped by 
immunological pressure from nAbs, with Liu et al. demonstrating that for one 
individual the HVR1 remained stable for almost two years, but begun 
mutating once nAbs were introduced 123. It has been suggested that the 
HVR1 could act as an immunological decoy – the presence or absence of 
HVR1 does not impact entry and infection, but HVR1 is highly immunogenic 
and could serve to “distract” host nAbs from epitopes that are necessary for 
HCV 124.  
In 2014 Palmer et al. – using ultra-deep pyrosequencing (UDPS) – observed 
the emergence and disappearance of resistant HCV quasispecies over the 
course of 9.6 years of chronic and untreated HCV genotype 4a infection, 
identifying two primary lineages – L1 and L2. Ten samples were taken over 
the course of the 9.6 years (RL1 through RL10). L1 was further divided into 
three sub-lineages – L1a, L1b, and L1c. The group tracked the dominance of 
L1 over L2 for the first few years of the study, but L2 dominance began to 
occur as the L1 variants were suppressed by the host humoral system. It 
was found that L2 variants had a distinct evolutionary trajectory when 
compared to L1 variants. L2 variants showed a higher rate of synonymous (a 
single base substitution that does not change the amino acid produced) 
mutations, with dominant L2 variants demonstrating lower diversity but 
higher genetic stability. In contrast, L1 variants seemed to target IgG as their 
primary method of immune response evasion, with no IgG-targeting 
observed in the dominant L2 virions. The dominant L2 variants sampled from 
RL4, RL7, RL8, and RL10 varied by just a single synonymous mutation, 
implying the existence of host humoral immune pressure under which only a 
narrow range of L2 HVR1 variants could survive. Coupled with the L1 
variants undergoing an extinction event (driven by nAb evolution and 




variants, L2 emerged as the dominant quasispecies from RL7 to RL10 27. 
Naik et al. added to this research by examining four serum samples taken 
from the same untreated HCV genotype 4a patient, extending the study to 
thirteen years. The four samples taken showed the continued dominance of 
the L2 lineage, but that a new HVR1 variant had superseded the primary 
HVR1 variant 125.  
A number of conserved nAb epitopes have been discovered on the E1 and 
E2 glycoproteins, and two immunogenic domains covering the N-terminal 
and C-terminal regions of the HVR1 have been described, with the C-
terminal region being the primary HVR1 neutralisation determinant 126. 
However, glycosylation of the envelope glycoproteins appears to protect 
these conserved epitopes from nAbs – see Section 1.2.4 for further 
information 107 126.  
HCV particles circulate throughout the host as a mixture of LVPs and 
apolipoprotein B (apoB) subviral particles. These apoB particles only express 
the HCV envelope glycoproteins, meaning that they can become a target and 
distraction for nAbs and prevent the nAbs from reaching proper HCV 
particles 127. A number of studies have suggested that LVPs are resistant to 
nAbs and that LVPs are needed for the establishment of chronic infections – 
this suggestion is supported by research showing that low levels of LVPs 
during acute HCV infections are a predictor of spontaneous HCV clearance 
128. Chronic HCV infections are associated with reduced amounts of 
cholesterol and apoB (because they have been ‘hijacked’ by HCV to produce 
LVPs and subviral particles) causing increased rates of steatosis and 
fibrosis, and resistance to IFN-based therapies.  
1.4.8 HCV and Hepatic Immunity 
The liver has several unique immunological properties. For example, 
hepatocytes produce 80 – 90% of circulating innate immunity proteins. The 
liver must tolerate food antigens and molecules produced by the gut 
microbiome without wrongly producing an inflammatory response - but be 
able to respond to potential pathogens before they spread to the rest of the 
body. The liver houses the single largest population of macrophages (Kupffer 




macrophages in the human body. The liver is also enriched with NKs. Liver 
sinusoidal endothelial cells (LSECs) are responsible for removing soluble 
macromolecular waste from circulation and can detect microbial infection 
using PRRs 104. Blood arrives through the portal vein, where PRRs on KCs 
and hepatocytes bind to MAMPs and DAMPs and phagocytose and degrade 
the products to prevent the body from mounting an excessive immune 
response 129.  
KCs are equipped with a large range of PRRs, Fc receptors (a receptor that 
recognises the Fc fragment of antibodies) and complement receptors. KCs 
are derived from circulating monocytes, and have varied physiological and 
cytological characteristics depending on their location. For example, large 
KCs are present near the periportal region, where they have access to 
incoming pathogens. These large KCs also show higher production of TNF-α 
and IL-1 when compared to other KCs 130. TLR3 is an endosomal sensor of 
dsRNA expressed by KCs. TLR3 signals induce IRF-3 and NF-κβ to produce 
IFN, chemokines, and cytokines. Chemokine and cytokine induction from 
TLR3-HCV interactions has been shown to be delayed when compared to 
TLR3 interactions with other pathogens – HCV is an ssRNA virus, and that 
the dsRNA that TLR3 detects are replication intermediates produced late 
during the HCV lifecycle 131. TLR3 sensing of HCV could serve as an 
important secondary detection system once the primary RIG-1 detection of 
HCV has been completed 132. 
Dendritic cells (DCs) are antigen-presenting cells (APCs), and act as a 
bridge between the innate and adaptive immune systems by processing 
antigens and presenting them to T-cells to induce the adaptive immune 
response. Both myeloid (mDCs) and plasmacytoid (pDCs) are present in the 
healthy liver. mDCs secrete IL-12, IL-6, TNF, and chemokines, and display 
TLR2 and TLR4, whereas pDCs produce large amounts of IFN-α and display 
TLR7 and TLR9. Previously, the hepatic DC population was considered to be 
immature, but evidence has emerged that DCs can induce strong T-cell and 
cytokine responses. CD141(+) – a subtype of hepatic mDCs – has shown to 
produce increased levels of CD141 when compared to circulating mDCs 




circulating mDCs). The CD141(+) mDC population was also found to be 
severely depleted during hepatic disease, suggesting a role for CD141(+) in 
maintaining normal function 133.  pDCs detect HCV PAMPs and trigger the 
IFN response. The pre-treatment ISG mRNA expression patterns of patients 
with chronic HCV infections were examined by Stone et al. It was found that 
IFN was being produced endogenously. Patients with the favourable IFNL3 
SNPs tended to have higher levels of IFNL3 and lower levels of hepatic ISG - 
but increased macrophage ISG levels, suggesting that “bystander” 
uninfected hepatocytes can detect infected hepatocytes and produce IFN – 
“bystander” hepatocytes such as pDCs 134. This response can be triggered 
by sub-genomic HCV particles, implying that a type of RNA transfer process 
exists between pDCs and other hepatocytes, circumventing the “typical” 
pathogen recognition pathways 135.  
LSECs (also known as hepatic sinusoids) account for about 3% of the total 
hepatocyte volume, but are important components of the innate immune 
system. LSECs are responsible for the clearance of blood-borne waste, the 
mediation of lymphocyte migration across the sinusoidal endothelium and the 
prevention of fibrosis and steatosis. LSECs are characterised by their unique 
fenestrae (open pores), which are arranged across the LSEC surface in 
groups known as “sieve plates”. These fenestrae are crucial for filtration 
activities, but can become damaged during hepatic disease. Damaged 
LSECs lose their fenestrae, develop a continuous basal membrane (absent 
from undamaged LSECS), and acquire pro-inflammatory features 136. The 
loss of fenestrae is known as “capillarisation”, and is associated with the 
development of fibrosis 137. It has been demonstrated that the capillarisation 
of LSECs is furthered by the increased levels of liver X receptor alpha 
(LXRα) (a regulator of macrophage function and a modulator of steatosis 
development) – HCV core and NS5A proteins have both been shown to 
indirectly upregulate LXRα, meaning that HCV contributes to LSEC 
capillarisation and therefore the development of steatosis 138 139.  
1.4.9 Summary of HCV Infection and the Immune Response  
The immune response to HCV infection can be divided between the innate 




innate immune response. RIG-I or MDA5 recognise cytoplasmic ssRNA are 
crucial for the early detection of HCV. IFN is produced and activates the 
JAK-STAT pathway – responsible for the transcription and expression of 
genes that regulate apoptosis, oncogenesis, and immunological functions. 
APCs – such as the hepatic DCs – act as the bridge between the innate and 
adaptive immune response, and present antigens to T-cells. The adaptive 
response can be separated into cellular and humoral responses. The cellular 
response includes the production of phagocytes, CTLs, and cytokines. The 
humoral response refers to the antibody response to HCV infection. HCV has 
a number of methods to evade both the innate and adaptive immune 
responses – for example, blocking part of the JAK-STAT pathway, 
upregulating inflammatory responses to damage host tissues, and producing 
numerous HCV variants to evade nAbs, among other methods.  
1.5 HCV AND VACCINATION 
 
The development of both a prophylactic and a therapeutic HCV vaccine is 
important for combating the global HCV epidemic. Key to the development of 
an HCV vaccine is the identification of the immunological factors that enable 
~15% of people to experience only acute HCV infections and prevents the 
~85% of those from clearing chronic HCV infections. Therapeutic HCV 
vaccine development can be divided between those that concentrate on 
inducing strong CD4+ helper T and CTL responses during the acute stages, 
and those that focus on promoting the generation of functional nAbs. There 
are several obstacles impeding the development of an HCV vaccine – 
namely HCV’s extraordinary genetic diversity. There exists a broad range of 
vaccine strategies, such as recombinant, DNA, peptide, and vector designs.   
A recombinant protein vaccine is produced by isolating and purifying the 
pathogen proteins expressed by a model system. This system has the 
advantage of not having the actual pathogen. Experimental vaccines have 
attempted to use the E1 and E2 glycoproteins to generate the desired 
immunological response – for example, Innogenetics tested a prophylactic 




ceased development around 2007. Novartis tested a prototype vaccine 
combining the HCV core protein and the ISCOMATRIX adjuvant 140. Another 
study examining a vaccine generated from the HCVcc system found that an 
HCVcc particle combined with the K3-SPG adjuvant triggered the production 
of nAbs against HCV genotypes 1a, 1b, 2a, and 3a. The production of IFN-γ 
was also triggered as a response to the presence of the HCV core protein 
141. A research group examining a vaccine containing genotype 1 E1E2 and 
a MF59C.1 adjuvant found that the vaccine induced a “significant” response 
142. During the course of prophylactic vaccine studies on chimpanzees, 
researchers found that out of the chimpanzees that had been vaccinated but 
remained infected, 45.8% of the chimpanzees had been administered a 
vaccine using HCV NS proteins, compared to 13.8% that were administered 
vaccines using HCV structural proteins 143.  
An epitope (antigenic determinant) is the part of an antigen to which 
antibodies bind. Epitopes can be linear or conformational: linear epitopes are 
epitopes that are recognised through their primary protein structure (amino 
acid sequence), whereas conformational epitopes are recognised using their 
tertiary protein structure (3D structure). Identifying conformational HCV 
epitopes provides a means of avoiding the problem of HCV’s genetic 
diversity, as 3D structures have a greater chance of being conserved across 
genotypes and subtypes. An investigation of bnAbs derived from B 
lymphocytes taken from subjects with chronic HCV infections has identified a 
number of clusters of epitopes on E1E2. Four clusters are designated as 
antigenic domains A – D and are conformational epitopes on E2. There are 
two conformational epitope clusters defined as antigenic regions (AR) 4 and 
5, and antigenic domain E is another cluster containing linear epitopes 
located adjacent to the HVR1 144. A 2020 study examined the use of 
monomeric forms of E2 as a potential vaccine candidate. Previous work from 
the same group used an HCVcc-derived high molecular weight (HMW) form 
of E2 and found that it elicited a broad neutralisation response against the 
seven major HCV genotypes. The HMV form lacked the three variable 
regions of E2 (HVR1, HVR2 and IgVR) and was thus named Δ123-HMW for 




produced at low yields and did not have a homogenous composition. The 
2020 update to this study used sequential reduction and oxidation to improve 
Δ123-HMW yield and homogeneity, naming the new structure Δ123r. Δ123r 
largely retained the same immunogenic properties of Δ123-HMW – both 
showed strong reactivity to bNAbs with linear epitopes (those targeting 
AS412 and AS434, for example), but showed reduced reactivity to bNAbs 
with epitopes from the LEL of the CD81-binding domain and conformation-
dependent epitopes that are occluded by the assembled glycoprotein 145 146. 
A study focusing on HIV – another virus with notable antigenic diversity that 
uses glycan shielding to evade antibodies – found that they were able to 
“reverse engineer” a nanoparticle that improved B lymphocyte activation and 
guided bnAb maturation. The nanoparticle used the atomic, hydrophobic, 
and electrostatic features of promising bnAbs that targeted the HIV gp120 
and originated from the VH1-2*02 variable heavy gene. Further, the VH1-2 
genes are present across ~2% of the human Ab repertoire 147. This approach 
- targeting the structural conformation of the virus - represents a way of 
overcoming the sequence variations and evasion strategies of a broad range 
of viruses.  
For prophylactic HCV vaccines, a meta-analysis has been conducted on 
experiments using chimpanzee models for vaccine development. The study 
noted that humans and chimpanzees had a spontaneous clearance rate of 
83% for secondary HCV infections, compared to ~25% for humans and 
~38% chimpanzees for primary HCV infections. Prophylactic vaccines tested 
against chimpanzees were able to induce a memory response upon 
exposure to HCV and were somewhat able to control HCV replication. 
However, the duration of viremia was not shortened by vaccination, 
suggesting that the “natural” immunity produced during a secondary infection 
was superior to vaccine immunity. The vaccines that seemed to have the 
best rates of resolving infection included parts of E1E2 glycoprotein that 
induced nAbs, T cell responses, or a combination of both. That said, the 
induction of nAbs does not guarantee the success of the treatment. The 
analysis concluded that vaccines containing HCV structural proteins (core 




a prophylactic vaccine inducing complete immunity against HCV might not be 
possible – however, if the prophylactic HCV vaccine could reduce HCV 
persistence, natural immunity could be capable of clearing the virus 143 148.  
The advent of DAAs as an effective treatment for the majority of HCV 
patients has raised the question of whether an HCV vaccine – therapeutic or 
prophylactic – is needed. As Rosen argues, having a treatment or “cure” for 
a disease does not mean that the disease has been eradicated, as 
evidenced by the persistence of syphilis throughout the decades. Further, 
only widespread vaccination was able to completely eradicate smallpox and 
polio 149. The subsequent question arises of which patient populations should 
be chosen for expensive DAA treatment and potential vaccination. Among 
developed countries, IDUs continue to represent the largest source of 
chronic HCV infections, but this population is vulnerable to subsequent 
infections due to the use and sharing of drug paraphernalia. The use of 
vaccination once DAA therapy has been completed could be a powerful 
method for protecting against secondary infections and slowing the spread of 
HCV among the IDU population. Hahn et al. proposed that widespread 
vaccination could reduce chronic HCV incidence among IDUs to 2-7% thirty 
years after the vaccine’s introduction, contrasted to the 2009 chronic HCV 
incidence rate of 14-22% 150. In 2019 Scott et al. conducted a study 
examining the impact of a HCV vaccine on the feasibility and cost of 
achieving the WHO HCV elimination target of an 80% reduction in the 
incidence of HCV by 2030 in the age of DAA treatment. Projections were 
made for 2018 – 2030 for 167 countries and involved two population groups 
– PWID and the general community. Scott et al. found that only 0 – 48 of the 
countries modelled would be able to achieve the 80% reduction of HCV 
incidences by 2030 without a vaccine, whereas 15 – 113 countries would be 
able to achieve this goal if a 75% efficacious vaccine with a 10-year duration 
was available. The study found that the optimal way of deploying a potential 
vaccine would be alongside test-and-treat programmes and vaccinating 
adolescents from communities with high levels of transmission. The study 
also predicted that if a course of vaccination cost US$200, the cost of 




US$7.4 billion 151. Despite the effectiveness and increasing accessibility and 
affordability of modern DAA treatments, predictive models such as Scott et 
al.’s suggest that widespread elimination of HCV is unlikely without 
vaccination.  
1.6 METHODS OF STUDYING HCV  
 
1.6.1 In Vivo Systems 
One of the major obstacles to studying HCV infection has been the lack of 
appropriate systems that can support the infection and replication of HCV. 
The past decades have shown a distinct movement away from animal 
systems and towards in vitro systems. The chimpanzee system was among 
the first systems used for the studying of HCV – the 1989 isolation of a cDNA 
clone of HCV was derived from infected chimpanzee serum, for instance 18. 
Humans and chimpanzees are the only species that are susceptible to HCV 
infection. Despite the valuable information obtained from the chimpanzee 
system, growing financial, ecological, and ethical concerns about the usage 
of this system has led to many countries banning the use of chimpanzees for 
research purposes. In 2013, the European Union issued Directive 
2010/63/EU which restricts the use of great apes for research, “only for the 
purposes of research aimed at the preservation of those species and where 
action in relation to a life-threatening, debilitating condition endangering 
human beings is warranted, and no other species or alternative method 
would suffice in order to achieve the aims of the procedure”.  
One in vivo alternative to chimpanzees is the usage of murine models that 
have been altered and made susceptible to HCV infection. Rodents are 
resistant to HCV infection, but there are several ways to overcome this 
resistance, including genetic approaches, xenotransplantation, and the use 
of HCV homologs. Researchers investigated viruses that were related to 
HCV and capable of causing hepatitis among various species. GBV-B can be 
used to infect various species of New World monkeys, but the establishment 
of a persistent infection has proven troublesome. Recent deep sequencing 




hepaciviruses among dogs, horses, rodents, bats, and non-human primates 
– these new viruses could prove to  useful as homologs for HCV infection 152. 
Another strategy involves the genetic humanisation of the mouse model, 
removing barriers to HCV infection and introducing human HCV entry 
factors. One study introduced human CD81 and OCLN to render the 
transgenic mice vulnerable to HCV infection, but found that the adaptive and 
innate immune responses restricted HCV persistence. In response, the gene 
producing cyclophilin A was removed from the murine systems, enabling the 
infection and replication of HCVcc particles 153. Xenografts are a second 
method of making the murine system susceptible to HCV infection. The 
chimeric mice are generated by transplanting primary human hepatocytes to 
an immunodeficient mouse that has constitutive or introduced liver damage. 
Then, the human hepatocytes repopulate the damaged liver and can support 
HCV infection. The uPA-SCID mouse and the FRG mouse are the two 
dominant strains used for generating the chimeric mice, but TK-NOG and 
MUP-uPA have been shown to support HCV. However, both the humanised 
and chimeric murine systems need immunodeficiency, and might not 
produce an accurate image of the response to HCV infection 152. 
1.6.2 In Vitro Systems 
In vitro systems for studying HCV have been developed over the past two 
decades and have proven crucial for understanding the mechanisms of HCV 
infection and replication. These in vitro systems include sub-genomic 
replicons, the soluble E2 glycoprotein, HCV pseudoparticles, and HCVcc 
system. The first obstacle to the creation of in vitro systems for studying HCV 
was the identification of cellular systems that could support HCV infection. 
Primary hepatocytes from humans and chimpanzees could support HCV 
infection, but primary hepatocytes from baboons were not susceptible to 
infection. Peripheral blood mononuclear cells (PBMCs) were also permissive 
to HCV infection, but the PBMCs and primary hepatocytes did not display 
adequate efficiency and made for unsuitable systems. Additionally, primary 
hepatocytes could contain antibodies against HCV, reducing the infectious 
potential of HCV+ sera 154. To avoid these problems, a number of 




human hepatoma lineages Huh7, HepG2, and PH5CH were found to be very 
susceptible to HCV infection, – with Huh7 being particularly favourable for 
HCV replication 155.  
Liver biopsies taken from HCV-infected patients were tested as a potential in 
vitro HCV system. The liver biopsies underwent collagenase digestion to 
isolate the hepatocytes before infection, and the presence of HCV RNA was 
used to verify successful HCV propagation. However, the awkwardness of 
obtaining biopsy samples from patients and the poor reproducibility of the 
system meant that this approach was not pursued further 154.  In 1999, 
Lohmann et al. defined the minimal set of HCV proteins needed for the 
initiation and maintenance of in vitro HCV replication – the NS3/4A protease, 
the NS5A protein, and the NS5B were found to be indispensable for 
replication, and this discovery led to the creation of the subgenomic replicon 
system 156. The subgenomic replicon contains the HCV non-structural 
proteins expressed on an encephalomyocarditis virus (EMCV) construct, and 
an antibiotic resistance gene used for selection purposes. The replicon can 
then be introduced to various hepatoma lineages, enabling the identification 
of permissive lineages and adaptive mutations favourable for in vitro HCV 
replication. For instance, a clone harbouring one of the adaptive mutations 
identified using the subgenomic replicon system was found to be infectious 
to chimpanzees. The subgenomic replicon system has the advantage of not 
being restricted to specific HCV genotypes, and has been helpful for 
screening novel molecules for the presence of antiviral activity against HCV 
157 158. The production of soluble E2 glycoprotein ectodomain (sE2) is 
another method of studying HCV. The transmembrane region of the E2 
glycoprotein is removed, with the remaining E2 ectodomain retaining proper 
folding properties and having the ability to interact with the HCV entry 
receptors CD81 and SR-BI 158. Various culture systems have enabled the 
purification of the E2 ectodomain, with Tello et al. purifying 2 mg of the 
glycoprotein from 1 L of culture media 159. The sE2 system has enabled the 
further characterisation of the E2 glycoprotein, such as elucidation of the 
glycosylation pattern, oligomerisation state, and secondary structure of E2 




1.6.3 HCV Retroviral Pseudoparticles (HCVpp) 
The HCV pseudoparticle (HCVpp) system has emerged as one of the most 
successful methods for studying the HCV glycoproteins’ importance for virus 
entry and infection. The method involves incorporating the E1 and E2 HCV 
glycoproteins onto a lentiviral or retroviral core particle and the introduction of 
a reporter gene. This “three plasmid” system then forms a pseudoparticle 
which closely mimics the entry and infection capabilities of wildtype HCV 161. 
Bartosch et al. are credited with pioneering the HCVpp system, creating a 
functional and infectious genotype 1a pseudoparticle around March 2003. 
The pseudoparticle used genotype 1a E1 and E2 glycoproteins derived from 
a pTM1p5E1E2(745) plasmid, and inserted those glycoproteins onto a CMV-
Gag-Pol murine leukaemia virus (MLV) packaging vector, coupled with a 
MLV-GFP plasmid to act as the reporter gene. Gag and pol are two of the 
three major proteins encoded within the retroviral genome – gag (an 
acronym for group antigens) codes for the core structural proteins of a 
retrovirus, whereas pol acts as the reverse transcriptase needed for 
replication. Together, the gag and pol of the MLV (a retrovirus) plasmid 
package and form the functional pseudoparticle. The reporter plasmid 
consisted of a second MLV construct containing green fluorescent protein 
(GFP). 293T HEKs were transfected with the three plasmids to produce the 
pseudoparticles, and a range of infection assays were carried to measure the 
infectivity of the pseudoparticles. The assays showed that the 
pseudoparticles were highly infectious and showed a distinct preference for 
hepatocytes. Importantly, Bartosch et al. now had a system that could 
reliably produce infectious pseudoparticles 162. Since 2003, the 
pseudoparticle system has been verified by numerous laboratories. MLV and 
HIV are both used the retroviral packaging vectors, and GFP and luciferase 
are used for the reporter gene. Importantly, the HCVpp system works across 
numerous genotypes and subtypes.  
However, there are disadvantages to the HCVpp system. Generation of 
pseudoparticles using E1 and E2 glycoproteins from infectious/patient-
derived HCV samples does not guarantee that the pseudoparticle produced 




clones originating from 63 patients that contained complete E1E2 ORFs, with 
118 clones found be infectious. Despite this, only 78 pseudoparticles were 
produced, and several of the clones were found to be incompatible with the 
pseudoparticle system. Additionally, it was found that the pseudoparticles 
were more vulnerable to neutralisation when compared to corresponding 
HCVcc chimeras, meaning that findings from the pseudoparticle assays 
would need to be validated using the HCVcc system 163. Similarly, Lavillette 
et al. found that only 24 infectious pseudoparticles could be produced from 
88 clones, and found that the infectious titres of genotype 3 pseudoparticles 
were over a log lower than pseudoparticles derived from other genotypes 164.   
Despite these problems with the pseudoparticle system, Urbanowicz et al. 
has made progress with optimising the system and identifying the factors that 
prevent patient-derived clones from becoming functional pseudoparticles. 24 
– 27% of glycoprotein clones had been previously reported to yield infectious 
pseudoparticles, but Urbanowicz et al. found that the packing vector used 
had a distinct influence on the infectivity of the pseudoparticles. It was found 
that the infectivity phenotype of HCVpp generated from MLV packaging 
vectors was not the same as the infectivity phenotype of HCVpp generated 
from HIV packaging vectors. The quantity used of the packaging vector was 
also important for the production of functional particles, with the greatest 
incorporation of the E1E2 glycoprotein observed at 1.6 µg and 8 µg of 
packing vector 165. In 2019, Bailey et al. published an updated standardised 
protocol for producing HCVpp, with the latest recommended reagents and 
two specific transfection protocols for HIV Gag and MLV Gag packaging 
vectors 166. Additionally, Soares et al. demonstrated that co-expression of a 
p7NS2 ORF alongside HCVpp could enhance the infectivity of HCVpp. The 
exact mechanism of the increased mechanism was not defined, but Soares 
et al. were able to eliminate increased virus particles and increased envelope 
density as the causes of the increased infectivity 167. The HCVpp system 
remains one of the most important systems for studying HCV and has been 
used to investigate various aspects of HCV entry and host receptors, 




investigate the interaction between antibodies and the entry pathways of 
HCV. 
1.6.4 Cell Cultured HCV (HCVcc) 
The HCVcc system represents another model for studying HCV and 
originated from a genotype 2a isolate taken from a Japanese patient with 
fulminant hepatitis – this clone was named JFH-1. Kato et al. extracted the 
total RNA from the patient and produced 14 fragments of HCV cDNA 
covering the entire HCV genome. The non-structural proteins were selected 
and assembled to form subgenomic replicons (Figure 6), which were 
introduced to Huh7s. It was found that the JFH-1 subgenomic replicon 
(pSGR-JFH-1) was capable of replication and could transmit G418 
resistance (G418 was the selective antibiotic used during this study) during 
replication. pSGR-JFH-1 displayed superior colony formation efficiency when 
compared to an adapted mutant construct, and was the first successful 
subgenomic replicon to be derived from a genotype other than HCV 
genotype 1 168. Studies have shown that the JFH1 HCVcc isolate has the 
ability to replicate in vivo using the chimpanzee model, with the chimpanzees 
developing symptoms that mimic the symptoms of chimpanzees infected with 
HCV derived from infected humans 169. 
 
Figure 6 – A comparison of the complete JFH-1 genome and the sub-genomic pSGR-JFH-1 
replicon assembled by Kato et al. 168 
 
Since Kato et al., the HCVcc system has expanded to include other HCV 
genotypes. Gottwein et al. managed to produce an intergenotypic 3a/JFH1 
recombinant with the core, E1, E2, p7, and NS2 proteins from the genotype 




putative adaptive mutations, and only two of the nine recombinants with 
mutations were viable. However, the 3a/JFH1 recombinants proved useful 
for studying the dependence of HCV infection on CD81, and provided a 
means of studying therapeutics targeting the HCV genotype 3a core and 
NS2 proteins 170. It has also been found that clones that were not viable 
when produced by the pseudoparticle system could become viable and 
infectious once transferred to the HCVcc system 171. Biophysical studies of 
HCV and potential vaccine development requires the generation of 
concentrated and purified HCVcc stocks – however, culture conditions for 
HCVcc tend to include foetal bovine serum (FBS), which impedes the 
production of purified stocks. Mathiesen et al. have had success producing 
HCVcc particles using serum-free culture conditions, and found that the 
serum-free HCVcc (sf-HCVcc) were 0.6 – 2.1 log10 more infectious than 
HCVcc produced using media supplemented with FBS 172. One disadvantage 
to the HCVcc system is the use of intergenotypic NS5B – NS5B influences 
the replication efficiency of the completed HCVcc construct, and it has been 
found that introducing intergenotypic NS5B can cause the HCVcc construct 
to have reduced replication efficiency or become completely nonviable 173.    
1.7 THESIS RESEARCH SUMMARY 
 
The hypothesis for the thesis states that epitope mapping antibodies isolated 
from patient-derived antibody-associated virus (AAVs) complexes can be 
used to identify conserved HCV epitopes.  
In chronic HCV infections, the body produces antibodies against HCV. 
However, the host Abs are inefficient and further drive the evolution of the 
circulating HCV quasispecies population. HCV variants resistant to the 
current iteration of host Abs become the dominant variant in the population 
through selective pressure, and the infection perpetuates. The host antibody 
response is not enough to clear a chronic HCV infection, but host Abs can 
and do bind to circulating HCV variants. Complexes of antibodies and virus 
particles are detectable in the blood of patients with chronic HCV infections 




AAVs – where a host antibody has bound to HCV – could identify conserved 
viral structures and reveal vulnerable HCV epitopes. Using techniques based 
on previous research carried out by Molecular Virology Research and 
Diagnostic Laboratory (MVDRL), Department of Medicine, University College 
Cork, the antibodies could be cleaved from the AAVs and examined. Twenty 
HCV genotype 3a serum and plasma samples were obtained from the 
National Virus Registry Laboratory (NVRL) and from the MVDRL. HCV 
genotype 3a was chosen for this research project given its prevalence 
(estimated to be 17.9% worldwide), resistance to treatment, and increased 
risk of causing severe steatosis and HCC 174. IgG was cleaved and purified 
from the AAVs isolated from the patient samples. The antibodies were then 
used for a series of in vitro neutralisation experiments on HCV 
pseudoparticles generated using the HCV H77 isolate. H77 (GenBank: 
AAB67037.1) is an infectious genotype 1a isolate that has undergone 
complete genome sequencing. The antibodies that showed the greatest 
neutralisation potential against the H77 pseudoparticles were selected for 
epitope mapping. The epitope mapping tested the selected samples against 
a synthesised H77 E2 glycoprotein structure, and characterised the sites 
where the antibodies bound to the E2 structure. The epitope mapping 
procedure identified the conserved epitope 
532NDTDVFLLNNTRPPPLGNWFGC553. However, this sequence contains 
two glycosylation sites (E2N6 and E2N7), with a third glycosylation site 
(E2N8) positioned nearby. The presence of these glycosylation sites may 
prevent nAbs from accessing this conserved epitope. This characterisation 
provided insight into vulnerable epitopes on the HCV E2 glycoprotein and the 







The reagents and materials used during this research project were stored 
and prepared according to the manufacturer’s recommendations. 
2.1.1 Reagents 
Name Producer 
6X DNA Loading Dye ThermoScientific 
100 mM dNTP Set Biosciences Ltd. 
Ab Buffer Kit GE Healthcare 
Agarose Sigma-Aldrich 
Biotinylated Molecular Weight Marker Sigma-Aldrich 
Bovine Serum Albumin Sigma-Aldrich 
Bright-Glo Luciferase Assay System Promega 
Brilliant Blue Sigma-Aldrich 
Calcium Phosphate Transfection Reagent Invitrogen 
Cell Freezing Media Sigma-Aldrich 
Dulbecco’s Modified Eagle Medium – High Glucose Sigma-Aldrich 
Dulbecco’s Phosphate-Buffered Saline Sigma-Aldrich 
Ethanol – BioUltra, For Molecular Biology - ≥99.8% Sigma-Aldrich 
Foetal Bovine Serum Sigma-Aldrich 
Gel Loading Dye, Blue (6X) NEB 
GeneRuler 1kb DNA Ladder ThermoScientific 
GeneJET PCR Purification Kit ThermoScientific 
Glo Lysis Buffer (1X) Promega 
HEPES-Buffered Saline Sigma-Aldrich 
IgG (Total) Human Uncoated ELISA Kit Invitrogen 
illustra™ Ready-To-Go™ GenomiPhi™ V3 DNA 
Amplification Kit 
GE Healthcare 
Luria-Bertani Broth Sigma-Aldrich 
Luria-Bertani Agar (Lennox) Sigma-Aldrich 




Phosphate Buffered Saline Sigma-Aldrich 
Protein G HP SpinTrap GE Healthcare 
One Shot Top10 Chemically Competent E. coli Invitrogen 
QIAamp Viral RNA Mini Kit Qiagen 
QuikChange Lightning Site-Directed Mutagenesis Kit Agilent Tech 
Random Hexamer Primers ThermoScientific 
SuperScript ® II Reverse Transcriptase Invitrogen 
SYBR ® Safe DNA Gel Stain Invitrogen 
Taq DNA Polymerase – Recombinant Invitrogen 
Trizma® (TRIS Base) Sigma-Aldrich 
Trypan Blue Solution 0.4% Sigma-Aldrich 
Trypsin-EDTA Solution Sigma-Aldrich 
Water – Molecular Grade Sigma-Aldrich 
     
2.1.2 Patient Samples 
HCV genotype 3a samples were sourced from the National Virus Registry 
Laboratory (NVRL), Dublin and from the Molecular Virology Research and 
Development Laboratory (MVDRL), Cork. Patient samples were consented 
for research purposes. Patient information was appropriately anonymised 
before being transferred to this project and any information was stored 
securely.  
Sample ID Date of 
Collection 




A 10/11/2016 NVDRL 5.84 - 
B 11/01/2016 NVDRL 6.02 - 
C 08/02/2016 NVDRL 5.12 + 
D 05/12/2015 NVDRL 4.79 - 
E 07/11/2016 NVDRL 5.59 - 
F 08/02/2016 NVDRL 6.33 - 
G 24/01/2016 NVDRL 4.19 + 
H/J 13/09/2016 NVDRL 6.85 + 
I/K 13/09/2016 NVDRL 5.96 - 




M 20/09/2016 NVDRL 6.24 + 
N 20/09/2016 NVDRL 5.35 - 
O 25/10/2016 NVDRL 5.44 - 
246 31/03/2011 MVDRL 6.57 - 
859 28/01/2010 MVDRL 4.70 - 
425 01/07/2010 MVDRL 4.91 + 
718 03/12/2009 MVDRL 6.28 - 
690 06/11/2009 MVDRL 5.18 - 
502 16/06/2011 MVDRL 6.74 + 
052  MVDRL ~6.00 + 
 
2.1.3 Oligonucleotide Primers 
Primer Name Tm (°C) Sequence 
OR(I-II) 53.7 5'-ATGGCATGGGATATGAT-3' 
OF (I) 47.3 5'-AAGGCCGTCCTGTTGA-3' 
IF(I) 49.9 5'-GCATGGGATATGATGATGAA-3' 
IR(I-II) 52.4 5'-GTCCTGTTGATGTGCCA-3' 
Core FWD 64.4 5'-CTTGTGGTACTGCCTGATAGGGTG-3' 
Core REV  5'-CCARYTCATCATCATRTCCCANGCCA-3' 
REV Spec2 59.0 5'-GGTTCTTGTCCCGGCCTGTGAGG-3' 
HCV Mod FWD 66.7 5'-CACCATGGGTTGCTCYTTYTCTATCTTCC-3' 
HCV pcDNA REV 61.4 5'-TTATATCATBAGCATCARCCARARRGC-3' 
NSREV1 61.4 5'-AGYTCTRTBAGYCCYGCDGC-3' 
NSREV2 58.0 5'-YTYGCDACRGCRAGYTCTRT-3' 
E2REV1 54.2 5'-HTTCAGRYTGACBAGYTTCT-3' 
E2REV2 59.3 5'-BAGYTTCTCCAHYGCRGCRT-3' 
 
2.1.4 Plasmids 
MLV gag-pol packaging vector and phCMV-ΔC/E1/E2 H77 constructs, used 
to produce HCV pseudoparticles, were acquired through a previous research 
project at the MVDRL, and originated from a material transfer agreement 




la Recherche Médicale), France. The MLV luciferase reporter vector was 
also acquired through a previous research project at the MVDRL, and was a 
kind gift from Dr. Arvind Patel, CVR (Centre for Virus Research), University 
of Glasgow, Scotland.   
2.2 AGAROSE GEL ELECTROPHORESIS 
 
Products from PCRs were analysed using the agarose gel electrophoresis 
technique. Agarose gel electrophoresis uses the principle that nucleic acid 
molecules possess a negative charge, and molecules with negative charges 
tend to migrate towards a positive charge. The agarose gel matrix means 
that the nucleic acid molecules are separated out by molecular weight during 
this migration to the positive charge. A 1% agarose gel was prepared by 
microwaving 0.5 g agarose with 50 ml 1X tris-acetate ethylene diamine tetra 
acetic (TAE) buffer. 50X TAE buffer was prepared using 40 mM Trizma® 
base (Sigma-Aldrich), 20 mM glacial acetic acid, and 1 mM ethylene diamine 
tetra acetic acid (EDTA), and then appropriately diluted using dH2O to 
produce 1X TAE buffer. SYBR Safe DNA Gel Stain (ThermoScientific) was 
added prior to casting the 1% agarose gel at 2 µl per 50 ml – the SYBR Safe 
DNA Gel Stain is necessary for visualising the products under UV. The 
products were analysed next to either the GeneRuler™ 100bp DNA Ladder 
(100 – 3,000bp) or the GeneRuler™ 1kb DNA Ladder (250 – 10,000bp), 
depending on the expected size of the product. 10 µl of the PCR product 
were added to 2 µl 6X DNA Loading Dye (ThermoScientific), mixed 
thoroughly, and loaded onto the agarose gel. The power supply was set at 
80 - 100 V and 80 - 100 mA for 35 – 45 minutes. The products were 
visualised and photographed using the AnalytikJena UV/White 
transilluminator and the UVP VisionWorks® software.  
2.3 PROTEIN G COLUMN AFFINITY CHROMATOGRAPHY 
 
The Protein G HP SpinTrap™ (GE LifeSciences) columns were used to 
screen the samples for AAV and for the purification of VF-FAbs. The 




protein G columns have a high binding capacity for the Fc region of IgG from 
a variety of species. The column membrane captures the IgG, and the 
antibody can be eluted once the remaining components have been washed 
through the column. The column must be shaken vigorously to re-suspend 
the storage medium before starting. The end closure was removed, and the 
storage medium removed by centrifugation for 30 seconds at 70 – 100 x g. 
600 µl binding buffer was added to the column, and removed by 
centrifugation. A maximum of 600 µl of the serum or plasma sample was 
added to the column and incubated at room temperature for 4 minutes on the 
end-over-end rotator. Centrifugation was used to remove the sample once 
the incubation period was complete. 5 – 8 column washes were carried out 
using 300 µl binding buffer. The final wash was saved to confirm that there 
was no remaining virus being washed through the column before the elution 
step. Once the washes were completed, 400 µl elution buffer was added to 
the column, and the column placed into 1.5 ml microcentrifuge tube 
containing 30 µl neutralising buffer. The neutralising buffer contained sodium 
azide to preserve the elute and prevent contamination. The column was 
incubated at room temperature for 1 minute and centrifuged for 1 minute at 
70 – 100 x g to elute the desired sample. The elution step was repeated to 
extract the remaining antibody. The elutes were stored at -20 °C.  
2.4 VRNA EXTRACTION 
 
vRNA isolation was carried out using the QIAamp Viral RNA Mini Kit 
(Qiagen). Carrier RNA was used to enhance the binding of target RNA to the 
QIAamp column, and to reduce vRNA degradation during the denaturing 
phase. First, the recommended volume of carrier RNA and buffer AVE was 
added to the recommended volume of buffer AVL. 140 µl of the sample was 
added to the mixture, mixed by pulse-vortexing, and incubated at room 
temperature for 10 minutes. This step denatured the sample and inactivated 
any potential RNases. 560 µl 96 – 100% ethanol was added, mixed by pulse-
vortexing, and 630 µl of the mixture applied to the QIAamp column. The 
QIAamp column uses a silica-based membrane, which has selective binding 




filtrate discarded. This step was repeated, and 500 µl of buffer AW1 was 
applied to the column. Buffer AW1 and AW2 were washes designed to 
remove proteins, nucleases, and contaminants from the product. The column 
was centrifuged at 8,000 RPM for 1 minute, the filtrate discarded, and 500 µl 
of buffer AW2 was added. The column was centrifuged at 14,000 RPM for 3 
minutes, and an optional secondary centrifugation step at 14,000 RPM for 1 
minute was included to remove any residual buffer AW2. The QIAamp 
column was placed into a 1.5 ml microcentrifuge tube, 40 µl of buffer AVE 
was added, and the column was incubated at room temperature for 1 minute. 
Buffer AVE contained 0.04% sodium azide to prevent microbial growth and 
contamination of the RNA product. The column was centrifuged at 8,000 
RPM for 1 minute, and the elute from this stage contained the vRNA. A 
second 40 µl elution using the same conditions was performed to improve 
the RNA yield. The vRNA was immediately stored at -20°C once eluted.  
2.5 CDNA SYNTHESIS 
 
cDNA synthesis from the isolated vRNA was carried out using a previously 
optimised RT-PCR protocol and using SuperScript ® II Reverse 
Transcriptase (Invitrogen). 11 µl of vRNA was mixed with 1 µl of random 
hexamer primer (ThermoScientific) and incubated at 75°C for 10 minutes. 
The tubes were quickly added to “slush ice” as 8 µl of the reaction mixture 
(Table 3) was added. Keeping the tubes cold ensured that the RT-PCR did 
not progress any further during the brief interruption. The samples were 
returned to the thermal cycler and incubated at 42°C for 60 minutes, and the 
reverse transcriptase was inactivated by incubation at 95°C for 3 minutes. 
Table 3 – Components and Reaction Parameters for cDNA Synthesis - Per One Reaction 
Reaction Component Volume (µl) 
5X First Stand Buffer 4.0 
0.1 M DTT 2.0 
10 mM dNTP  1.0 




SuperScript ® II Reverse 
Transcriptase 
0.25 
Nuclease-Free H2O To 20.0 
 





2.6 320BP REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR) 
 
The 320bp RT-PCR was used during the project to verify the presence of 
HCV and for generating the initial sequence information for the patient 
samples. RT-PCR involved synthesising cDNA from vRNA (per Section 2.5) 
and using a nested PCR approach to amplify a 320bp region which spanned 
the junction of the E1 glycoprotein and the E2 glycoprotein. The nested PCR 
approach was used to reduce the frequency of non-specific binding. This 
specific RT-PCR protocol had been previously optimised by the Molecular 
Virology Research and Diagnostics Laboratory, University College Cork. 
Table 4 - Components and Reaction Parameters for the Primary RT-PCR – Per One 
Reaction 
Reaction Component Volume (µl) 
10 pm/µl “OF” FWD Primer 1.5 
10 pm/µl “OR” REV Primer 1.5 
10 mM dNTP  1.0 
10X Pfu Buffer  5.0 
25 mM MgSO4 1.5 
Pfu DNA Polymerase 0.5 
cDNA 5.0 
Nuclease-Free H2O To 50.0 
 




94 3:00 1 
94 0:15  
35 51 0:30 
72 0:45 
72 7:00 1 
 
Table 5 - Components and Reaction Parameters for the Secondary RT-PCR – Per One 
Reaction 
Reaction Component Volume (µl) 
10 pm/µl “IF” FWD Primer 1.5 
10 pm/µl “IR” REV Primer 1.5 
10 mM dNTP  1.0 
10X Pfu Buffer  5.0 
25 mM MgSO4 1.5 
Pfu DNA Polymerase 0.5 
Primary PCR Product 4.0 
Nuclease-Free H2O To 50.0 
 
Temperature (°C) Duration (Minutes) Cycles 
94 3:00 1 
94 0:15  
35 53 0:30 
72 0:45 
72 10:00 1 
 
2.7 CORE PROTEIN PCR 
 
The core protein PCR was used to amplify the HCV core protein for the 
purposes of phylogenetic analysis. A nested PCR approach was used to 
reduce the frequency of non-specific binding. The cDNA used as the 
template for the primary PCR was generated as per Section 2.5. The 




Table 6 - Components and Reaction Parameters for the Core Protein PCR – Per One 
Reaction 
Reaction Component Volume (µl) 
10 pm/µl “All Core” FWD Primer 1.5 
10 pm/µl “All Core” REV Primer 1.5 
10 mM dNTP  1.0 
10X PCR Buffer  5.0 
50 mM MgCl2 1.5/1.0 
Taq Polymerase 0.5 
Target cDNA/Primary PCR Product 5.0 
Nuclease-Free H2O To 50.0 
  
Temperature (°C) Duration (Minutes) Cycles 
94 3:00 1 
94 0:15  
35 60 0:30 
72 1:30 
72 10:00 1 
 
The volume of MgCl2 was 1.5 µl for the primary PCR, and 1.0 µl for the 
secondary PCR, with the volume of H2O adjusted accordingly. The same 
reaction parameters were used for the primary and secondary reactions and 
can be viewed below.  
2.8 SPECTROPHOTOMETRY 
 
Spectrophotometry was used to assess to the quality and quantity of DNA 
produced from various procedures. The Eppendorf BioPhotometer 
Spectrophotometer UV/VIS was used for the spectrophotometry portion of 
this project. The spectrophotometer was first “blanked” using dH2O, and the 
samples were diluted with dH2O at a ratio of 1:10 and analysed. The 
260/280nm and 260/230nm values were used to assess the quality of the 




value of ~1.7 and a 260/230nm value of ~2.2 indicated a clean preparation 
with minimal contamination.  
Spectrophotometry was used on one occasion as an alternative to IgG 
ELISAs for IgG quantification. The concentration of IgG in solution was 
determined by substituting the molecular weight of IgG, the extinction 
coefficient (the measure of how strongly a substance absorbs light at a 
particular wavelength), and the λmax (the wavelength along the absorption 
spectrum where a substance has its strongest photon absorption) value into 





𝐸𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑒𝑛𝑡 ×  𝑃𝑎𝑡ℎ𝑙𝑒𝑛𝑔𝑡ℎ
 × 𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑊𝑒𝑖𝑔ℎ𝑡  
 
2.9 PURIFICATION OF PCR PRODUCTS 
 
Before sending the PCR products for sequencing, the products were purified 
using GeneJET PCR Purification Kit (ThermoScientific) according to the 
manufacturer’s recommended protocol. The binding buffer contained a 
chaotropic agent to denature proteins and facilitate the binding of DNA to the 
silica membrane of the GeneJET column. Equal volumes of binding buffer 
and the PCR product were added to the GeneJET column and centrifuged at 
10,000 RPM for 30 seconds. If the PCR product was <500bp, 100 µl 
isopropanol was added to 100 µl binding buffer and combined with 100 µl of 
the PCR product before adding to the GeneJET column. Once the elute had 
been discarded, 700 µl wash buffer was added to remove unincorporated 
nucleotides, primers, and enzymes. The column was centrifuged at 10,000 
RPM for 30 seconds, the elute was discarded, and the column centrifuged at 
14,000 RPM for 1 minute to remove any trace amounts of wash buffer. The 
DNA was eluted using 30 µl elution buffer and centrifuged at 10,000 RPM for 
1 minute. The DNA was quantified and qualified by spectrophotometry and 




2.10 SEQUENCING AND BIOINFORMATICS 
 
Purified PCR products and plasmids were sequenced by Eurofins Genomics 
(https://www.eurofinsgenomics.eu/), Germany. Sequencing reads were 
aligned with reference sequences from the HCV Sequence Database 
(https://hcv.lanl.gov) 175 and the NCBI Viral Genome RefSeq Database 
(https://www.ncbi.nlm.nih.gov/genome/viruses/), and analysed using the 
MEGA7 software 176. The sequencing files were curated using the provided 
electropherogram from Eurofins Genomics, where needed.  
2.11 IGG ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
ELISA is an assay technique used for detecting and quantifying peptides, 
proteins, antibodies, and hormones. The antigen of interest is immobilised on 
the surface of the plate and complexed with a secondary antibody. This 
secondary antibody is conjugated with an enzyme that acts as a reporter – 
such as HRP (horseradish peroxidase) or biotin. The reaction between the 
antigen and antibody is measured using a microplate spectrophotometer. An 
IgG ELISA was carried out using the IgG (Total) Human Uncoated ELISA Kit 
(Invitrogen) to quantify the IgG purified from the genotype 3a patient 
samples. The Corning™ Costar™ 9018 ELISA plates were coated with 100 
µL/well of capture antibody (pre-titrated and purified anti-human IgG mAb) 
diluted with coating buffer (PBS), sealed, and incubated overnight at 4 °C. 
The next day the Blocking Buffer was prepared by making a 1:10 dilution of 
Assay Buffer A Concentrate (20X) with deionised water. The plates were 
aspirated and washed twice with 400 µl/well Wash Buffer (1X PBS and 
0.05% Tween™20). About 1 minute of soaking between washing was used 
to improve the effectiveness of the washes. Blocking Buffer (250 µl/well) was 
added and plates incubated for 2 hours at room temperature. The standard 
(recombinant human IgG – 200 ng/ml upon reconstitution with dH2O) was 
prepared and the plates aspirated and washed with Wash Buffer as 
previously described. To prepare the standard curve, 100 µl Assay Buffer 
(1:10 dilution of Assay Buffer A Concentrate (20X) with deionised water) was 




to A1, mixed by repeated aspiration, and 100 µl of the mixture transferred to 
B1. This was repeated five times to give a concentration gradient of 100 
ng/ml, 50 ng/ml, 25 ng/ml, 12.5 ng/ml and 6.25 ng/ml. F1 contained just 
Assay Buffer to act as a “zero” for calculation purposes. The samples – 
including the standard curve – were done in duplicate. The experimental 
samples – which had been diluted down to 10-5 and 10-6 using Assay Buffer 
– were added to 100 µl/well Assay Buffer and the plate sealed and incubated 
for 2 hours at room temperature on a shaker. The plates were aspirated and 
washed four times using the previous wash protocol and 100 µl/well diluted 
detection antibody (pre-titrated HRP-conjugated anti-human IgG mAb, 
diluted 1:250 with 1X Assay Buffer A) was added. The plates were sealed 
and incubated for 1 hour at room temperature on a shaker. The plates were 
aspirated and washed four times using the previous wash protocol and 100 
µl/well Substrate Solution (tetramethylbenzidine (TMB)) was added. The 
plates were incubated for 15 minutes at room temperature and 100 µl/well of 
Stop Solution (2 N H2SO4) was added. The plates were read using a 
microplate spectrophotometer (Promega GloMax System) to read the plates 
at 570 nm and 450nm. 
Analysis of the procedure was done using Microsoft Excel using the standard 
antibody to generate a standard curve of absorption against concentration 
(ng/ml), which enabled the quantification of the samples using linear 
regression.  
2.12 SODIUM DODECYL SULPHATE – POLYACRYLAMIDE GEL ELECTROPHORESIS 
(SDS-PAGE) 
 
SDS-PAGE (sodium dodecyl sulphate – polyacrylamide gel electrophoresis) 
is a technique used for the separation of proteins based on their molecular 
weight. SDS is a detergent used to disrupt the tertiary structure of the 
proteins and reduce them to linear molecules - by applying an electrical 
current, this enables the proteins to migrate through a polyacrylamide gel 
based solely on their molecular weight. Without the introduction of SDS, the 
tertiary structure and charge of the proteins would change the proteins’ rate 




The polyacrylamide gel is prepared by making a separating gel and a 
stacking gel. The stacking gel is used to load the protein samples and ensure 
that the proteins enter the separating gel simultaneously. The stacking gel 
(4.6%) is made using 950 µl stacking buffer (0.5M Tris (4X) and 0.4% SDS), 
550 µl 30% acrylamide, 50 µl 10% SDS, 27.5 µl 10% APS (ammonium 
persulphate), 3.75 µl TEMED (tetramethylethylenediamine), and 2.25 ml 
H2O. The separation gel (10%) is made using 1.75 ml separating buffer 
(1.5M Tris (4X) and 0.4% SDS at Ph 8.8), 2.33 ml 30% acrylamide, 75 µl 
10% SDS, 41 µl 10% APS, 3.9 µl TEMED, and 2.92 ml H2O. APS should be 
added just before pouring the gels, as this starts the polymerisation reaction.  
Using the glass plates and the casting apparatus, pour the separating gel to 
~2 cm under the top of the shorter glass plate. Place a layer of dH2O on the 
top of the separating gel to prevent meniscus formation. The separating gel 
should take about 30 minutes to solidify at room temperature. Remove the 
dH2O and pour the stacking gel to the top of the shorter glass plate. Insert 
the comb. The stacking gel should take about 1 hour to solidify at room 
temperature. The comb was removed once the gel had completely solidified.  
The plates were transferred to the SDS-PAGE electrophoresis chamber (Bio-
Rad PowerPac Basic) and the space between the two plates and 
approximately a third of the space outside the plates was topped up using 
running buffer. The running buffer was prepared using 400mM Tris, 190 mM 
glycine, 0.1% SDS, and dH2O. To prepare the PAGE for loading, the sample 
areas were washed out twice using a syringe and running buffer. The 
samples were prepared using PBS to a quantity of 50 µg protein and a 
volume of 20 µl. Before loading, the samples were heated to 95°C for 5 
minutes to linearise them and enable them to become properly coated with 
SDS. 4 µl of Sigma Biotinylated Molecular Weight Marker (6,500 – 180,000 
Da) was added to the first sample chamber. 15 µl of the samples were 
loaded with 5 µl Gel Loading Dye, Blue (6X) (New England BioLabs). The 
loading dye contained bromophenol blue as a standard tracker and added 
SDS to improve band sharpness. The electrophoresis was run at 50 mA for 
approximately 45 minutes – however, the time needed depends on the size 




gel. The blue dye should reach the end of the gel before removing the gel 
from the electrophoresis apparatus. The polyacrylamide gel should be cooled 
for the duration of the electrophoresis, as excess heat can cause warping 
throughout the gel, particularly towards the centre where heat dispersion is 
poorer. This manifests as the typical “frowning” bend. Icepacks designed for 
the chamber can be used, switching them out as they thaw.  
Once the gel was removed from the apparatus, the gel was stained using the 
Coomassie Blue (Brilliant Blue R, Sigma-Aldrich) staining method. The 
Coomassie Blue was prepared by adding 0.25 g Brilliant Blue R-250 to 90 ml 
MeOH and H2O (50/50 mixture by volume) and 10 ml glacial acetic acid. The 
solution was passed through Whatman paper to remove any clumps. The 
prepared Coomassie Blue can be stored at room temperature and reused. 
The polyacrylamide gel was rinsed with dH2O and transferred to a container 
and covered with the prepared Coomassie Blue. The gel was rocked 
overnight at room temperature to complete the staining. The Coomassie Blue 
was removed from the container and the gel rinsed using dH2O. A 10% 
acetic acid solution was used to de-stain the gel. The gel was covered with 
the 10% acetic acid solution and rocked at room temperature for 2 – 4 hours. 
The 10% acetic acid solution was replaced as it became saturated with 
Coomassie Blue. The de-stained transferred to the UV Trans-Illuminator and 
photographed.  
2.13 SITE-DIRECTED MUTAGENESIS (SDM) AND TRANSFORMATION INTO XL10-
GOLD ULTRACOMPETENT CELLS 
 
SDM is a procedure used to make specific and intentional changes to a DNA 
sequence by using short oligonucleotide primers to introduce the mutation of 
choice. The QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent 
Tech) was used to perform SDM during this project. The primers used for 
SDM were previously designed by Dr. Amruta Naik using the Agilent primer 
design program: 
https://www.genomics.agilent.com/primerDesignProgram.jsp. The SDM and 
transformation using XL10-Gold UltraCompetent Cells were performed 




thermal cycler conditions can be viewed in Table 7. Once the reaction was 
complete, 2 µl Dpn I restriction enzyme was applied to the amplification 
reaction and incubated at 37°C for 5 minutes to digest the parental dsDNA. 
The XL10-Gold UltraCompetent Cells were defrosted and kept cold, and 45 
µl transferred to a cold 14 ml BD Falcon polypropylene round bottomed tube. 
2 µl β-mercaptoethanol mix (β-ME) was added and swirled. The tube was 
incubated on ice for 2 minutes before 2 µl of reaction solution was added. 
The solution was incubated on ice for a further 30 minutes before being heat 
shocked at 42°C for 30 seconds. The tube was incubated on ice for 2 
minutes before 0.5 ml of preheated NZY+ broth was added, and the mixture 
incubated at 37°C for 1 hour, shaking at 225 RPM. 10 – 250 µl of the 
transformation reaction was plated on LB agar plates containing 50 µg/ml 
ampicillin, 80 µg/ml X-gal, and 20 mM IPTG, and incubated at 37°C for >16 
hours. These plates were designed for colour screening of transformed 
colonies.  
Table 7 - Components and Reaction Parameters for QuikChange Lightning Site-Directed 
Mutagenesis Reaction 
Reaction Component Volume (µl) 
10X Reaction Buffer 5 
dsDNA Template X (10 – 100 ng) 
Oligonucleotide Primer #1  X (125 ng) 
Oligonucleotide Primer #2 X (125 ng) 
dNTP Mixture 1 
QuikSolution Reagent 1.5 
dd H2O To 50.0 
QuikChange Lightning Enzyme 1 
 
Temperature (°C) Duration (Minutes) Cycles 
95 2:00 1 
95 0:20  
18 60 0:10 
68 0:30/kb Plasmid Length 







Bacterial colonies grown overnight on LB agar at 37°C were inoculated into 5 
ml of LB broth with 50 µg/ml ampicillin. The inoculated cultures were grown 
overnight at 37°C and shaking at 225 RPM. The bacteria were harvested by 
centrifugation of the inoculum at 6,000 RPM for 15 minutes at 4°C. The 
supernatant was discarded and the pellet re-suspended using 250 µl re-
suspension solution, which contained RNase A. The re-suspension solution 
was kept cold before use. The re-suspension was transferred to a 1.5 ml 
microcentrifuge tube. The bacteria were subjected to lysis by adding 250 µl 
of lysis solution and were mixed by 4 – 5 inversions. The solution was 
neutralised, and the lysis stopped by adding 350 µl neutralisation solution 
and mixed thoroughly by inverting. Debris and chromosomal DNA was 
removed by centrifugation at 10,000 RPM for 5 minutes, and the supernatant 
added to a GeneJET spin column. The GeneJET column was centrifuged at 
10,000 RPM for 1 minute, washed twice with 500 µl wash solution, and 
centrifuged again. A further centrifugation at 10,000 RPM for 1 minute was 
used to remove any residual wash solution. The elution buffer was brought to 
room temperature and 50 µl was added to the GeneJET column to elute the 
plasmid DNA. The yield and quality of the plasmid DNA was determined 
using spectrophotometry. The plasmid preparation was stored at -20°C. 
2.15 MAXIPREP 
 
An E. coli colony containing the plasmid of choice was grown overnight on a 
selective agar plate at 37°C. A suitable colony was picked and inoculated 
into a starter culture of 5 ml LB broth containing 50 µg/ml ampicillin. The 
starter culture was incubated for 8 hours at 37°C and shaking at 225 RPM, 
before being used to inoculate a 200 ml volume of LB broth containing 50 
µg/ml ampicillin – this was to ensure a sufficient amount of plasmid was 
obtained for downstream procedures. The 200 ml volume was incubated for 




was the PureYield™ Plasmid Maxiprep System (Promega). The inoculum 
was centrifuged ay 5,000 x g for 10 minutes and the supernatant discarded. 
The bacteria were re-suspended using 12 ml of cell re-suspension solution 
and mixed vigorously by vortexing. 12 ml of cell lysis solution was added, 
and the mixture inverted 3 – 5 times. The mixture was incubated for 3 
minutes at room temperature before 12 ml of neutralisation solution was 
added to stop the lysis process. The lysate was then centrifuged at 14,000 x 
g for 20 minutes at room temperature, and the supernatant added to the blue 
PureYield™ Clearing Column. A vacuum manifold and the two PureYield™ 
columns (the clearing column stacked on the binding column) were used to 
draw the lysate through the clearing column. Once the lysate was passed 
through the clearing column, the clearing column was discarded. 5 ml of 
endotoxin removal wash was added to the PureYield™ Maxi Binding Column 
and the vacuum applied. Contaminants were removed by adding 20 ml of 
column wash to the binding column, and the binding membrane dried by 
applying the vacuum for 5 minutes once the column wash solution had 
completely passed through the binding column. Once the membrane was 
completely dried, the binding column was placed onto a 50 ml Falcon tube 
and 1.5 ml of nuclease-free H2O was added to the binding membrane. The 
column and 50 ml tube were centrifuged using a swinging bucket rotor at 
room temperature at 2,000 x g for 5 minutes. The filtrate was transferred to a 
1.5 ml microcentrifuge tube and analysed using spectrophotometry. The 
plasmid preparation was stored at -20°C. 
2.16 ILLUSTRA™ READY-TO-GO™ GENOMIPHI™ V3 DNA AMPLIFICATION KIT 
 
The illustra™ Ready-To-Go™ GenomiPhi™ V3 DNA Amplification Kit was 
used during the E1E2 glycoprotein PCR to increase the amount of primary 
PCR product for the secondary PCR. The GenomiPhi™ kit uses Phi29 DNA 
polymerase, random hexamer primers, and dNTPs to amplify the template 
DNA using the isothermal strand displacement methodology. The kit can 
amplify 10 ng input DNA to ~18 μg DNA. 10 μl 2X denaturation buffer was 
added to 1 μl of 10 ng template DNA. 9 μl of molecular H2O was added. The 




Go GenomiPhi V3 cake (which contains the Phi29 DNA polymerase, random 
hexamers, and dNTPs) was reconstituted with the denatured template DNA. 
20 μl of the template DNA was added to the cake, and the mixture incubated 
at 30°C for 1.5 hours. The Phi29 DNA polymerase was inactivated by 
heating the samples to 65°C for 10 minutes. The amplified DNA was cooled 
to 4°C and stored at -20°C.  
2.17 CELL CULTURE 
 
The Human Embryonic Kidney 293T (HEK 293T) and Human Hepatoma 7 
(Huh7) lineages were chosen for the preparation of HCV pseudoparticles. 
HEK 293T and Huh7 were grown using Dulbecco’s Modified Eagle Medium 
High Glucose (DMEM) (Sigma-Aldrich), supplemented with 10% foetal 
bovine serum (FBS) and 1% PenStrep – a mixture of 10,000 units of 
penicillin and 10 mg/ml streptomycin suspended with 0.9% NaCl. The HEK 
293Ts were also supplemented with 1% non-essential amino acids (NEAA). 
The HEKs and Huh7s were grown using T-75 ml flasks at 37°C and 5% CO2 
and passaged once confluency reached 80 – 90%. Once the media had 
been removed and the internal surface of the flasks washed twice with 10 ml 
PBS, 2 ml trypsin-EDTA was used to trypsinise the HEKs/Huh7s from the 
surface of the flask. After 5 minutes of trypsinisation, 8 ml DMEM containing 
FBS was added to neutralise the trypsin-EDTA, and the solution was 
centrifuged at 1,500 RPM for 5 minutes. The supernatant was discarded, and 
the re-suspension used to seed fresh flasks. The passage numbers were 
tracked and kept under p35 during the project. 
Stocks were prepared using 1ml of cell freezing media (Sigma-Aldrich). The 
HEKs/Huh7s were grown to a confluency of ~90%. The flask was washed, 
trypsinised, and centrifuged as described, and resuspended using 1 ml of 
freezing media at the desired density. The stocks were slowly frozen to -
80°C overnight using an isopropanol freezing container to prevent damage 





2.18  GENERATION OF HCV PSEUDOPARTICLES 
 
The HCV pseudoparticle (HCVpp) system is a retrovirus model system 
developed by Bartosch et al. and involves transfecting HEK 293Ts with three 
plasmids - a plasmid containing HCV E1E2 glycoproteins, a gag-pol 
packaging plasmid, and reporter plasmid, which tends to have a luciferase or 
GFP gene. The HCV E1E2 glycoproteins enable the pseudoparticle to enter 
and infect Huh7s – a type of hepatocyte – but the pseudoparticles are unable 
to replicate.  
The transfection of HEK 293Ts with the three plasmids is based upon the 
CaPO4 transfection method. This technique was pioneered during the 1970s 
and remains popular because of the simple and inexpensive reagents used. 
The DNA/plasmid of interest is combined with calcium chloride to generate a 
CaPO4-DNA/plasmid precipitate. CaPO4 enables the precipitate to bind to 
the surface of the HEKs, and the HEKs can internalise the DNA/plasmid 
through endocytosis.  
1. Day One 
HEKs were seeded at a 1 - 1.5 x 106 density using a 10 cm diameter 
tissue culture plate, with ~15 ml supplemented DMEM (see Section 
2.17). The HEKs were incubated for ~16 hours at 37°C at 5% CO2. 
 
2. Day Two 
The HEKs were a minimum of 40% confluency before starting the 
transfection procedure. The HEKs were transfected using a CaPO4 
transfection kit (Invitrogen). The reagents must be kept cold during the 
transfection process. A “no envelope” control pseudoparticle should 
be prepared using dH2O instead of the E1E2 glycoprotein plasmid. 
For a single pseudoparticle, the components from Table 8 were added 
to a 1.5 ml microcentrifuge tube. The reagents should be added as 
per the order of Table 8. 500 µl of 2X HBS (HEPES-Buffered Saline) 
was added to an empty 50 ml Falcon tube, and the transfection 
components were added dropwise to the 2X HBS. Using a 




were added, as the aeration generates a finer CaPO4 precipitate – 
finer precipitates are associated with improved rates of pseudoparticle 
uptake by the HEKs. The mixture was vortexed and incubated at room 
temperature for 20 minutes. The 1 ml of the mixture was then 
distributed dropwise over the prepared HEK plate and incubated 
overnight at 37°C at 5% CO2. 
 
3. Day Three 
The medium from the transfection plate was discarded and replaced 
with 6 ml DMEM (supplemented for HEKs are described during 
Section 2.17) containing 10 mM HEPES buffer and incubated 
overnight at 37°C at 5% CO2. 
 
4. Day Four 
The first round of HCVpp was harvested. The media from the plate 
was taken up using a syringe and passed through a 0.45 µm filter to 
an empty 15 ml Falcon tube. The HCVpp harvest can be stored at 4°C 
for two weeks. The HCVpp can also be stored at -80°C, but storage at 
this temperature causes a 50% reduction of infectivity. The HEK plate 
was replenished with 6 ml supplemented DMEM containing 10 mM 
HEPES buffer and incubated overnight at 37°C at 5% CO2. 
 
5. Day Five 
The second harvest of HCVpp are more infectious than the first 
harvest of HCVpp, and were the pseudoparticles used for the 
experiments during this project. The second harvest was harvested as 






Table 8 - Components required for transfection of HEK 293T cells. 
Tissue Culture Dish 10 cm 6 cm 3.5 cm 
Area 48 cm2 21 cm2 8.5 cm2 
HEK Seeding Density 1 x 106 4 x 105 2 x 105 
Luciferase Plasmid 8 µg 3 µg 1.5 µg 
pMLV gag-pol 8 µg 3 µg 1.5 µg 
E1E2 Glycoprotein 3 µg 1.2 µg 0.5 µg 
dH2O (to) 400 µl 160 µl 80 µl 
2M CaCl2 100 µl 40 µl 20 µl 
2X HBS 500 µl 200 µl 100 µl 
Total Volume 1000 µl 400 µl 200 µl 
 
2.18.1 Infectivity Assay Using HCVpp 
Huh7s are seeded the day before the planned infection assay at the 
densities stated on Table 9. The next day, the volume of harvested HCVpp 
inoculum stated on Table 9 is added to the Huh7s. The Huh7s are incubated 
at 37°C for 3 – 4 hours and tapped every 30 minutes during the incubation 
period to ensure an even spread of pseudoparticles. Once the incubation 
period has ended, the HCVpp inoculum is removed and replaced with fresh 
DMEM, supplemented for Huh7s. The amount of DMEM added depends on 
the type of plate used, but the standard working volumes of the plates should 
be used. The plates are incubated for 72 - 96 hours at 37°C at 5% CO2.  
2.18.2 Neutralisation Assay Using HCVpp 
The Huh7s are seeded as described in Section 2.18.2. Before the HCVpp 
inoculum is added to the Huh7s, the chosen antibodies are incubated with 
HCVpp for 1 hour at 37°C – this can be done using an incubator or water 
bath. The antibodies used for the neutralisation assay should be at a 
consistent concentration (mg/ml) and equal volumes of antibody and HCVpp 
should be used. Once the incubation period has been completed, the HCVpp 
and antibody inoculum should be added to the Huh7s and the Huh7s 
incubated as described for Section 2.18.1.  
2.18.3 Luciferase Assay Using HCVpp 
Once the incubation period for the infection/neutralisation HCVpp assay has 




~20 minutes at room temperature. The plate can also be rocked during the 
lysis stage. The volume of 1X Lysis Buffer used should match the HCVpp 
inoculum volume from Table 9. The lysate was transferred to a black 
luminometer plate and 100 µl BrightGlo Luciferase Substrate (Promega) was 
added. Relative light unit (RLU) emission was measured using a 
luminometer (Promega GloMax System).   
Table 9 - Infection parameters for infectivity assays using HCVpp. 
Tissue Culture Dish 6-Well 12-Well 24-Well 48-Well 96-Well 
Area 8.5 cm2 3.8 cm2 2.0 cm2 0.8 cm2 0.25 cm2 
Huh7 Density 1 x 105 4.5 x 104 2.5 x 104 1.0 x 104 4.0 x 103 
HCVpp Inoculum 600 µl 300 µl 150 µl 90 µl 50 µl 
 
Figure 7 - Summary of process for generating HCV pseudoparticles. 
 
 
Day 5 - Second harvest of HCVpp is completed and the HCVpp are stored at 
4°C. HCVpp are ready to be used for infectivity and neutralisation assays.
Day 4 - First harvest of HCVpp is completed and media replaced as per Day 3.
Day 3 - HEK media replaced with supplemented DMEM and 10mM HEPES.
Day 2 - HEKs transfected with the MLV gag-pol, luciferase reporter, and E1E2 
vectors using the CaPO4 transfection method.  




2.19 EPITOPE MAPPING 
 
Epitope mapping is the process of identifying the binding sites (epitopes) of 
antibodies to their corresponding antigens. Epitopes can be categorised as 
linear epitopes or conformational epitopes. Linear epitopes are formed by 
continuous sequences of amino acids, whereas conformational epitopes are 
composed of discontinuous sequences that are brought together by the 
tertiary structure of the protein. For this project, the epitope mapping was 
carried out by Pepscan Presto B. V. using the existing H77 E2 glycoprotein 
chemically-linked peptides on scaffolds (CLIPS) technology platform from Dr. 











The linear and CLIPS peptides were synthesized based on the amino acid 
sequence of H77 E2 glycoprotein using Fmoc (fluorenylmethyloxycarbonyl 
protecting group) chemistry and de-protected using trifluoric acid with 
scavengers. The constrained peptides were synthesized using CLIPS 
technology to reconstruct the conformational epitopes. The side-chains of the 
multiple cysteines in the peptides are coupled to CLIPS templates by 
reacting onto the polypropylene PEPSCAN cards with a 0.5 mM solution of 
CLIPS template such as 1,3-bis (bromomethyl) benzene in ammonium 
bicarbonate (20 mM, pH 7.9)/acetonitrile (1:1(v/v)). The cards were shaken 
for 30 - 60 minutes while completely covered by the solution. The cards were 
washed thoroughly with H2O and sonicated in disrupt-buffer containing 1% 




followed by sonication in H2O for another 45 minutes. The binding of 
antibody to each peptide was tested using a PEPSCAN-based ELISA. The 
polypropylene cards containing the peptides were incubated with primary 
antibody solution consisting of 1 µg/ml diluted with a blocking solution (4% 
horse serum, 5% ovalbumin (w/v) in PBS/1% Tween, for example). The card 
was washed and the peptides were incubated with a 1/1000 dilution of 
antibody peroxidase conjugate for 1 hour at 25°C. The card was washed, 
and the peroxidase substrate 2,2’-azino-di-3-ethylbenzthiazoline sulfonate 
(ABTS) and 2 µl of 3% H2O2 are added, and the card incubated for 1 hour. 
The colour development was quantified with a charge coupled device (CCD) 







3.1 WORK PERFORMED ON NAIK ET AL. PAPER 
3.1.1 Hypothesis 
The hypothesis, proposed by Dr. Amruta Naik, was that a single amino acid 
change to the E1E2 glycoprotein would be enough to increase or decrease 
the infectivity of a HCV pseudoparticle. Two plasmids (1b-1-2 and 1b-1-3) 
coding for the E1E2 glycoprotein were generated from two serum samples 
from a single patient, separated by six months. However, the second plasmid 
(1b-1-3) was found to have amino acid changes at position 292 at the E1 
glycoprotein, and positions 388 and 395 at the HVR1 domain. When HCV 
pseudoparticles were generated using the two plasmids, there was found to 
be significant change to the infectivity, with 1b-1-2 being highly infectious and 
1b-1-3 being only moderately infectious. It was proposed that the amino acid 
changes could be the cause of this. 
This work contributed to the paper: 
“Reverse epitope mapping of the E2 glycoprotein in antibody associated 
hepatitis C virus” Amruta S. Naik, Ania Owsianka, Brendan A. Palmer, 
Ciaran J. O’Halloran, Nicole Walsh, Orla Crosbie, Elizabeth Kenny-Walsh, 
Arvind H. Patel, Liam J. Fanning – PLOS ONE, May 30th, 2017.  
3.1.2 Methodology 
The following methodologies were used during the course of this experiment. 
Please refer to the named sections for further information on the protocols 
used.  
 Site-Directed Mutagenesis and Transformation (Section 2.13)  
 MiniPrep (Section 2.14)  
 MaxiPrep (Section 2.15)  
 Generation of HCV Pseudoparticles (Section 2.18)  
 Infectivity Assay Using HCV Pseudoparticles (Section 2.18.1)  
For the purpose of this study, a number of mutant HCVpp were generated, 
using single amino acid changes to verify whether that particular amino acid 




mutations were introduced using site-directed mutagenesis. Once the site-
directed mutagenesis was carried out, the plasmids underwent 
transformation, MiniPrep, and MaxiPrep to prepare them for the generation 
of the HCVpp. Once the HCVpp were generated, infectivity assays were 
carried out as quadruplets and using three technical replicates to verify the 
data.  







Regarding the notation of “I388V”, “I” indicates that the original amino acid at 
position 388 on plasmid 1b-1-2 was changed from isoleucine to valine – “V”. 
“DM” refers to the double mutation of 1389V and V396A. The generation of 
the mutants and the infectivity assays were carried out by Amruta Naik. 
Ciaran O’Halloran, Nicole Walsh, and Kian Hearty.  
3.1.3 Results 
 
Figure 8 - Changes to three single amino acids were found to influence the infectivity of 




represents the percentage of infectivity. The unaltered 1b-1-2 and 1b-1-3 plasmids serve as 
comparisons for the mutant HCVpp. 177 
3.1.4 Discussion 
It had been observed that HCVpp 1b-1-2 was, on average, twice as 
infectious as HCVpp 1b-1-3, despite both the E1E2 glycoproteins for these 
pseudoparticles being sourced from the same patient. The two samples were 
taken six months apart, and 1b-1-3 was shown to have three amino acid 
changes from 1b-1-2. It was hypothesised that these amino acid changes 
were responsible for the reduced infectivity of 1b-1-3.    
It was found that the amino acid changes did contribute to the infectivity of 
the two plasmids, as demonstrated by Figure 8. One of the mutants was 
generated to copy two of the amino acid changes seen throughout the 
original 1b-1-3, with the hypothesis being that plasmid 1b-1-2T292A+I388V and 
the unaltered 1b-1-3 should have the same percentage of infectivity, given 
that the amino acid sequences are identical – this was shown to be the case, 
and confirmed that the threonine residue at position 292 and the isoleucine 
residue at position 388 were important for infectivity. 
The statistical significance of the HCVpp infectivity when compared to the 
original HCVpp 1b-1-2 was determined by using one-way analysis of 
variance (ANOVA) and Dunnet’s Test. The statistical analysis showed that 
the amino acid at position 292 (the E1 glycoprotein) appears to have some 
impact on the degree of infectivity in vitro, and that the T292A 1b-1-2 DM 
clone had the closest infectivity profile to the HCVpp 1b-1-3 wildtype.  
The information generated from the study showed the importance of single 
amino acid residues and positions for HCV infectivity, and demonstrated the 
degree of change an HCV quasispecies population can undergo. 
The main work carried out by Nicole Walsh was part of the SDM performed 
on the mutants to determine whether these amino acid substitutions were 
related to the increased infectious capacity of 1b-1-2. However, the epitope 
mapping portion of this paper (“Reverse epitope mapping of the E2 
glycoprotein in antibody associated hepatitis C virus”) was the basis for the 
epitope mapping of this project. Amruta Naik isolated antibodies from AAV+ 




Protein G columns and created the protocol for the pseudoparticle assays 
carried out during this project. During Section 3.5, the epitopes found by 
Amruta Naik and mentioned during this paper are compared to the putative 





3.2 ISOLATION AND AMPLIFICATION OF THE HCV E1E2 GLYCOPROTEIN 
3.2.1 Hypothesis 
For the generation of HCV pseudoparticles, a vector containing the HCV 
E1E2 glycoprotein is needed – this is what enables the pseudoparticle to 
enter the target. The goal of this experiment was to isolate the E1E2 
glycoprotein from one of the 3a HCV serum or plasma samples obtained 
from the NVRL using PCR techniques. Once the glycoprotein had been 
isolated, the glycoprotein would be added to an appropriate vector and used 
for the pseudoparticle experiments – see Section 3.4. 
3.2.2 Methodology 
The following methodologies were used during the course of this experiment. 
Please refer to the named sections for further information on the protocols 
used.  
 vRNA Extraction (Section 2.4) 
 320bp RT-PCR (Section 2.6) 
 Agarose Gel Electrophoresis (Section 2.2) 
The primers below were used during this experiment. These primers were 





Primer Name Tm (°C) Sequence 
OR(I-II) 53.7 5'-ATGGCATGGGATATGAT-3' 
OF (I) 47.3 5'-AAGGCCGTCCTGTTGA-3' 
IF(I) 49.9 5'-GCATGGGATATGATGATGAA-3' 
IR(I-II) 52.4 5'-GTCCTGTTGATGTGCCA-3' 
Core FWD 64.4 5'-CTTGTGGTACTGCCTGATAGGGTG-3' 
Core REV  5'-CCARYTCATCATCATRTCCCANGCCA-3' 
REV Spec2 59.0 5'-GGTTCTTGTCCCGGCCTGTGAGG-3' 
HCV Mod FWD 66.7 5'-CACCATGGGTTGCTCYTTYTCTATCTTCC-3' 
HCV pcDNA REV 61.4 5'-TTATATCATBAGCATCARCCARARRGC-3' 
NSREV1 61.4 5'-AGYTCTRTBAGYCCYGCDGC-3' 
NSREV2 58.0 5'-YTYGCDACRGCRAGYTCTRT-3' 
E2REV1 54.2 5'-HTTCAGRYTGACBAGYTTCT-3' 
E2REV2 59.3 5'-BAGYTTCTCCAHYGCRGCRT-3' 
3.2.3 Results 
At the start of this experiment, the primers generated by Dr. Amruta Naik 
were used, as these had been used to isolate the E1E2 glycoprotein from a 
number of HCV genotypes. A nested PCR approach was used, and the outer 
primers were Core FWD and REV Spec2. The inner primers were HCV Mod 
FWD and HCV pcDNA REV, which was a designed for genotype 3a. The 
start of the HCV Mod FWD primer included a CACC sequence at the 5’ end 
to support directional cloning using the TOPO group of cloning vectors from 
Invitrogen. TOPO cloning refers to the technique of cloning DNA fragments 
to vectors without the need for DNA ligases – instead, the inherent properties 
of DNA topoisomerase I is used to cleave and ligate DNA ends.  
Despite Dr. Naik’s previous success using the above primers, we were 
unable to isolate the E1E2 glycoprotein using the protocol. Instead, using a 
genotype 3a reference sequence, the primers NSREV1, NSREV2, E2REV1, 
and E2REV2 were designed. A number of experiments with various 





Reaction Component Volume (µl) 
10 pm/µl Core FWD Primer 1.5 
10 pm/µl NSREV1/NSREV2 Primer 1.5 
10 mM dNTP  1.0 
10X Pfu Buffer + MgSO4 5.0 
Pfu DNA Polymerase 0.5 
cDNA 5.0 
Nuclease-Free H2O To 50.0 
  
Temperature (°C) Duration (Minutes) Cycles 
95 3:00 1 
95 0:30  
35 58 0:30 
72 3:00 
72 10:00 1 
 
Table 10 - The conditions for the primary PCR. 
 
Reaction Component Volume (µl) 
10 pm/µl HCV Mod FWD Primer 1.5 
10 pm/µl E2REV1/E2REV2 Primer 1.5 
10 mM dNTP  1.0 
10X Pfu Buffer + MgSO4 5.0 
Pfu DNA Polymerase 0.5 
Primary PCR Product 5.0 






Temperature (°C) Duration (Minutes) Cycles 
95 3:00 1 
95 0:30  
35 58 0:30 
72 2:00 
72 10:00 1 
 
Table 11 - The conditions for the secondary PCR. 
The primary PCR was tested using the secondary PCR reagents and 
conditions from the 320bp RT-PCR procedure and agarose gel 
electrophoresis to verify that there was product present. With the 
combinations of the Core FWD and NSREV1 primers, the 320bp secondary 
PCR produced a clear band, implying that product had been isolated during 
the primary PCR. However, various combinations of the secondary PCR 
primers could not produce a product. Hoping to increase the amount of 
primary PCR product present – to improve the odds of the secondary PCR 
product being produced – the illustra Ready-To-Go GenomiPhi V3 DNA 
Amplification Kit (GE LifeSciences) was used on the primary PCR product. 
The protocol for the GenomiPhi DNA Amplification Kit can be found at 
Section 2.16. Unfortunately, the amplification of the primary PCR product did 
not enable the isolation of the secondary PCR product.  
3.2.4 Discussion 
We were unable to isolate the E1E2 glycoprotein through PCR. There are a 
few explanations for why the E1E2 glycoprotein was hard to isolate. First and 
foremost, the HCV E1E2 glycoprotein contains three hypervariable regions 
(HVR1, HVR2, and IgVR). The extreme genetic diversity that the E2 
glycoprotein demonstrates complicates designing functional primers for PCR. 
The primary PCR primers were designed for the core protein and NS2 
protein – both of which are more conserved across HCV genotypes and 
subtypes – and were able to generate a primary PCR product. The stable 
nature of the HCV core protein meant that the Core FWD primer did not need 




primers did include degenerate bases. The primers were designed using the 
Eurofins Genomics primer design program 
(https://www.eurofinsgenomics.eu/en/ecom/tools/pcr-primer-design/) and a 
reference HCV genotype 3a sequence. The HCV Mod FWD primer was used 
as the forward primer because it contained the CACC sequence for TOPO 
cloning, and the Eurofins Genomics primer design program suggested the 
E2REV1 and E2REV2 reverse primers. Both E2REV1 and E2REV2 
contained many degenerate bases because the N-terminal end of the E2 
glycoprotein contains the HVR1. The large number of degenerate bases, and 
the presence of the hypervariable regions, could be one explanation for why 
the secondary PCR did not work.  
A future option for the isolation of the E1E2 glycoprotein for HCV 
pseudoparticle production could be using a MinION DNA sequencer (Oxford 
Nanopore Technology) to determine the sequence of the E1E2 glycoprotein. 
Once the sequence is determined, a plasmid construct carrying the E1E2 
glycoprotein could be synthesised. A MinION unit was obtained by the 
University College Cork Department of Medicine and is a portable DNA and 
RNA sequencer capable of sequencing 10 – 20 Gb DNA/RNA within 48 
hours. Synthesising the plasmid with the E1E2 glycoprotein would remove 
the obstacle of cloning experiments and would enable a quicker progression 
to pseudoparticle production. However, depending on how the glycoprotein 
insert and the plasmid are synthesised, there would be the risk that some of 





3.3 PHYLOGENETIC ANALYSIS OF THE 320BP REGION AND CORE PROTEIN 
3.3.1 Hypothesis 
The 320bp RT-PCR was optimised by the MVDRL and served as a useful 
measure for verifying the presence or absence of HCV for a variety of 
procedures. However, the 320bp region also covers an area of interest 
regarding the HCV genome – the junction between the E1 and E2 
glycoproteins. As previously mentioned, the E2 glycoprotein contain three 
HVR regions – HVR1, HVR2, and the intergenotypic variable region. 
Because of the high degree of genetic diversity displayed by the E2 
glycoprotein, any sequences including the E2 glycoprotein could be used to 
identify a given sample. This would help confirm the genotype of the sample 
– by using BLAST to match the sample against other HCV 3a genomes – 
and could be used to start the process of phylogenetic analysis. Despite the 
fact the samples came from the NVRL, it cannot be assumed that the 
samples came from a single population or group of patients. The 
phylogenetic analysis would serve to check the relatedness of the samples 
and how the samples relate to groups of reference samples, both HCV 3a 
references, and references from other genotypes and subtypes.  
The HCV core protein forms the viral capsid, which protects the vRNA as the 
virus moves throughout the host. The immature form of the core protein 
requires cleavage by several host signal peptidases. Polymorphisms of the 
HCV core protein have been associated with poor treatment responses. This 
experiment – conducted by Mr. Jack Kenny and Dr. Brendan Palmer – 
involved sequencing the core protein of the NVRL samples and carrying out 
phylogenetic analysis to examine the genetic variations between those 
samples. The core protein from the Pyro2 project samples had already been 
sequenced by Dr. Brendan Palmer. 
3.3.2 Methodology 
The following methodologies were used during the course of this experiment. 
Please refer to the named sections for further information on the protocols 
used.  
 vRNA Extraction (Section 2.4) 




 Core Protein PCR (Section 2.7) 
 Agarose Gel Electrophoresis (Section 2.2) 
 Purification of PCR Products (Section 2.9) 
 Spectrophotometry (Section 2.8) 
 Sequencing and Bioinformatics (Section 2.10) 
RNA was extracted from the serum samples obtained from the NVRL and 
MVDRL. The 320bp RT-PCR procedure was carried out and the PCR 
products purified and sent for sequencing once the agarose gel 
electrophoresis confirmed that the 320bp region has been properly amplified. 
The samples underwent sequencing at Eurofins Genomics and the 
sequences curated using the provided electropherogram. MEGA 7 was the 
bioinformatics software used. Based on the secondary PCR primers and the 
HCV H77 1a genome on which they were based, the 320bp region covers 
from nucleotide position 1316 to position 1749, with most of the sequences 
ending up being 320 – 300bp once primer residues were trimmed from the 
sequences.  
Primer Name Tm (°C) Sequence 
OR(I-II) 53.7 5'-ATGGCATGGGATATGAT-3' 
OF (I) 47.3 5'-AAGGCCGTCCTGTTGA-3' 
IF(I) 49.9 5'-GCATGGGATATGATGATGAA-3' 
IR(I-II) 52.4 5'-GTCCTGTTGATGTGCCA-3' 
 
Table 12 - Oligonucleotide primers used for the 320bp RT-PCR procedure. The primers 
were created based on the HCV “H77” genotype 1a genome. 
Based on the core protein PCR primers and the HCV H77 1a genome on 
which they were based, the core protein primers covered from nucleotide 
position 304 to position 1293, with most of the sequences ending up being 
~500bp once the primers and degraded residues were trimmed from the 






Primer Name Tm (°C) Sequence 
Core FWD 64.4 5'-CTTGTGGTACTGCCTGATAGGGTG-3' 
Core REV  5'-CCARYTCATCATCATRTCCCANGCCA-3' 
 
Table 13 - Oligonucleotide primers used for the core protein PCR procedure. The primers 
were created based on the curated HCV “H77” genotype 1a genome. 
 






Figure 9 - Phylogenetic analysis of the 320bp samples and using 20 genotype 3a reference 
sequences submitted by the MVDRL. ▲ indicates samples from this study, and △ indicates 
the reference HCV 3a 320bp sample. The evolutionary history was from 500 replicates is 
taken to represent the evolutionary history of the taxa analysed. Initial tree(s) for the 
heuristic search were obtained automatically by applying Neighbor-Join and BioNJ 
algorithms to a matrix of pairwise distances estimated using the Maximum Composite 
Likelihood (MCL) approach, and then selecting the topology with superior log likelihood 
value. The analysis involved 32 nucleotide sequences. Codon positions included were 
1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated. 
There were a total of 304 positions in the final dataset. Evolutionary analyses were 
conducted in MEGA7. The sequences were aligned using ClustalW. 
 
 
Figure 10 - Phylogenetic analysis of the 320bp samples when aligned with a number of HCV 
reference sequences across various genotypes. ▲ indicates samples from this study. The 
evolutionary history was inferred by using the Maximum Likelihood method based on the 
Tamura-Nei model. The analysis involved 112 nucleotide sequences. Codon positions 
included were 1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were 
eliminated. There were a total of 291 positions in the final dataset. Evolutionary analyses 
















































































































Figure 11 - Phylogenetic analysis of the core samples and 20 genotype 3a core sequences. 
▲ indicates samples from this study. The evolutionary history was inferred by using the 
Maximum Likelihood method based on the Tamura-Nei model. The bootstrap consensus 
tree inferred from 500 replicates [3] is taken to represent the evolutionary history of the taxa 
analysed]. Branches corresponding to partitions reproduced in less than 70% bootstrap 
replicates are collapsed. The percentage of replicate trees in which the associated taxa 
clustered together in the bootstrap test (500 replicates) are shown next to the branches. 
Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor-Join 
and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum 




likelihood value. The analysis involved 31 nucleotide sequences. Codon positions included 
were 1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were 
eliminated. There were a total of 521 positions in the final dataset. Evolutionary analyses 




Figure 12 - Phylogenetic analysis of the core proteins samples when aligned with a number 
of HCV core protein sequences. ▲ indicates samples from this study. The evolutionary 
history was inferred by using the Maximum Likelihood method based on the Tamura-Nei 
model. The analysis involved 111 nucleotide sequences. Codon positions included were 
1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated. 
There were a total of 509 positions in the final dataset. Evolutionary analyses were 
conducted in MEGA7. The sequences were aligned by ClustalW. 
 
3.3.4 Discussion 
See Appendix I – Sequences Used for the accession numbers of the 









Sample G - Core
Sample L - Core
Sample F - Core
Sample J - Core












































of a statistical estimate, and the method was introduced by Felsenstein 
around 1985 178. Regarding phylogeny, bootstrapping can be considered a 
re-sampling method - the data is re-sampled several times (for example, a 
bootstrap 1,000 on MEGA 7 would mean that the data is re-sampled 1,000 
times), and a confidence value for each node of the phylogenetic tree is 
given, based on the number of times that that particular clade appeared 
during the re-sampling process. For example, a confidence value of 0.75 for 
a particular node from a bootstrap of 1,000 can be interpreted as that 
particular clade appearing 750 times during the re-sampling process, or 75% 
of the total re-samples. Bootstrapping has a number of advantages and 
disadvantages. The major advantage of bootstrapping is the simplicity of the 
process, and it also tends to be more accurate than the standard intervals 
obtained using sample variance and assumptions of normality. However, the 
bootstrap values do not indicate whether the clades would be present on the 
true phylogenetic tree - only the tree generated from data used. Short 
sequences can produce low bootstrap values. A clade with a bootstrap value 
of 0.70 (displayed as 70 in the above figures) and above is considered to 
have strong support for that clade appearing on the true tree - provided the 
data used to generate the tree was appropriate. The values produced for the 
above figures were low – this is likely due to the shortness of the sequences 
used and the genetic variability of the HCV genome.  
The 320bp section of the HCV genome chosen for sequencing covers the 
junction between the E1 and E2 glycoproteins. The E2 glycoprotein contains 
three hypervariable regions and displays the highest genetic diversity of the 
HCV proteins. For the 320bp sequence phylogenetic analysis, the bootstrap 
values were below the acceptable threshold. This was probably caused by 
the short sequences used, and the fact that many of reference sequences 
and experimental sequences were not varied enough to produce a 
phylogenetic tree that properly represented the diversity of the samples. The 
320bp region does not cover the HVR1 - a region diverse enough that it 
could have provided a clearer picture of the evolution of the experimental 
samples when compared to reference sequences from a variety of 




genotype 3a 320bp samples obtained from patients in Ireland and added to 
GenBank by the MVDRL. The comparison samples appear to show grouping 
in Figure 9 but do not appear to be closely related to any of the samples from 
this study. The HCV genotype 3a reference sequence was trimmed to the 
length of the 320bp region and searched against the BLASTn database. The 
first 100 sequences matched to the 3a reference sequence were used to 
generate Figure 10. A condensed tree was generated, which hid bootstrap 
values for nodes where the bootstrap value was <70. The samples from the 
study appeared to group together, with two sequences interspersed between 
the samples. KY620474.1 is a genotype 3 (no subtype specified) sample 
submitted from the United Kingdom and collected in 2013. AM423059 is a 
genotype 3a sample that was submitted from France in 2007. Several HCV 
genotypes were represented in the BLASTn matches to the HVC 3a 320bp 
reference. The large clades with bootstrap values of 99 and 90 (DQ50XXXX 
– see Appendix I – Sequences Used) represent sequences obtained from 
perinatal infections in Italy, with genotypes ranging from 1a to 4d. 
The mature form of the HCV core protein is a 21 kDa protein and has two 
domains – D1 and D2. These domains are separated by their amino acid 
compositions and hydrophobicity, and cleavage of the HCV core protein by 
host signal peptidases is needed for proper HCV assembly. The core protein 
is the most conserved of the HCV proteins, and sequence variations have 
been correlated with pathologies associated with HCV infection and disease 
progression – for instance, changes to D1 have been found to be associated 
with resistance to interferon therapy, and particular amino acid substitutions 
have been correlated with an increased risk of HCC 179 180. The core protein 
can be used to distinguish between genotypes 1a and 1b, but many 
diagnostic laboratories rely on the 5’-UTR for distinguishing between 
genotypes.  
The bootstrap values for the core protein phylogenetic analysis gave poor 
support for the Maximum-Likelihood tree produced. Again, as stated during 
the discussion of the 320bp phylogenetic analysis, there are a number of 
factors that could have caused the low bootstrap values. The sequences 




enough to generate a proper Maximum-Likelihood tree. However, the 
bootstrap values were an improvement on the 320bp phylogenetic analysis 
bootstrap values - probably because of the increased sequence lengths 
used. Figure 11 was generated by comparing the core samples to 20 
BLASTn matches to the HCV 3a reference sequence – this was increased to 
100 matches for Figure 12. Compared to the 320bp sequences, greater 
distancing between the core sequences from this study can be seen. In 
Figure 12 samples G, L, F, J, and K have clustered together, whereas 
samples M, C, and A are distanced from the cluster. Examining the 
uncondensed tree, sample A shows a weak relationship (bootstrap value = 
25) with KY620456, which is genotype 3 sample from the United Kingdom, 
and was included in the same group of submissions as KY620474 – which 
was interspersed among the 320bp samples. Sample E showed a weak 
relationship (bootstrap value = 21) to KC143935, a genotype 3a sample 
collected in 2009 from Saudi Arabia.  
Ultimately, the bootstrap values from the 320bp and core protein sequences 
were not high enough to support definitive phylogenetic relationships 
between the samples from the study and the samples from the GenBank 
database. Longer sequences that include conserved regions of the HCV 
genome would need to be obtained to improve the reliability of the 





3.4 PREPARATORY WORK FOR HCV PSEUDOPARTICLE GENERATION AND 
EPITOPE MAPPING 
 
3.4.1 Introduction  
This section covers the preparatory experiments carried out for the reverse 
epitope mapping procedure. As covered by Section 3.2, a genotype 3a E1E2 
glycoprotein was unable to be isolated from the HCV samples received from 
the NVRL. Instead, a H77 E1E2 glycoprotein construct was used to create 
the pseudoparticles. H77 is a genotype 1a HCV isolate that has known 
infectious properties when used to create pseudoparticles, and has the 
complete genome sequenced (see  
Appendix I – Sequences Used). This H77 E1E2 plasmid (phCMV-ΔC/E1/E2) 
was already stocked by the MVDRL, alongside the luciferase plasmid and 
packing vector (MLV gag-pol). 
The first step for the preparatory experiments was determining which of the 
samples contained to the presence of antibody associated virus (AAV) 





Figure 13 - Graphical summary of the preparatory process for selecting and sending 
samples for epitope mapping. 
 
3.4.2 Screening of Serum/Plasma Samples for the Presence of Antibody 
Associated Virus (AAV) Complexes  
3.4.2.1 Hypothesis 
The first stage of the process was determining which of the samples received 
from the NVRL and from the Pyro2 project were AAV+. Because it was 
known that the antibodies from the AAV complexes could bind to HCV, the 
antibodies could be separated from the complex and later used to perform 
neutralisation assays using the HCV pseudoparticle system.  
3.4.2.2 Methodology 
Serum and plasma samples were obtained from the National Virus 
Reference Laboratory (NVRL) for 13 unrelated patients diagnosed with 
chronic HCV 3a infections. 6 HCV 3a samples were obtained from the Pyro2 
project that the MVDRL had undertaken, and a single HCV 3a sample was 
Selection of VF-FAbs for Epitope Mapping
Pseudoparticle Neutralisation Assays with VF-FAbs
Creation and Testing of H77 HCV Pseudoparticle
Purification and Quantification of VF-FAbs and IgG from AAV- Samples
Creation of VF-FAbs and AAV- Challenge




taken from the MVDRL stocks that had been approved for research. The 
serum and plasma samples were stored at -80°C. The following 
methodologies were used during the course of this experiment. Please refer 
to the named sections for further information on the protocols used.  
 Protein G Column Chromatography (Section 2.3) 
 vRNA Extraction (Section 2.4) 
 320bp RT-PCR (Section 2.6) 
 Agarose Gel Electrophoresis (Section 2.2) 
 
The samples underwent Protein G column chromatography to segregate the 
AAV+ samples from the AAV- samples – if the samples contained AAV, the 
complex would be captured by the Protein G membrane and eluted. 
However, if the same did not contain AAV, the virus particles would be 
washed through the column. The first and eighth washes (W0 and W8) from 
the Protein G columns also underwent the subsequent vRNA extraction and 
320bp RT-PCR procedure to check that any unbound virus was properly 
washed through the Protein G column – W0 should have some unbound 
virus and produce a 320bp band, whereas W8 should be free of unbound 
virus and not produce a band. To verify whether any of the samples were 
AAV, a vRNA extraction and 320bp RT-PCR was used to check for the 
presence of HCV genetic material. If the AAV had been captured by the 
Protein G membrane, the subsequent vRNA extraction and PCR would 
amplify the genetic material from the virus portion of the complex. Negative, 
H2O, and positive controls were used throughout the process to verify the 
protocols worked and to demonstrate that the preparations were not 
contaminated. The primary PCR and secondary PCR products were not 
processed at the same location, to reduce to chance of contamination 





















Table 14 - The AAV- and AAV+ samples, as determined by the screening process. The rate 







Figure 14 - Gel image showing positive bands for AAV+ samples at the 320bp molecular 
weight. Samples C, G, and J are AAV+, whereas Sample A did not show a 320bp band, and 
can be considered AAV-. H2O was used as a control and to show the preparations were not 
contaminated by external DNA. 
 
3.4.2.4 Discussion 
7 of the 20 samples screened tested positive for the presence of AAV. This 
frequency of AAV+ samples was 35%, which matched previous AAV 
screening procedures carried out by the MVDRL. The antibodies isolated 
from the AAV- samples (using the Protein G columns) during the 
categorisation of the samples as AAV- or AAV+ was saved for the future 
pseudoparticle experiments - despite the fact there was no AAV complexes 
present for these genotype 3a samples, it was hypothesised that the 
antibodies could display some activity towards the genotype 1a H77 
pseudoparticle. 
Once the AAV+ samples had been identified, the antibodies needed to be 
separated from the AAV complex using proteinase K - these antibodies 
would be known as VF-FAbs (Virus-Free FAbs). The VF status of the 
antibodies was verified by using the 320bp PCR protocol (see Section 2.6). 
3.4.3 Dissociation of AAV Complexes for the Generation of Virus-Free 
Antigen Binding Fragments (VF-FAbs) and AAV- Sample Challenge 
3.4.3.1 Hypothesis 
The reasoning behind the generation of VF-FAbs was based around the idea 
that an antibody from one AAV+ sample could be used to identify potential 
conserved epitopes among the AAV- samples. VF-FAbs originate from AAV+ 
samples which have undergone a proteinase K digestion to remove the virus 
portion of the AAV complex. The generated VF-Fab retains the antigen 
binding properties of the original antibody, but the Fc region of the antibody 
is degraded during the procedure.  
3.4.3.2 Methodology 
The following methodologies were used during the course of this experiment. 
Please refer to the named sections for further information on the protocols 
used.  




 vRNA Extraction (Section 2.4) 
 320bp RT-PCR (Section 2.6) 
 Agarose Gel Electrophoresis (Section 2.2) 
Proteinase K (5 mg/ml) was used to remove the virus from the AAV complex, 
generating the VF-FAbs for further processing. Proteinase K is a serine 
protease commonly used to digest proteins and remove contamination from 
nucleic acid preparations. The primary site of cleavage is the peptide bonds 
adjacent to the carboxyl group of aliphatic and aromatic amino acids with 
blocked alpha amino groups. The decision to use proteinase K to separate 
the antibodies from the AAV complex was based on previous work 
performed by Dr. Amruta Naik – Dr. Naik found that a 1-hour incubation at 
37°C with a 50/50 mixture of the sample and proteinase K was enough to 
separate the antibodies.   
A 1:1 volume of proteinase K and the AAV+ sample was added to a 1.5 ml 
microcentrifuge tube and incubated at 37°C for two hours. Once the 
incubation was completed, the mixture was added to a Protein G HP 
SpinTrap™ Column and washed according the instructions. A second wash 
through the Protein G HP SpinTrap™ was performed to remove any residual 
Proteinase K. A 320bp RT-PCR and agarose gel electrophoresis was 
performed to verify that the sample did not contain any virus. The VF-FAb 
was stored at -20°C. The isolated and purified VF-FAbs were used to 
challenge the serum samples that had not tested positive for the presence of 
antibody-associated virus complexes (AAV-). A 1:5 volume of the VF-FAb 
and the AAV- serum were added to a 1.5 ml microcentrifuge tube and 
incubated at 37°C for two hours. Once the incubation period was completed, 
the mixture was added to a Protein G HP SpinTrap™ Column and washed 
according the instructions. A 320bp RT-PCR and agarose gel 
electrophoresis was performed to check whether the VF-Fab had bound the 





Figure 15 - Procedure for generation of VF-FAbs. A secondary protein G column wash was 
included to ensure complete removal of any residual proteinase K. 
3.4.3.3 Results 
 
Figure 16 - Agarose gel electrophoresis on the VF-FAbs after proteinase K digestion and 
column washes. Sample M appeared to have some residual DNA remaining, and the HCV 
was not dissociated from the Sample C AAV complex. However, Sample G and J were 
Quantification of VF-FAb Through IgG ELISA or Spectrophotometry
320bp RT-PCR to Confirm Removal of Virus
vRNA Extraction
Secondary Protein G Column Wash
Protein G Column Wash




suitable for use as purified VF-FAbs and were confirmed to be free of HCV. 
 
3.4.3.4 Discussion 
The aim of this experiment was to produce VF-FAbs from the four AAV+ 
samples discovered during the AAV screening process. There were four 
AAV+ samples, and from that, three purified VF-FAbs were produced. Figure 
16 shows that Sample C, despite the proteinase K digestion, showed 
evidence of HCV genetic material, and was not used for downstream 
experiments, as the residual DNA could produce false positives during the 
AAV- experiments. Sample G and J had the virus completely digested and 
were suitable for use against the AAV- samples. Sample M had some 
remaining genetic material, but subsequent washes and a longer proteinase 
K digestion were able to remove the smearing seen on Figure 16. The VF-
FAbs and the AAV- samples were pooled for the experiments to preserve the 
stocks of HCV samples. Unfortunately, none of the VF-FAbs were able to 
capture the AAV- samples. This could mean that the antibodies from the G, 
J, and M AAV+ complexes bound to epitopes that were not found on the 
AAV- samples. The antibodies were investigated further using pseudoparticle 
experiments and epitope mapping.  
It was also examined whether the VF-FAbs produced could “recapture” the 
original AAV+ samples that they were isolated from, but the VF-FAbs were 
unable to recapture the AAV+ samples. This could be because the 
proteinase K digestion damaged or changed the structure of the antibodies, 
or because the original samples already had antibodies blocking the VF-









3.4.4 Isolation and Purification of IgG from Patient Samples for HCVpp 
Neutralisation Assays 
3.4.4.1 Hypothesis 
To use the IgG from the HCV 3a patients for the HCVpp assays, the IgG first 
needed to be isolated and purified from serum/plasma.  
3.4.4.2 Methodology 
The following methodologies were used during the course of this experiment. 
Please refer to the named sections for further information on the protocols 
used.  
 Protein G Column Chromatography (Section 2.3)  
 Proteinase K Digestion (Section 3.4.3.2)  
 IgG ELISA (Section 2.11)  
 SDS-PAGE (Section 2.12)  
For consistency and accuracy when carrying out the antibody experiments, 
the IgG content of the samples was quantified using an IgG ELISA. During 
the SDS-PAGE procedure, the IgG isolated using Protein G column 
chromatography underwent heating at 95°C for 5 minutes. This was done to 
separate the disulphide bonds between the heavy (H) and light (L) IgG 
chains. The H chain is estimated to have a molecular weight of 50 kDa and 
the L chain around 25 kDa, meaning that two bands would separate out 
during the SDS-PAGE procedure. Observing the H and L chains would 
confirm that the IgG remained undamaged throughout the column 
chromatography procedures. 
3.4.4.3 Results 
The IgG ELISA was used to quantify the amount of protein isolated from the 
column chromatography. 




















Average Yield 1.98 
 
Table 15 - Quantities of IgG observed. As previously noted, AAV+ samples underwent 
proteinase K digestions to remove the virus from the AAV complex. However, the proteinase 
K also had an impact on the amount of IgG detected during the ELISA procedure. The R2 
value for the standard curve used was 0.9739. 
The samples underwent the aforementioned heat treatment and were 





Figure 17 - A gel generated using the isolated IgG and the SDS-PAGE technique. Samples 
I, L, M, N, O, and VF-G showed clear separation of the IgG chains. Nothing was visible for 
sample VF-J or VF-M. Degradation of the tenth lane prevented the use of a negative H2O 
control. 
3.4.5 Generation of HCV Pseudoparticles and IgG Neutralisation Assays 
3.4.5.1 Hypothesis 
As discussed during Section 2.18, HCV pseudoparticles are generated using 
a variation of CaPO4 transfection, combining a plasmid containing HCV 
E1E2 glycoprotein, a packaging vector, and a reporter plasmid. HCVpp were 
generated using the H77 E1E2 glycoprotein – a genotype 1a isolate that is 
known to produce infectious HCVpp. Once infectious HCVpp were produced, 
the pseudoparticles would be used to determine which of the isolated 
antibodies would be sent to Pepscan Presto B.V for epitope mapping. A 
number of scoping assays were performed to determine the best candidates 
for epitope mapping. Firstly, the IgG concentration of the antibodies was 
standardised. The antibodies were used to neutralise infectious H77 
pseudoparticles. The antibodies that demonstrated the most neutralisation 
underwent further experiments using varying IgG concentrations. For the last 
experiment, the chosen antibodies were combined to examine whether 
combined antibodies would have increased neutralisation against H77 
pseudoparticles when compared to single antibodies.  
3.4.5.2 Methodology 
The following methodologies were used during the course of this experiment. 
Please refer to the named sections for further information on the protocols 
used.  
 Generation of HCV Pseudoparticles (Section 2.18) 
 Infectivity Assay using HCVpp (Section 2.18.1) 
 Neutralisation Assay using HCVpp (Section 2.18.2) 
 Luciferase Assay using HCVpp (Section 2.18.3)  
 
It was shown from the infectivity assays using Huh7s that the H77 
pseudoparticles were functional and would be suitable for working with the 
VF-FAbs – this was validated by comparing the H77 pseudoparticles to 




pseudoparticles) and a H2O control, showing that the H77 pseudoparticles 
were infectious compared to the empty pseudoparticles.  
3.4.5.3 Results 
The purified antibodies were brought to the same concentration and tested 
against the H77 pseudoparticles to get a rough estimate of which antibodies 
would be the most suitable for further experimentation.  
Sample Relative Light Units (RLUs) Reduction of 
Infectivity (%) 
H77 8777 - 
A 71 99.19 
B 97 98.89 
C 269 96.94 
D 43 99.51 
E 179 97.96 
F 1147 86.93 
G 29 99.67 
H 197 97.76 
I 469 94.66 
L 265 96.98 
M 617 92.97 
N 649 92.61 
O 499 94.31 
VF-G 291 96.68 






























Table 16 - Initial neutralisation assay on the IgG antibodies purified from the HCV 3a patient 
samples. Every antibody sample was able to neutralise the H77 pseudoparticle. The 
average reduction of infectivity was 95.68%. 
From Table 16, samples G, J, M, VF-G, VF-J, and VF-M were selected for 
further examination. Samples G, J, and M had proven to be AAV+ and the 
proteinase K digests had created copies of the samples that contained the 
antibodies but not the virus – VF-G, VF-J, and VF-M. The second 
pseudoparticle experiment used four concentrations of IgG to determine 




















Figure 18 - Comparison of neutralisation between “whole” samples of antibodies and 
samples that have undergone proteinase K digestion (VF). On average, the “whole” samples 
demonstrated superior neutralisation – but the difference was not significant when compared 
to the control H77 sample. At the concentrations tested, the concentration of IgG did not 
appear to have any relationship to the antibodies’ neutralisation. The control H77 sample 
was measured at 417 RLUs – this was excluded from the graphs to make the figures more 
readable. 
 






























neutralisation. The “whole” samples appeared to have improved 
neutralisation compared to their VF counterparts, but this improvement was 
not significant when compared to the control H77 sample.  
A third experiment was performed to compare the neutralisation of combined 
antibodies to single antibodies. The hypothesis was that increased 
neutralisation from combined samples would imply that the individual 
samples (G, J, or M) targeted separate epitopes on the H77 E1E2. If 
neutralisation was not increased, it would suggest that the samples share the 
same epitope on the H77 E1E2, and that combining the samples only 
caused the competition for a single epitope. The “whole” samples G, J, and 
M were used for the third experiment.  
 
Figure 19 - Comparison between single and combined antibody samples. The combined 
samples did not demonstrate increased neutralisation when compared to the single 
samples. This implies that the antibodies isolated from the G, J, and M samples share the 
same epitope. 
 
It was decided that samples G, J, and M would be sent to Pepscan Presto B. 















Single vs. Combined Antibody Neutralisation




3.5 EPITOPE MAPPING 
3.5.1 Hypothesis 
Epitope mapping refers to the process of identifying the epitopes of 
antibodies to the corresponding antigens. For this project, “reverse” epitope 
mapping was used, meaning that antibodies that were known to bind to the 
HCV E2 glycoprotein were used to examine E2 epitopes.  
3.5.2 Disclaimer 
The discussion for Section 3.5 references research performed by Naik et al. 
and published as “Reverse epitope mapping of the E2 glycoprotein in 
antibody associated hepatitis C virus.” (PLoS One. 2017 May 
30;12(5):e0175349. doi: 10.1371/journal.pone.0175349). As stated during 
Section 3.1, some site-directed mutagenesis was performed by Nicole Walsh 
for the purpose of this paper. However, the epitope mapping was performed 
completely by Naik et al. and Nicole Walsh does not claim to have performed 
any of the epitope mapping related to the paper.  
3.5.3 Methodology  
The following methodologies were used during this experiment. Please refer 
to the appropriate sections for further information on the protocols used.  
 Epitope Mapping (Section 2.19) 
3.5.4 Results 
Several peptides were synthesised for the epitope mapping procedure. The 
order of the peptides on the cards was randomised. The epitope mapping 






SET Mimic Type Label Description Sequences  
SET 1 Linear LIN Linear peptides (length = 15aa) derived from the target 
sequence, with an offset of one residue. Cysteine 
residues were protected by acetamidomethyl (denoted 
“2”). 
 
SET 2 Loop – mP2 
CLIPS 
LOOP Constrained peptides (length = 17aa). On positions 2 – 
16 are 15-mer sequences derived from the target 
sequence. To introduce structural constraints, cysteine 
residues were inserted on positions 1 and 17, and were 
then constrained by mP2 CLIPS. Native cysteine 







SET Mimic Type Label Description Sequences  
SET 3 Helical – mP2 
CLIPS 
HEL Structured peptides (length = 23aa) derived from the 
target sequence, with an offset of one residue. On 
positions 1 and 5 there are cysteine residues which 
are joined by mP2 CLIPS. Native cysteine residues 
were protected by acetamidomethyl (denoted “2”). 
 
SET 4 β-turn –mP2 
CLIPS 
BET Structured peptides (length = 22aa). On positions 2 – 
21 there are 20-mer sequences derived from the 
target sequence, with an offset of one residue. “PG” 
residues supplant the residues present on positions 
10 and 11 to induce the β-turn formation. On 
positions 1 and 22 there are cysteine residues which 
are joined by mP2 CLIPS. Native cysteine residues 
were protected by acetamidomethyl (denoted “2”). 
 
 














This amino acid sequence is based on the E2 glycoprotein of the H77 HCV 
genotype 1a isolate. The above sequence covers the hypervariable region of 
the E2 glycoprotein.  
 
Figure 20 - A rendering of the HCV E2 glycoprotein structure, produced by Pepscan for the 
epitope mapping report. The blue ribbon represents the protein structure, and the grey 






Figure 21 - The intensity profiles of the linear and conformational epitope mimics for Sample 
AP33. (A) represents the linear peptide mimics and (B) represents the conformational 
peptide mimics. The signal intensity is on the Y axis and positions of the last residues of a 
peptide with respect to the target sequence is on the X axis. LIN = linear; BET = beta-turn; 
HEL = helical; LOOP = looped mimic. 
No binding peaks were observed for Sample AP33.  
Sample J 
 
Figure 22 - The intensity profiles of the linear and conformational epitope mimics for Sample 
J. (A) represents the linear peptide mimics and (B) represents the conformational peptide 
mimics. The signal intensity is on the Y axis and positions of the last residues of a peptide 
with respect to the target sequence is on the X axis. LIN = linear; BET = beta-turn; HEL = 




For Sample J, a number of binding peaks for linear and conformational 
mapping were observed, suggesting the presence of putative epitopes. 
Some binding peaks were observed during the linear mapping (Figure 22A), 
but these peaks were not consistent between repeated screenings. Several 
peaks were observed in the conformational mapping (Figure 21B); regions 
revolving around sequences 107YAPRPCGIVPAAQVCGPVYCF127, 
211TYTRCGSGPWLTPRCMVHYPY231, and 
149ENETDVLLLPGTRPPRGNWF168 demonstrated binding to the helical 
mimics and/or beta-turn mimics. During the linear peptide screening, minor 
peaks were also observed at position 149ENETDVLLLPGTRPPRGNWF168. 
Additionally, the conformational screening flagged sequence 
5TVGGSASRAPGRVTTFITRG24 as perhaps being part of a putative epitope. 
 







Figure 24 - The intensity profiles of the linear and conformational epitope mimics for Sample 
M. (A) represents the linear peptide mimics and (B) represents the conformational peptide 
mimics. The signal intensity is on the Y axis and positions of the last residues of a peptide 
with respect to the target sequence is on the X axis. LIN = linear; BET = beta-turn; HEL = 
helical; LOOP = looped mimic. 
For Sample M, several binding peaks were observed during the linear and 
conformational mapping, suggesting the presence of putative epitopes. It 
should be noted that residues outside of the major peaks could contain 
residues involved with a putative epitope. Figure 24A shows the binding 
events observed during the linear mapping, but because of the low signal-to-
noise ratio these peaks were not considered as putative epitopes. The best 
binding was observed on 154VLLLNNTRPPRGNWFGC170. This region was 
also present during the conformational array (Figure 24B). The main peak for 
the conformational arrays was centred on the helical mimic at the sequence 
40NRTALNCNDSLNTGFLAALFY60. The β-turn mimic 
5TVGGSASRPGHRVTTFITRG24 was a consistent presence during multiple 
screens but did not meet the criteria for an epitope – however, it could form 









Figure 26 - The intensity profiles of the linear and conformational epitope mimics for Sample 
G. (A) represents the linear peptide mimics and (B) represents the conformational peptide 
mimics. The signal intensity is on the Y axis and positions of the last residues of a peptide 
with respect to the target sequence is on the X axis. LIN = linear; BET = beta-turn; HEL = 
helical; LOOP = looped mimic. 
For Sample G, multiple peaks were observed for both the linear and 
conformational mapping, suggesting the presence of several putative 
epitopes. However, because of the presence of numerous peaks, the proper 
identification of epitopes was complicated. Pepscan identified the main 
peaks based on the intensity of the signal. (Table 17).  






















































Table 18 - The epitope candidates identified by the screening process. The peptide groups 
are ordered by the intensity of the signal, and only binding events of >3 times the median 
value were included. 
The four categories of putative epitopes (LIN, BET, HEL, and LOOP) were 
investigated further. The putative epitopes were examined, and “consensus” 
epitopes made by paring the putative epitopes down to their shared residues. 
These consensus epitopes were examined against the H77 sequence to see 
where on the E2 glycoprotein they targeted, and whether they overlapped 
against known antigenic sites. 
Area Positions 
HVR1 384 - 410 
AS412 412 - 423 
AS434 434 - 446 
HVR2 460 - 482 
E2 β-Sandwich 492 - 566 
IgVR 572 - 588 
Table 19 – A guide to key regions of the E2 glycoprotein. 
Name Sequence Notes 
LIN_1 536VLLLNNTRPPRGNWFGC552  
LIN_2 495GIVPAAQVCGPVY507 E2 β-Sandwich 
LIN_3 481DQKPYCWHY489  
LIN_4 589HPEATYTRCGSGPWL608  
LIN_5 429CNDSLNTGFL438 AS434 
LIN_6 516VGTTDRFGVPTYSW529  
Table 20 – Linear epitopes identified by reverse epitope mapping.  
 
Name Sequence Notes 
AN1 393SRAAHRVTTFITR405 Inside HVR1 
AN2 433LNTGFLAALFYTH445 AS434 




AN4 539LLNNTRPPRGNWF551  
AN5 599SGPWLTPRCM608 Beside IgVR (572 – 588) 
Table 21 – Epitopes identified by Naik et al. 
 
When comparing the positions of the consensus linear epitopes and the 
epitopes identified by Naik et al., several overlaps can be seen – AN2 and 
AN3 with LIN_5, AN4 with LIN_1, and AN5 with LIN_4. At the time the paper 
was released (May 2017), AN5 had not been described by any other 
research groups. 
 
Figure 27 - Alignment of AN2, AN3, and LIN_5 against H77. The sequence “LNTG#L” is 
conserved across the sequences. The # symbol represents a residue that varies between 
the sequences. Note the conserved region of amino acids with hydrophobic side chains. 
Figure 28 - Alignment of AN4 and LIN_1 against H77. The sequence “LNNTRPP#GNWF” is 
conserved across sequences. The # symbol represents a residue that varies between the 
sequences. Regarding the properties of the amino acid residues, note the pattern of 
hydrophobic -> polar uncharged -> charged side chains. 
 
 










Table 22 - Final consensus binding sites. C_LIN meaning “consensus linear”. The # symbol 
indicates an amino acid residue varies across the sequences. 
β-Turn Epitopes  
Refer to Table 19 for key areas of the E2 glycoprotein.  
The E2 ectodomain is a stable protein with a Tm of 85°C. The E2 
glycoprotein is modified post-translation by eleven N-glycans and nine 
conserved disulphide bonds. Four structural faces have been defined on the 
E2 glycoprotein – the glycan face, the occluded face, the non-neutralising 
face, and the neutralising face. The majority of the neutralising face is 
hydrophobic. It has been suggested that non-neutralising mAbs that target 
HVR1 could shield the neutralising face and protect the HVR1 from the 
binding of nAbs 181. 
For the putative epitopes described by this study, both samples J and G 
displayed β-Turn epitopes. The most common conformation of AS412 is the 
β-hairpin conformation. A backbone of internal hydrogen bonds stabilises the 
conformation. The hydrophobic face of the β-hairpin conformation forms a 
“binding pocket” containing antibody heavy chains and light chains. Despite 
AS412 being conserved across many mutations of HCV, HCV evasion of 
nAbs that target AS412 has been reported for several mutations. One 
mutation is the N417S/T mutation, which changes glycosylation from N417 to 
N415. N415 is located inside the “binding pocket” of AS412, and a mutation 
of N415 causes steric clashes that prevent nAb binding.  
 
Figure 30 – Alignment of J and G putative β-Turn epitopes with H77. 
The J β-Turn epitopes and one of the G epitopes shared a C residue at 
position 503. There was a “gap” of 29 residues and a conserved section of 
“NETDV”. There was a conserved section of amino acids with hydrophobic 
side chains. The “RPP” section was conserved across the sequences, with a 
probable “GNWFGC” section at the end of the epitope. The putative epitope 





Figure 31 – Alignment of G_1 putative β-Turn epitopes with H77. 
G_BET_1.1 and G_BET_1.2 both showed the same C residue at the start 
and end of the putative epitope as Figure 31. The “PSPVVVG” region and 
“PTYSW” was also conserved across the sequences. The putative epitope 
spans positions 503 – 553, the same as above. Combining the two sets of 
putative epitopes, we can create a consensus epitope. Some of the residues 
are not completely conserved, the chemical properties of the side chains 
remained the same. 
 
Figure 32 – Alignment of both sets of putative β-Turn epitopes with H77. 
The remaining G β-Turn epitopes were not a good match to the H77 
sequence, but did contain some of the residues between the 503 – 553 area, 
with some of them containing the conserved “RPP” region. The β-Turn 
epitopes are on the E2 β-Sandwich, showing some overlap with AN4, LIN_1, 
LIN_2, and LIN_6. 
Helical Epitopes 
Refer to Table 18 for key areas of the E2 glycoprotein. 
 
Figure 33 – Alignment of G_1 and G_3 putative helical epitopes with H77. 
A number of the G_HEL sequences showed the conserved 
“LLNNTRPPRGNWF” sequence. The same sequence can be seen when 





Figure 34 – Alignment of G_5 putative helical epitopes with H77. 
The G_HEL_5 putative epitope was not a complete match to the H77 
sequence, but did have matching sequences – “PYCWHY” and G_HEL_5.4 
having the “PRP” motif. The G_HEL_5 putative epitopes spanned from 
position 468 – 494 – placing G_HEL_5 inside HVR2.  
Loop Epitopes 
Refer to Table 18 for key areas of the E2 glycoprotein. 
Sample G was the only sample that displayed loop epitopes.  
 
Figure 35 – Alignment of putative loop epitopes with H77. 
The LOOP_1 samples showed a conservation of the hydrophobic -> polar 
uncharged -> charged pattern of side chain properties – similar to the LIN_1, 
β-Turn, and helical epitopes.   
3.5.5 Discussion 
There are several ways epitope mapping can be performed, with x-ray 
crystallography and multi-dimensional nuclear magnetic response (NMR) 
being the most popular methods. One the major advantages of x-ray 
crystallography is that it provides the atomic resolution of residues involved 
with the interaction of the epitope and the complementarity determining 
regions (CDRs) of the antibody paratope (antigen binding site). There are 
three CDRs (CDR1 – 3) present on the amino acid sequence of the variable 
domain of an antigen receptor, and these CDRs determine the specific 
antibody binding of that particular immunoglobulin 182. Epitope mapping using 
the x-ray crystallography technique requires that both the antigen and the 
antibody are purified before crystallisation of the complex. The expense and 




the major disadvantages of this technique 183. NMR can be used to generate 
precise epitope mapping information but requires that the previous structure 
of chosen antigen to already be determined. A rough epitope mapping can 
be performed using the hydrogen-deuterium exchange methodology - this 
technique can be used on impure antibodies and antigens but has the 
disadvantage of not giving much information about the sites examined. For 
instance, the hydrogen-deuterium exchange method might only be able to 
determine that a sequence of 10 – 20 residues does or does not contain an 
epitope.  
Using a peptide-based approach to epitope mapping can avoid many of the 
obstacles associated with NMR and x-ray crystallography. As discussed 
during the methodology, peptides are synthesised to cover the whole 
sequence of the antigen and immobilised on a surface. This method is ideal 
for linear peptide sequences, but disulphide bonds can be used to mimic 
discontinuous and conformational epitopes. This method does not require 
the same expertise and expense as the NMR and x-ray crystallography 
methods and does not require purified antigens or antibodies. However, the 
peptide method might not work for complex conformational epitopes 184. 
Another cheap and accessible method of determining epitopes is a 
mutagenesis approach. Epitopes are determined by examining the binding of 
the antibody to mutated forms of the antigen. This method can be used to 
screen thousands of proteins using “shotgun mutagenesis” or alanine 
scanning and can be combined with x-ray crystallography to determine the 
contribution of individual amino acids to an antibody-antigen interaction. A 
disadvantage of the mutagenesis method is that it can be hard to distinguish 
whether an amino acid change on one of the antigen mutants has changed 
the tertiary structure (blocking the interaction) or whether it’s a genuine 
contributory residue 184.  
For the purposes of this study, linear epitope mapping was chosen. The 
epitope mapping was carried out by Pepscan Presto B. V., and four 
antibodies were used during the procedure – VF-G, VF-J, VF-M, and AP33. 
AP33 defines an epitope on the E2 glycoprotein (412QLINTNGSWHIN423 – 




The majority of bnAbs isolated from infected patients and tested against the 
E2 glycoprotein target three adjacent sites and block the E2 glycoprotein 
interacting with the host CD81 receptor. These epitopes are antigenic site 
412 - 423 (AS412, AKA Antigenic Domain E or Epitope I), antigenic site 434 
– 446 (AS434, AKA Antigenic Domain D or Epitope II), and antigenic region 
3 (AR3). As mentioned above, the AS412 includes the epitope that was 
bound by AP33. The AR3 is a cluster of discontinuous epitopes formed by 
the E2 front layer (FL) and the CD81 binding loop (CD81bl). These sites 
have been found to cluster on an exposed surface of the E2 core domain 
that is devoid of glycans – this area has become known as the E2 
neutralising face, and comprises one of the four structural surface regions of 
the E2 core domain, the other three surface regions being the glycan face, 
the occluded face, and the non-neutralising face 186 187.  
One region appeared to be conserved across the four categories of putative 
epitopes – 532NDTDVFVLNNTRPPLGNWFGC552 located on the E2 β-
Sandwich of the H77 E2 glycoprotein. Sample G, Sample J, and AN4 
demonstrated amino acid variations, most showing a LL substitution for the 
VF residues and an additional P residue before the GNW section. L, V, and F 
are amino acids with hydrophobic side chains, meaning that the chemical 
properties of the section VFVL could have been preserved during the change 
to VLLL. On the other hand, Naik et al. found that a single amino acid 
change in the HVR1 of a HCV genotype 4a isolate was enough to 
significantly improve the ability of the isolate to evade and resist humoral 
immune responses. It was found that an F residue at position 399 (with the 
positions referencing GenBank NC_004102) improved antibody evasion 
when compared to an isolate with L at the same position. Despite F and L 
both having hydrophobic side chains, F is aromatic (containing a benzene 
ring) and L is aliphatic (containing a branched side chain), suggesting that 
the structure of individual amino acids is enough to impact the epitope, even 
when certain properties (such as hydrophobicity) are conserved 125. 
Name Origin Sequence 




NW1 Experimental 532NDTDVFLLNNTRPPPLGNWFGC553 
For ease of discussion, the sequences have been named HE1 and NW1. 
The changes between HE1 and NW1 are bolded. 
Using the BLASTp software, searching HE1 indicated other matches to HCV 
genotype 1a sequences. However, searching the NW1 sequence using the 
BLASTp database brought up matches to genotype 1b sequences despite 
the fact the G and J were isolated from genotype 3a infections. In clinical 
settings, HCV infections are genotyped by examining a mixture of the core, 
5’-UTR, and NS5B regions, but the high genetic variability of HCV can pose 
problems when distinguishing between subtypes – such as distinguishing 
between genotype 1a and 1b infections. The accurate genotyping and 
subtyping of HCV infections is critical for developing robust DAA treatment 
plans in the age of RAVs. Saludes et al. reported that when using a 
commercial assay that examined the 5’-UTR and NS5B regions, about 5.4% 
of genotype 1 infections were not assigned a subtype. A second commercial 
assay (GT Plus, Abbot Molecular Inc.) was designed to resolve ambiguous 
HCV genotype 1 samples and targets the core region – when applied to a 
selection of ambiguous HCV genotype 1 samples, it was able to assign a 
subtype to 88.8% of samples (142/160) 188. Therefore, it is not completely 
surprising that the BLASTp database matched NW1 to genotype 1b 
sequences, considering that the sequence covers one of the least conserved 
regions of the entire HCV genome, and considering that genotyping and 
subtyping HCV samples can present a challenge even when modern 
techniques are used.  
Kong et al. mentioned during their 2016 paper that when using E2 constructs 
during the course of their research that two sections of HE1 and NW1 are N-
linked glycosylated189. As previously stated, N-linked glycosylation is the 
attachment of an oligosaccharide (a carbohydrate consisting of a number of 
sugar molecules and known as a glycan) to a nitrogen atom. There are three 
major types of N-glycans. The first type is the high mannose glycan, which 
consists of two N-acetylglucosamine molecules joined to several mannose 
residues. The second type is the complex oligosaccharide, which contains 




contain sialic acid. The third type of glycans are the hybrid glycans, which 
contain N-acetylglucosamine, galactose, mannose, and sialic acid. Hybrid 
and complex glycans are produced during the movement of the protein 
through the Golgi apparatus.79  As shown from 
 
Figure 36, the glycosylation sites present on the portion of the E2 
glycoprotein that underwent epitope mapping have asparagine residues 
(asparagine contains an amide nitrogen). 
 
Figure 36 - Figure from Kong et al. showing the N-linked glycosylation sites of Epitope1 and 
Epitope2.189 
 
Figure 37 - The glycan shield masking the E2 neutralising epitopes (green area). The 
structure shows the E2 core and the N-terminal antigenic region (AS412). The HVR1 is not 
shown. The molecular surface is represented by the grey area, and the glycans are 
numbered N1 – N11 (gold sticks). Adapted from Lavie et al. 79 
The ectodomains of E1 and E2 are highly glycosylated – see section 1.2.4 
for further information. Lavie et al. characterised the glycans of the E2 
glycoprotein (see Figure 17). E2N6 corresponds to position 532 – the start of 
HE1 and NW1. E2N8 corresponds to position 556, the glycosylation site just 




glycosylation sites are conserved across genotypes. Both Lavie et al. and 
Helle et al. state that E2N7 (position 540) is absent in genotypes 3 and 6 - 
however position 540 corresponds to the NNT sequence displayed by HE1 
(genotype 1a) and NW1 (antibodies derived from genotype 3a infections). It 
would be worth examining whether the same antibodies used for the reverse 
epitope mapping would be able to detect a NNT sequence on genotype 3a 
E2 glycoprotein card. Helle et al. have also observed the importance of 
glycosylated asparagine residues in E2 for masking epitopes recognised by 
bnAbs. For example, the glycosylated asparagine residues at N417 and 
N423 (termed E2N1 and E2N2) have been associated with decreased 
sensitivity to bnAbs in HCVcc and HCVpp and increased binding with soluble 
forms of CD81, suggesting the two glycans might mask the CD81-binding 
epitope on E2 81. In addition to glycan shielding, Pantua et al. observed 
glycan shifting where a N417S HCVcc variant was shown to be resistant to 
two common HCV bnAbs – AP33 and HCV1. Analysis of glycosylation states 
showed that glycosylation had transferred from N417 to the adjacent N415, 
enabling the variant to escape the bnAbs. The HCVcc used during this study 
were challenged with AP33 and underwent UDPS, showing that the immune 
pressure exerted by AP33 had caused a cumulative 82-fold increase in the 
number of N417 mutations as soon as five days post treatment 190.  
HIV is one of the foremost examples of a virus that utilises glycan shielding. 
Similarly to HCV, the HIV glycan shield has also been shown to evolve under 
immune pressure. Key epitopes have been discovered on the HIV Env 
protein, but the glycan shield surrounding the Env protein prevents nAbs 
accessing the vulnerable epitopes. A 2017 study aiming to characterise HIV 
Env glycan shield reported the presence of glycan holes. The omission of 
specific Env glycans led to the production of glycan holes, exposing epitopes 
to nAbs. It was noted that the presence of a glycan hole impacted the 
conformational properties of surrounding glycans and the underlying 
protein.191 The 241 glycan site is conserved across 97% of HIV-1 isolates, 
and the site was recognised by three separate nAb lineages.  However, 
McCoy et al. found that even though many HIV-1 isolates lacked more than 




missing glycans and withstand nAbs. McCoy et al. referenced Wei et al., who 
found that viruses from one donor lacked a conserved glycan at position 234, 
but at day 212 the virus was able to escape from the autologous plasma, 
implying the existence of an evolving glycan shield 192 193.  
Alongside an evolving and adaptable glycan shield, the physical amount of 
glycan structures present on a virus appears to correlate to the amount of 
protection the structures grant. A 2020 study investigated the relationship 
between glycan and oligomannose abundance and the degree of immune 
evasion granted by glycosylation. The study first examined the glycosylation 
of the severe acute respiratory syndrome (SARS) and Middle East 
respiratory syndrome (MERS) coronaviruses (CoVs). CoVs are enveloped 
RNA viruses that cause respiratory diseases in mammals and birds. Vaccine 
development against SARS-CoV-2 has largely focused on the primary target 
of the host humoral response; the spike (S) glycoprotein. The trimeric S 
glycoproteins protrude from the viral envelope and are extensively 
glycosylated, with 88 – 87 N-linked glycosylation sites per trimeric spike. The 
CoV S glycoproteins are among the largest Class I viral fusion proteins 
known, and are used to mediate viral entry and membrane fusion. Watanabe 
et al. utilised a combination of cryo-electron microscopy (cryo-EM) and 
computational modelling to characterise the glycan shields of the SARS and 
MERS viruses and then compared them to the glycan shields of “evasion 
strong” viruses, including HIV-1 and SIV. Glycan shield densities were 
calculated using analyses of glycoproteins and abundance of oligomannose 
structures on glycosylated models of the viruses, and by examining the 
number of aa residues interacting with N-linked glycans to determine the 
“spread” of the glycan shield over the viral particle. There appeared to be 
correlation between the density of the glycan shield and the protection that 
the glycan shield conferred against the humoral immune response. The 
SARS and MERS viruses were found to have sparse glycan shields and are 
known to elicit strong nAb responses in humans, whereas HIV-1 was found 
to have an extremely dense glycan shield and does not induce an effective 





Despite the high degree of evasion conferred by glycosylation, a number of 
treatments strategies have been proposed for glycosylated viruses. 
Additionally, improved analytical techniques have helped develop the 
concept of a “glycome” – the aggregate of glycoproteins within an organism. 
In 2020, Jia et al. used a combination of mass spectrometry, Western blots, 
and staining techniques to characterise the N- and O-glycome from two 
human lung samples. Host receptor recognition by the influenza A virus (IAV) 
has been studied extensively as an example of pathogen-host interaction, 
and the glycans expressed on the surface of the host’s respiratory tissues 
are essential for guiding entry and infection by IAV. It was widely believed 
that hemagglutinin (the IAV envelope protein) recognised glycans with 
terminal sialic acids (a family of acidic sugars with a backbone of nine 
carbons) with α2,3- or α2,6-linkages, and that this recognition was required 
for proper IAV infection. Neuraminidase (present on the IAV surface) later 
cleaves sialic acid to help release new viral particles replication is completed. 
However, previous shotgun glycomics work by same research group found 
that IAVs can also recognise phosphorylated glycans, suggesting that IAVs 
can recognise and bind to a range of host receptors 195. The characterisation 
of the human lung glycome by Jia et al. showed that the human lung 
expresses N-glycans with diverse structures and lengths (sialylated and 
fucosylated, and a minor population of phosphorylated glycans), and that the 
O-glycome was dominated by two sialylated structures. These insights could 
lead to improvements to IAV treatment and vaccine development, and could 
generate more accurate predictions of how IAV hemagglutinin and 
neuraminidase variants might bind to the human respiratory system – an 
approach that could be applied to HCV if the hepatic glycome was explored 
and characterised 196.  
Glycosylation structures tend to be conserved among mammals, leading to 
the exploration of polysaccharides from non-mammalian sources as a 
potential therapeutic agents for infections caused by glycosylated viruses. Li 
et al. found that soluble HCV E2 produced from a Drosophila S2 culture had 
a novel glycosylation pattern and had increased immunogenic properties 




explored the use of algae polysaccharides as therapeutic agents, stating that 
a number of algae polysaccharides showed promising activity against 
enveloped viruses 198. Of particular interest is griffithsin derived from red 
algae (GRFT), which has demonstrated strong anti-viral activity in vitro and 
in vivo against a number of enveloped viruses, with minimal toxicity to the 
host. Initially GRFT was isolated from an aqueous extract of the red algae 
Griffithsia sp. collected from waters off the shores of New Zealand. 
Researchers at the U.S. National Cancer Institute first reported the potent 
activity of GRFT against HIV-1 in 2005, noting that GRFT bound to 
glycoproteins gp120, gp41, and gp160 in a glycosylation-dependent manner 
– sites known to uses glycan shielding 199. GRFT is a lectin of 121 amino 
acids, with its antiviral activity stemming from a unique structural feature that 
forms a homodimeric complex with three carbohydrate-binding domains on 
each monomer. These three carbohydrate-binding domains target high-
mannose arrays present on many pathogenic enveloped viruses including 
HIV, SARS-CoV, MERS-CoV, and HCV. Wild-type GRFT has a non-
standard amino acid at position 31, but it is replaced by alanine in 
recombinant GRFT. A number of mechanisms of action of GRFT against 
HIV-1 have been proposed, including exposure of the CD4 binding site of 
gp120 through modification of the glycan at position 386 and the inhibition of 
mannose-binding to gp120 200. GRFT has also shown activity against HCV, 
demonstrating prevention of HCV infection in vitro and mitigation of HCV 
infection for murine models 201,202.  
α-glucosidases are ER enzymes necessary for the processing and 
production of glycoproteins. Qu et al. found that downregulating the 
expression of α-glucosidases in Huh7.5s inhibited the production of HCV and 
reduced HCV release. Qu et al. also explored the use of iminosugars 
(analogues of sugars where a nitrogen atom has replaced the oxygen atom), 
which are known to be α-glucosidase inhibitors. The iminosugars proved to 
inhibit the production of HCV, but the clinical development of iminosugars as 
drugs has been hampered by the fact that iminosugars struggle to reach 
therapeutic concentrations in vivo – an iminiosugar approved for the 




was an α-glucosidase inhibitor created for the treatment of HCV, but was 
terminated during phase II development because of Celogosivir’s plasma 
drug concentration and poor reduction of viremia (5% of patients 
experienced a >1-log10 reduction). The downregulation of α-glucosidases 
and/or the use of α-glucosidases inhibitors would avoid the development of 
drug resistance, because they target host activities, but further research is 
needed to create viable treatments using this strategy 203 204. 
Another strategy for overcoming the barrier of glycosylation could be the 
modification or removal of glycosylation sites. Lavie et al. found that removal 
of N-glycans made HCVcc and HCVpp constructs more vulnerable to nAbs. 
Similarly, a 2019 study by Urbanowicz et al. explored the relationship 
between glycosylation and the antigenicity and immunogenicity of the E2 
glycoprotein region. Urbanowicz et al. generated in vitro variations of 11 E2 
N-glycosylation sites using mammalian and insect model systems, and but 
found that modifications to the glycosylation sites did not make them more 
vulnerable to nAbs. It was only the complete deletion of glycosylation sites 
that induced increased sensitivity to nAbs – such as the removal of the N1 
and N6 glycans (see Figure 37). Urbanowicz et al. concluded that future 
vaccine development should perhaps focus on the complete deletion of 
specific N-glycans, as opposed to just modification 205. 
In terms of prophylactic treatments for HCV and other glycosylated viruses, 
conjugate vaccines (glycans conjugated to an immunogenic protein) have 
proven to induce protection against encapsulated bacteria. For example, the 
development of the Haemophilus influenzae type B (Hib) conjugate vaccine 
heralded the almost complete eradication of diseases caused by the 
pathogen. It was discovered that polyribosyl ribitol phosphate (PRP) was a 
component of the Hib capsule, but that the administration of anti-PRP 
antibodies could not induce sustained protection. This was because the PRP 
antigen was only producing a partial response, activating B lymphocytes but 
not T lymphocytes – known as a “T independent” (TI) response. The TI 
response also prevent the formation of memory B lymphocytes, preventing 
lasting immunity. PRP was conjugated to a immunogenic protein carrier, 




of a working vaccine 206. This strategy could provide a framework for the 
development of a conjugate HCV vaccine.  
4 DISCUSSION AND CONCLUSION 
4.1.1 Discussion 
Despite significant drug advancements HCV continues to cause an 
estimated 399,000 deaths per annum. The WHO estimates that “in the 
absence of additional efforts, 19 million hepatitis-related deaths are 
anticipated from 2015 to 2030 20. Modern DAA treatment regimens can cure 
>95% of those diagnosed with hepatitis C infections, but resistance to DAAs 
have already been observed. The emerging resistance to DAAs, coupled 
with the problems associated with proper access to diagnostic and treatment 
programmes for vulnerable populations, only further emphasises the 
importance of developing improved treatments and – ultimately – a HCV 
vaccine. 
HCV is an important model virus. In a practical sense, the scarcity of suitable 
animal model systems drove the development of novel in vitro systems for 
HCV, expanding the range of systems that could be used to support other 
viruses. For instance, the pseudoparticle system has been used to safely 
study the Lassa virus (an arenavirus that causes Lassa haemorrhagic fever) 
under Biosafety Level 2 conditions, instead of the Biosafety Level 4 
conditions the wildtype Lassa virus requires207. From an epidemiological 
perspective, HCV has served as an important lesson in disease prevention 
and tracing among vulnerable populations (IDUs, for example). 
Understanding the humoral immune response to HCV has been key for 
shaping our approach to the disease, and epitope mapping has proven to be 
an important tool for studying the antibody response to HCV infection. Keck 
et al. used epitope mapping to identify epitope determinants for E2 antibody 
targeting, an important step for the development of a B lymphocyte HCV 
vaccine 208. Beyond HCV, epitope mapping has also been used examine the 
human norovirus for epitopes that could serve as therapeutic targets for 
vaccines and immunotherapy 209. During the course of this project, reverse 




glycoprotein. Further examination of the epitope structure and location lead 
to the conclusion that despite the epitope being conserved across a number 
of HCV samples, the epitope was protected from nAbs by glycan structures. 
Glycan shielding has been observed in many enveloped viruses, including 
HIV-1, and is correlated with high degrees of immune evasion.  
To summarise, HCV remains an important virus from both a research 
perspective and a public health perspective, and the continued research into 
the humoral response to HCV is crucial for the future management and 
eradication of the disease.  
4.1.2 Future Work 
Regarding the continuation of the work done during this research project, the 
next stage would be isolating HCV E2 from the genotype 3a samples 
received from the NVRL and using those E2 glycoproteins to produce HCV 
pseudoparticles. E2N7, which has been stated to be absent from genotype 3 
isolates, was detected during this project using antibodies from genotype 3a 
patients. Using epitope mapping, a larger sample of genotype 3a antibodies 
could be tested against various HCV genotypes to further examine the 
presence/absence of E2N7. Glycosylation has been found to impede access 
to vulnerable epitopes by nAbs, and subsequent work could incorporate 
some of the methods mentioned in Section 3.5.5 to make the conserved 
epitopes more accessible to nAbs. SDM could be used to evaluate the 
importance of various residues from the identified epitopes and the impact 
they have on resistance to antibodies. The basis of the project (using patient 
antibodies to examine epitopes through reverse epitope mapping) could also 
be applied to other viruses known to form AAV complexes – such as Zika 
virus and Dengue virus 210 211.  
4.1.3 Conclusion 
Reverse epitope mapping using antibodies derived from patients with chronic 
HCV genotype 3a infections identified the conserved epitope 
532NDTDVFLLNNTRPPPLGNWFGC553. However, this sequence contains 
two glycosylation sites (E2N6 and E2N7), with a third glycosylation site 
(E2N8) present at position 556. The presence of these glycosylation sites 




research succeeded in identifying conserved epitopes from patient samples 
and contributed to the body of knowledge about HCV and the humoral 
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APPENDIX I – SEQUENCES USED 
 
HCV Genotype 1a H77 Reference Sequence 
GenBank: NC_004102.1 – Hepatitis C Virus Genotype 1 – Complete 
Genome 
 
HCV Genotype 3a Reference Sequence 
GenBank: AF046866.1 – Hepatitis C Virus Subtype 3a Strain CB Polyprotein 
Gene – Complete CDS 
320bp Sequence Analysis – Accession Numbers of Sequences Used for 
Figure 9 
n = 20 
KU897989.1 KU897985.1 KU897981.1 KU897976.1 
KU897988.1 KU897984.1 KU897979.1 KU897975.1 
KU897987.1 KU897983.1 KU897978.1 KU897974.1 
KU897986.1 KU897982.1 KU897977.1 KU897973.1 
KU897972.1 KU897970.1 KU897969.1 KU897947.1 
 
320bp Sequence Analysis – Accession Numbers of Sequences Used for 
Figure 10 
n = 100 
NC_009824.1 KY620418.1 DQ506019.1 KC967545.1 
D14305.1 KY620398.1 DQ506014.1 GQ356216.1 
KU180722.1 DQ506538.1 DQ506003.1 AM423059.1 
HQ108106.1 DQ506530.1 DQ505999.1 DQ506536.1 
KY620509.1 DQ506518.1 DQ505996.1 DQ506529.1 
KJ437318.2 DQ506515.1 DQ505978.1 DQ506517.1 




EU399722.1 DQ506505.1 DQ505969.1 DQ506507.1 
KY620492.1 DQ506503.1 DQ505958.1 DQ506481.1 
DQ506468.1 DQ506480.1 DQ505923.1 DQ506464.1 
KY704893.1 DQ506466.1 DQ505917.1 DQ506026.1 
DQ506516.1 DQ506461.1 DQ505913.1 DQ506000.1 
DQ506473.1 LC368352.1 DQ505881.1 DQ505993.1 
DQ506462.1 KY620603.1 DQ505878.1 DQ505986.1 
DQ506460.1 KY620474.1 DQ505876.1 DQ505965.1 
DQ506459.1 KY620375.1 AF416523.1 DQ505959.1 
DQ506458.1 DQ506533.1 KJ470613.1 DQ505841.1 
DQ506030.1 DQ506528.1 DQ506498.1 DQ505818.1 
D14311.1 DQ506526.1 LC368368.1 DQ437509.2 
KJ470614.1 DQ506510.1 KY704903.1 KY620387.1 
DQ506476.1 DQ506509.1 KY620462.1 MN628590.1 
KY620601.1 DQ506504.1 KY620396.1 KY704902.1 
KY620593.1 DQ506501.1 KY120332.1 KY704900.1 
KY620514.1 DQ506491.1 KX621475.1 KY620760.1 
KY620459.1 DQ506483.1 KX621470.1 KT735468.1 
 
Core Protein Sequence Analysis – Accession Numbers of Sequences 
Used for Figure 11 and Figure 12 
n = 100 
NC_009824.1 MK612031.1 MN026653.1 MN026688.1 
D14305.1 KY620776.1 MN026580.1 MN026652.1 
KY620603.1 KY620601.1 MN026568.1 MN026624.1 
KY704903.1 KY620490.1 KY620616.1 MN026571.1 
KY704902.1 KX621518.1 KY620516.1 MN026734.1 
KY620510.1 KF292092.1 LC368352.1 AM263092.1 
JX826592.1 KC143935.1 MN026674.1 AM263080.1 
MN026630.1 HQ912953.1 MN026597.1 AM263079.1 
AY522117.1 KY620602.1 MN026560.1 MN026676.1 




AY522110.1 KY620524.1 KY620585.1 KY704901.1 
AY522106.1 KY620502.1 KY620501.1 KY620719.1 
AY522102.1 KJ437307.2 KY620391.1 KY620634.1 
U10191.1 AY522115.1 KJ437314.2 KY620625.1 
D14311.1 AY522114.1 KF292108.1 KY620613.1 
MN026612.1 AY522111.1 MT632179.1 KY620606.1 
MN026573.1 AY522108.1 GU814263.1 KY620605.1 
KY620560.1 AY522104.1 AY522118.1 KY620554.1 
LC368368.1 AY522103.1 U10210.1 KY620539.1 
MN026668.1 AY522101.1 U10208.1 KY620537.1 
MN026561.1 U10197.1 L12355.1 KY620532.1 
KY620525.1 KY620461.1 KF292056.1 JF343784.2 
KY620508.1 KY620456.1 KF589884.1 GU814264.1 
KY620500.1 KY620366.1 KF134008.1 EU204645.1 







APPENDIX II – EPITOPE MAPPING REPORT 












































































































































































APPENDIX III – ABBREVIATIONS USED 
 








Also Known As 
bnAbs Broadly-Neutralising Antibodies 
CARD Caspase Activation and Recruitment Domain 
CARDIF CARD Adaptor Inducing IFN-β 
CD-81 Cluster of Differentiation - 1 
cDNA Complementary DNA 
CDC Centre for Disease Control (USA) 
CTL Cytotoxic T Lymphocyte 
DAA Direct-Acting Antiviral 





Dendritic Cell SIGN 
Deoxyribonucleic Acid 
European Association for the Study of the Liver 
European Centre for Disease Control 
EGF Epithelial Growth Factor 
ER 
FDA 
Endoplasmic Reticulum  




Green Fluorescent Protein  
Glecaprevir 
Griffithsin Derived from Red Algae  
GT Genotype 
HAV Hepatitis A Virus 
HBV Hepatitis B Virus 
HCC  Hepatocellular Carcinoma 
HCV 
HCVAg 
Hepatitis C Virus 
HCV Core Antigen 
HDL High Density Lipoprotein 
HGV Hepatitis G Virus 






Hepatic Stellate Cells 




Influenza A Virus 
IDU Intravenous Drug User 
IFN Interferon  
IRES 
IRF 
Internal Ribosome Entry Site 
Interferon Regulatory Factor 
JAK Janus Kinase 
KC Kupffer Cells 
LD Lipid Droplet 
LDL Low Density Lipoprotein 
LDL-R Low Density Lipoprotein Receptor 
LEL Large Extracellular Loop 
LSEC Liver Endothelial Sinusoidal Cells 
L-SIGN Liver/Lymph Node SIGN 
LVP Lipoviral Particle 
LXRα Liver X Receptor Alpha  
mAb Monoclonal Antibody 
MAVS Mitochondrial Antiviral Signalling Protein 
MDA5 Melanoma Differentiation Antigen – 5 
mDC 
MERS 
Myeloid Dendritic Cell 
Middle East Respiratory Syndrome 
MHC Major Histocompatibility Complex 
MLV Murine Leukaemia Virus  
mRNA Messenger RNA 
miRNA Micro RNA 
MSM Men-Who-Have-Sex-With-Men 
nAb Neutralising Antibody 
NANBH Non-A, Non-B Hepatitis 




Natural Killer Cells 
NK-Mediated Antibody-Dependent Cellular Cytotoxicity 
Natural Killer T Cells 
NLR NOD-Like Receptor 









Needle and Syringe (Exchange) Programme 
Ombitasvir 
ORF Open Reading Frame 
PAMP Pathogen-Associated Molecular Patterns 
PBMC Peripheral Blood Mononuclear Cell 
PCR Polymerase Chain Reaction 
pDC Plasmacytoid Dendritic Cell 













Pathogen Recognition Receptor 
People Who Inject Drugs 
Quality-Adjusted Life-Year 
Ritonavir 




RNA-Dependent RNA Polymerase 
Rhesus 






Severe Acute Respiratory Syndrome 
SIGN Specific Intercellular Adhesion Molecule-3-Grabbing Non-Integrin 
SMV   Simeprevir 
SOC Standard-of-Care 
SOCS Suppressor of Cytokine Signalling 
SOF Sofosbuvir  
SR-B1  Scavenger Receptor Class B – Member 1 
ssRNA Single-Stranded RNA 










Sustained Virologic Response 
Cytotoxic T Cells 




Target Not Detected 
TNF Tumour Necrosis Factor 
TRAF 
Tregs 
TNF Receptor Associated Factor 
Regulatory T Cells 
TRIF 
UDPS 
Toll-Interleukin-1 Receptor Domain-Containing Adaptor Inducing IFN 
Ultra-Deep Pyrosequencing  
UTR Untranslated Region 
VLDL Very Low Density Lipoprotein 
vRNA Viral RNA 






APPENDIX IV – AMINO ACID CODE 
 
Amino Acid Three Letter Code One Letter Code 
Alanine ala A 
Arginine arg R 
Asparagine asn N 
Aspartic Acid asp D 
Asparagine/Aspartic Acid asx B 
Cysteine cys C 
Glutamic Acid glu E 
Glutamine gln Q 
Glutamine/Glutamic Acid glx Z 
Glycine gly G 
Histidine his H 
Isoleucine ile I 
Leucine leu L 
Lysine lys K 
Methionine met M 
Phenylalanine phe F 
Proline pro P 
Serine ser S 
Threonine thr T 
Tryptophan trp W 
Tyrosine tyr Y 






APPENDIX V – IUPAC NUCLEOTIDE BASE CODE 
 






R A or G 
Y C or T 
S G or C 
W A or T 
K G or T 
M A or C 
B C or G or T 
D A or G or T 
H A or C or T 
V A or C or G 
N Any Base 
. or - Gap 
 
 
